Antibiotics and Host Responses in the Pathogenesis of Staphylococcus Aureus Infection by Swierstra, J.W. (Jasper)
Antibiotics and Host Responses in the 
Pathogenesis of Staphylococcus Aureus Infection
Jasper Wybe Swierstra
Layout and printed by: Optima Grafische Communicatie, Rotterdam, the Netherlands
ISBN: 978-94-92683-47-2
Antibiotics and Host Responses in the 
Pathogenesis of Staphylococcus Aureus Infection
Antibiotica en gastheerreacties in de pathogenese van 
Staphylococcus aureus infecties
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus University Rotterdam
op gezag van de
rector magnificus
Prof.dr. H.A.P. Pols 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
 dinsdag 20 juni 2017 om 13:30
door
Jasper Wybe Swierstra
geboren in Atalanta, Georgia, Verenigde Staten van Amerika
PROMOTIECOMMISSIE
Promotor:   Prof.dr. H.A. Verbrugh
Overige leden:  Prof. Dr. H. Wertheim
   Prof. Dr. G. van Wezel
   Prof. Dr. H.P. Endtz
Co-promotor:   Dr. W.J.B. van Wamel
TablE Of COnTEnTS
Chapter 1 Introduction 7
Chapter 2 IgG4 subclass-specific responses to Staphylococcus aureus 
antigens shed new light on host-pathogen interaction
29
Infect Immun. 2015 Feb;83(2):492-501
Chapter 3 Staphylococcus aureus immune modulators SCIN and CHIPS are 
produced during the early stages of biofilm formation
51
Manuscript submitted
Chapter 4 Bacterial determinants of persistent Staphylococcus aureus 
bacteremia 
67
Manuscript submitted
Chapter 5 Eliciting antibiotics active against the ESKAPE pathogens in a 
collection of actinomycetes isolated from mountain soils 
83
Microbiology. 2014 Aug;160(Pt 8):1714-25
Chapter 6 Structure, toxicity and antibiotic activity of gramicidin S and 
derivatives
107
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):763-9
Chapter 7 General discussion and summary 121
Chapter 8 Nederlandse samenvatting 137
Appendices Dankwoord 147
Curriculum Vitae 151
List of publications 153
PhD portfolio 155

Chapter 1
Introduction

Introduction 9
Bacterial infections have historically been a major burden in human health (11). Infec-
tions remain prevalent today and are involved in approximately 25% of all deaths, and 
are responsible for 28% of years lost due to disability worldwide (13). Infections occur 
in the general community, but are also prevalent and dangerous in acute care hospitals 
(14) and other health care settings. Patients in hospitals and other health care settings 
often have their skin barriers breached by catheters or surgical interventions, yielding 
wounds that provide gateways for infection. Hospitalized and health care patients also 
often have reduced immunity: transplantations, hematological malignancies, chemo-
therapies and radiation all reduce immune competence. The elderly (15), a growing de-
mographic group, are also more susceptible to infection than the young. Hand hygiene, 
aseptic surgical techniques (16) and more recently, antimicrobial prophylaxis, screening 
and targeted decolonization strategies (17) have all reduced, but not eliminated health-
care associated infection. Technologies such as sanitation, vaccination and antibiotics 
have played major roles in significantly reducing infectious diseases mortality in the 
community, in the USA from approximately 800 per 100,000 persons per year in the 
1900s to around 60 per 100,000 persons per year in the late 1990s (12).
Health care associated infections remain problematic, and may constitute a greater 
threat today than ever before. The Infectious Disease Society of America (IDSA) warns 
especially against a collection of healthcare associated pathogens abbreviated in the 
acronym ESKAPE (2, 18): Enterococcus faecalis (19, 20), Staphylococcus aureus (S. aureus) 
(21-23), Klebsiella spp. (24, 25), Acinetobacter baumannii (26, 27), Pseudomonas aerugi-
nosa (28, 29) and Enterobacter spp. (30, 31). These bacteria, also known as superbugs, 
currently have a significant impact on human health for several reasons: they produce 
many virulence factors by which they can cause life threatening infections (7, 32) and 
they are either intrinsically resistant to many antibiotics (33) or easily acquire resistance 
to many classes of antibiotics. Antimicrobial resistance is an area of special concern, as 
there are few new antimicrobials being developed, while the currently available com-
pounds are losing effectiveness (2). Since the 1980s only few compounds with a truly 
novel mode of action have been introduced into clinical practice (13), giving rise to the 
possibility of a post antibiotic era, in which infections can be diagnosed but no longer 
treated effectively.
By studying the pathogenesis of infectious diseases we gain more insight in how 
patients become sick and how we can best treat them. These studies are usually per-
formed without regards of the effects of intervening antimicrobial treatments. However, 
bacterial infections are commonly treated with antibiotics, which either kill bacteria or 
halt bacterial growth. After exposure to bacteria (or their products) the human immune 
system responds. Due to its specificity, the humoral immune response of the host can be 
used as indication which microbial factors have been expressed and are immunogenic in 
vivo. Differences in the humoral immune responses between patients undergoing differ-
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ent types of infections may shed light on which virulence factors are actually involved in 
pathogenesis (3-6). Examples of bacterial responses to antibiotics or to immune-induced 
stresses are the production by the bacteria of compounds that modulate the host’s im-
mune responses (7), the formation of biofilms (8, 9) (Figure 1), modifying their surface 
charge and generally altering their behavior, such as their metabolism, in response to 
antimicrobial peptides.
figure 1: Staphylococcus aureus biofilm formation.
Attachment of S. aureus to a surface is mediated by CWA proteins. Cell-to-cell interactions occur during ac-
cumulation phase and can be mediated by several factors. The magnified region shows this in more detail: 
(1) extracellular DNA linking recycled cytoplasmic proteins; (2) CWA proteins binding adjacent cell surfaces; 
(3) Homophilic interactions between CWA proteins. PSMs form amyloid-like fibers visible at the surface of 
the biofilm. They also act in the formation of channels within the biofilm to allow nutrient access, while 
their surfactant properties aid the dispersal phase. The different stages of biofilm formation are detailed 
from left to right across the diagram. From: Hobley et al., FEMS Microbiol Rev (2015) 39 (5): 649-669, doi: 
https://doi.org/10.1093/femsre/fuv015
Studying (changes in) the behavior of microbes faced with either antibiotics or chal-
lenges from the host’s immune system could help explain why antimicrobial therapy and 
the immune system sometimes fail to clear an infection, as is often the case with invasive 
Staphylococcus aureus infections: 10-20% of all patients suffering from Staphylococcus 
aureus bacteremia (SAB) today still die, even with appropriate antimicrobial therapy. 
Better understanding of the pathogenesis of infection, accounting for microbe-derived 
disease-inducing factors (virulence factors), the host’s defense response to these micro-
bial challenges and the effects of applying antibiotic treatments, both individually and 
in concert should lead to a better understanding of infection and ultimately, better strat-
egies to improve the outcomes of patients suffering from serious infectious diseases.
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StAPhylococcuS AurEuS and OuR IMMunE SySTEM
The pathogen studied in detail in this thesis is Staphylococcus aureus. This pathogen 
is present in the anterior nares of approximately 30-50% of all humans, approximately 
half of whom persistently carry these bacteria whereas others are intermittent carriers. 
S. aureus carriage is usually harmless, but carriage is not without risk: nasal carriers, 
especially persistent ones, have higher rates of infections by S. aureus than non- or inter-
mittent carriers (6, 34-36), although some reports suggest that, once infected, carriers 
have a decreased risk of dying from S. aureus bacteremia compared to non-carriers (37). 
S. aureus can cause many different types of infection (34): from acute bacteremia (10) 
to chronic osteomyelitis (38), from superficial skin infections (39) to deep seated endo-
carditis (40) and from relatively mild abscesses (41) to life threatening pneumonia (42). 
S. aureus causes more deaths in the USA annually than HIV and tuberculosis combined, 
and, worryingly, it is proving increasingly resistant to antibiotic treatment (18, 43, 44).
To successfully cause serious infection S. aureus must invade the host and escape the 
human immune system, which is composed of innate and adaptive responses. Innate 
immunity is a first line of defense against infection comprising of cells and mechanisms 
which rapidly repel or clear infectious agents without the generation of immunological 
memory, although recently it has been proposed that especially monocytes and mac-
rophages, which are important in innate immunity, may develop some level of memory 
called “trained immunity” or “innate immune memory”, most likely via epigenetic changes 
(111). One of the first innate defenses S. aureus must evade are host defense peptides 
and the complement system (Figure 2). Host defense peptides, such as human beta 
defensins and cathelicidin can efficiently kill bacteria at low concentrations (56); these 
peptides target the cellular membrane, but also affect several intracellular targets (56). 
They further function as signal molecules of infection, attracting other cells to the site 
of infection (56). Complement is a system of molecules present in blood in inactive form 
and has several functions (Figure 2) (57): firstly, it functions as an opsonin enhancing 
phagocytosis of particulate matter (57). Secondly, complement is capable of clumping of 
agents, targeting them for removal (57). A third function of complement is lysis of cells by 
forming membrane attack complexes and so rupturing cellular membranes (57). Finally, 
complement catalyzes its own activation and causes a gradients of metabolites that func-
tions as chemo-attractants to immune cells, including neutrophils (57). Complement can 
be activated in three different ways: the classical pathway, the alternative pathway and a 
lectin-mediated pathway. In the classical pathway, complement forms a complex with an-
tibodies after binding to their specific target, generally of class IgM or IgG. The alternative 
pathway is continuously active at a low level, leading to constant hydrolysis of C3. Finally, 
in the lectin binding pathway, bacterial sugar moieties containing mannose or glucose 
bind mannose binding lectin, which in turn activates the complement cascade. All 
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complement activation pathways converge at the formation of a C3-convertase complex, 
activating cleavage of additional inactive complement components present in serum to 
complete the complement cascade. Neutrophils in the bloodstream sense chemokines 
such as complement 5a (C5a), interleukin 8 (IL8), macrophage chemo-attractant protein 
1 (MCP-1) and leukotriene B4. In response to these chemokines, neutrophils circulating in 
the bloodstream slow down in a rolling motion and adhere to the endothelial inner sur-
face of blood vessels in the vicinity of the focus of infection, and ultimately leave blood 
vessels near the site of infection (57, 58). These chemokines also activate neutrophil 
metabolism and stimulate neutrophil release of granules containing various antibacte-
rial proteins such as the previously mentioned defensins, cathelicidin, and lysozyme (59). 
Activated neutrophils ingest invading pathogens either tagged with complement C3b 
using complement receptors CR1, CR3 and CR4 (60) or pathogens tagged with antibodies 
using Fc receptors (61), in a process called phagocytosis. Phagocytosis is facilitated in the 
presence of complement or antibodies, which function as opsonins. Ingested bacteria 
are killed by neutrophils: during respiratory burst hydrogen peroxide (H2O2), superoxide 
anions (O2-) and nitric oxide (NO) are generated from molecular oxygen by lysosomal 
NADPH and other enzymes, causing oxidative stress and ultimately bacterial death (58, 
62). Finally, neutrophils can form neutrophil extracellular traps (NETs) (63), which trap 
invading bacteria in a matrix of DNA and protein, including histones (64), which have 
antibacterial activity (63). When S. aureus invades the human host, it is thus quickly con-
fronted by various innate immune defenses and escape from all these systems is essential 
for the bacteria to survive and cause an infection.
 
figure 2: Major functions of the complement system
Complement is a system of molecules present in blood in inactive form and has several functions: firstly, 
complement lyses cells by forming membrane attack complexes and so rupturing cellular membranes. Sec-
ondly, it functions as an opsonin enhancing phagocytosis of antigens. A third function of complement is 
because complement catalyzes its own activation and causes a gradient it functions as a chemo-attractant 
to immune cells, such as neutrophils, and further primes them for degranulation. Finally, complement is 
capable of clumping of antigen-bearing agents, targeting them for removal. (From Kuby et al., Immunology 
2003)
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When innate immune system fails to clear the invading pathogens, approximately 96 
hours after primary infection, adaptive immunity responds (65). The adaptive immune 
response is composed of highly specialized systemic cells and processes that selectively 
target pathogens for neutralization and destruction, and results in immunological mem-
ory. Antigen presenting cells, mainly dendritic cells (DC), ingest invading pathogens and 
process them to antigens (66). These DC’s presenting antigens are transported to lymph 
nodes, where a response is initiated against the antigens presented via major histocom-
patibility complex (MHC) molecules (66). B-cells, the main players in humoral immunity 
of the adaptive immune system, produce antibodies against these DC presented an-
tigens (66). Antibodies consists of the hyper-variable antigen recognition part of the 
antibody called Fab and the constant part, called the Fc domain which is important for 
signaling and further immune activation (67). Antibodies have several functions (Figure 
3): firstly, they tag microbes or infected cells for destruction by specifically recogniz-
ing them (67). Secondly, they neutralize, agglutinate and precipitate foreign antigens. 
Finally, antibodies function together with complement in opsonization as mentioned 
earlier, with neutrophils using Fc receptors FcγRI, RIIA, RIIB2 and RIIIB to recognize and 
ingest pathogens (Figure 2 and 3) (67). Antibodies or immunoglobulins (Ig’s) exist in 5 
figure 3: Essentials of Human Anatomy & Physiology (11th Edition) 11th Edition by Elaine N. Marieb
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isotypes, with IgG providing the majority of antibody related immunity in the blood 
to invading pathogens, as 75% of all antibodies in serum are IgG’s. IgG is divided into 
four subclasses each with distinct characteristics and function, which are numbered 
according to serum abundance. IgG1 is primarily directed against proteins and is the 
predominant IgG subclass (68). IgG2 is primarily directed to polysaccharides and the 2nd 
most abundant serum IgG (68). IgG3 is predominantly directed against viral antigens 
and is less abundant is serum than IgG1 or IgG2 (67, 68). Serum levels of IgG1, IgG2 
and IgG3 increase within a week of infection, peak between one and two weeks and 
resolve after two to three weeks (67, 68). IgG1, 2 and 3 function as pro-inflammatory 
signals inducing Fc receptor-mediated and complement-mediated phagocytosis (67). 
IgG4 antibodies, the least abundant type of IgG, are only produced after prolonged 
exposure, typically taking months or years (68). IgG4 antibodies have less immune- and 
complement-activating capability than the other IgG antibodies, and IgG4 antibodies 
are correlated with tolerance after someone has overcome allergy and/or repeated and 
chronic exposure (67-69).
To actually be able to cause infection, S. aureus needs to evade all these previously 
described innate and adaptive immune responses. The first contact between S. aureus 
and the innate immune system occurs when the pathogen is confronted with host de-
fense peptides and complement. Host defense peptides beta-defensins and cathelicidin 
also function as signal molecules for infection, attracting other cells to the site of in-
fection (56). S. aureus reacts to these membrane stresses by altering the charge of the 
membrane surface: by adding D-alanines to teichoic acid via the dlt system and adding 
D-lysines to phosphatidylglycerol in the membrane via mprF, the net charge of their 
surface becomes more positive and host defense peptides are repulsed via electrostatic 
interactions (56). This could further have pathological effects when positively charged 
antibiotics are reflected, thereby conferring some level of resistance to these antibiotics. 
Complement activity can be modulated by the staphylococcal complement inhibitor 
(SCIN), the extracellular complement binding protein (Ecb) and extracellular fibrinogen 
binding protein (Efb), which all block the activity of the C3 convertase and, thus, block 
the classical, the alternative and the lectin pathway of complement activation (99, 106). 
Other molecules also interfere with the complement system and phagocytosis, such 
as staphylokinase (SAK), clumping factor A (ClfA), S. aureus Serine-Aspartate dipeptide 
repeat protein (SdrE) (100) and Staphylococcal super antigen-like proteins (SSL) 7 and 
10, all acting on different targets. Staphylokinase induced plasmin formation actively 
degrades complement C3b (106). ClfA binds complement regulator I protein (107). SdrE 
inhibits the alternative pathway of complement by recruiting the complement regula-
tory protein factor H (108). SSL7 binds and inactivates C3 and C5 (106). SSL7 and SSL10 
also sequester antibodies, thus blocking the classical activation of complement (106). 
Several staphylococcal proteins such as SSL5, SSL11 and FLIPr can bind to the FcR on 
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phagocytic cells preventing opsonophagocytosis. S. aureus is furthermore known to 
inhibit neutrophil extravasation and chemotaxis (106). Chemotaxis of neutrophils is in-
hibited by S. aureus by molecules such as the chemotaxis inhibitory protein of S. aureus 
(CHIPS), which interferes with the complement receptor C5aR, the formylated peptide 
receptor (FPR) on neutrophils (101). This FPR is further inhibited by formyl peptide 
receptor-like 1 inhibitor (FLIPr) and FLIPr-like (FLIPr-L) (106). In addition, SSL5 inhibits 
the PSGL1 signaling pathway, which allows neutrophils to slowly roll over endothelium 
(106). Neutrophils and other immune cells, such as monocytes, macrophages, T-cells, 
dendritic cells and NK cells are further targeted by molecules from the γ-hemolysin 
family consisting of gamma hemolysin HlgABC and leukocidin (Luk) A, B, D, E, F and 
S which form pores in the membranes of these cells by binding to the CCR5, CXCR1, 
CXCR2, CCR2, CD11b, C5aR and C5L2 (58, 109, 110). Finally, S. aureus is equipped with 
several mechanisms to prevent neutrophil-mediated killing (106). When live neutrophils 
home to the site of infection to form NETS, S. aureus can escape these by producing 
nuclease. This may help explain why MRSA strains excreting nuclease were associated 
with increased mortality when compared to a nuclease deficient strain (102). After al-
tering innate immune responses to escape clearance, S. aureus can evade the adaptive 
immune response as well. Bacterial super-antigens (Sag), such as staphylococcal entero-
toxins (SE) and toxic shock syndrome toxin (TSST-1), modulate adaptive responses by 
cross-linking MHCII with T-cell receptors, resulting in polyclonal T-cell activation and 
disruption of adaptive immune response (103). Staphylococcal protein A (Spa) binds 
antibodies not by their specific antigen recognizing Fab domain, but by their Fc domain 
(104), hampering downstream signaling of antibodies. Furthermore, Spa is capable of 
inducing apoptosis in B-cells by binding to the VH3 region of the B-cell receptor (105). 
Second Immunoglobulin Binding protein (SBI) functions in a similar manner to Spa 
(106). For an excellent review on all players in staphylococcal manipulation of the host 
immune responses see (106). Taken together, all these systems show that S. aureus is 
well equipped to respond to pressure caused by both the innate and adaptive immune 
responses, and that S. aureus interacts with several targets via several mechanisms.
Bacteria causing invasive disease in vivo are under selective pressure by the host’s 
system and modulate their behavior. Bacterial (pathogenic) behavior is altered by a 
multitude of factors: partial oxygen pressure, lack of iron ions, elevated temperatures, 
and exposure to the host’s immune responses and by exposure to antibiotics adminis-
tered to the host during his/her therapy. Two component systems monitor the bacterial 
environment and inside of the bacteria and alter bacterial behavior or metabolism to 
maintain homeostasis (80). S. aureus actively responds to immune pressure (7), as de-
scribed previously, and to antibiotic pressure (76, 81).
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anTIbIOTICS and baCTERIal bEhavIOR
Once inside a host, bacteria must escape the innate and adaptive immune system. Gener-
ally, patients are treated with antibiotics when the immune system fails to clear the bac-
teria and a clinical infection has developed. When antimicrobial therapy is prescribed S. 
aureus must also avoid clearance by these antibiotics. Antibiotics, which have only been 
in clinical use since the 1940s, have various bacterial targets by which interaction they 
interfere with the life of bacteria (Figure 4). The first antibiotic discovered by Alexander 
Flemming was penicillin, and was discovered by accident when he observed the fungus 
Penicillium inhibiting the growth of S. aureus. Shortly after the introduction of penicillin 
in clinical practice, S. aureus strains resistant to penicillin were detected. By confronting 
bacteria with antibiotics, selection pressure is applied. Fully susceptible bacteria are 
killed or halted in their growth, less susceptible or fully resistant variants in the bacterial 
population tend to remain viable and may even proliferate. As antibiotics are a mainstay 
in current clinical practice the emergence of resistance is a cause for alarm. Resistance 
to antibiotics can occur in several ways (Figure 5). S. aureus has proven notorious in that 
it can acquire resistance to many classes of antibiotics, which causes extensive problems 
in health care settings. This bacterium can show resistance to almost all antibiotics 
used to treat it, and resistance spreads quickly, not only vertically to progeny, but also 
through horizontal gene transfer to close relatives, mainly via plasmids and phages. The 
SSCmec cassette genes provide resistance to methicillin, and their presence classify a 
strain as Methicillin Resistant Staphylococcus aureus (MRSA), which is currently causing 
major problems in health care (21-23). Treatment options are diminishing, leading to 
fears of a post antibiotic era, in which infections can be diagnosed but no longer treated 
with antibiotics. Exacerbating this situation is the fact that drugs that have recently 
been introduced do not have novel modes of action as they are often derivatives of 
antibiotics currently used in the clinic. Either existing products are modified, or known 
antimicrobial producing sources are mined for novel compounds, leading to no new 
treatment options. It is therefore clear that novel antibiotics, with novel modes of action 
are essential to maintain treatment options.
In addition to evading clearance from either antibiotics or the immune system, S. 
aureus can alter its mode of growth, from planktonic life to a sessile state attached to a 
substrate (Figure 1); sessile life may facilitate infection and persistence (9). This growth 
mode is called a biofilm and is reportedly present in over 80% of all infections (95). They 
consist of an extracellular matrix of DNA, polysaccharide and/or proteins (51), which 
hinders the diffusion antibiotics prescribed to the diseased host (52) and excludes 
the immune system from clearing the infection. Much is known on the regulation and 
generation of biofilms (53), and bacterial virulence factors are typically reported to be 
produced only in the later phases of the formation of biofilm. In this multicellular sessile 
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mode of growth, S. aureus is much more recalcitrant to clearance for several reasons: 
bacteria are in different metabolic states, being either active or metabolically dormant, 
the so-called persister cells, reducing the efficacy of several classes of antibiotics (50). 
Furthermore, biofilm hinders antibiotics and the immune system to actually reach 
the bacteria. There are reports showing that some antibiotics influence the formation 
of biofilm by S.aureus, e.g gentamicin induces biofilm formation (101) whereas rifam-
 
figure 4: Bacterial targets of antibiotics
The bacterial cell wall is targeted by beta-lactam containing drugs such as penicillins (cephalosporins and 
carbapenems) and glycopeptides (vancomycin and teichoplanin). These drugs inhibit the correct forma-
tion of a complete cell wall, inducing bacterial cell death. Quinolones specifically target bacterial gyrases 
halting bacterial DNA unwinding and thereby replication, causing bacterial death. Bacterial DNA-depen-
dent RNA-polymerases are targeted by rifampicin, which halts bacterial translation and functions as bac-
teriostatic agent. Translation of RNA to protein is targeted by several drugs: aminoglycosides (gentamicin 
and streptomycin), lincosamide (clindamycin), macrolides (clarithromycin and erythromycin) and tetracy-
clines (tetracycline, tigecycline and doxycycline). The cytosolic bacterial membrane is targeted by colistin 
(polymyxin E), polymixin B and the previously mentioned host defense peptides, which all act bactericid-
ally. Finally, folic acid synthesis is inhibited by trimethroprim and sulfonamides, inhibiting the formation of 
bacterial DNA. (From Lewis et al Nature Reviews Drug Discovery 12, 371–387 (2013)
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picin inhibits biofilm formation (102). Several stages have been identified in S. aureus 
biofilm formation: attachment, adhesion, maturation and dispersion (Figure 1). During 
the maturation stage the production of exotoxins, such as alpha-toxin is enhanced. 
Immune-modulators such as CHIPS and SCIN are also up regulated at this stage. Dis-
persion of (clusters of ) cells from such matrices is the final stage of biofilm formation, 
by which metastatic infections may occur (49, 100). However, the exact kinetics of the 
production of virulence factors during biofilm formation remain unknown, especially 
in the early stages of biofilm formation, and more insight into the dynamics of these 
processes could influence our therapeutic options. These evasive behaviors of stressed 
S. aureus pose significant challenges, as relatively little is known of the exact status of S. 
aureus (during various phases of infections) in vivo.
 
figure 5: Modes of Antibiotic resistance
Alteration or modification of the antibiotic itself. β-Lactamases break open the β-lactam ring of penicillins, 
causing these types of antibiotics lose their function. Secondly, under pressure of the antibiotics, bacteria 
alter the target of these antibiotics, making bacteria no longer susceptible. For example, resistance to rifam-
picin occurs when the rpoB gene is mutated, which encodes the bacterial RNA-polymerase beta subunit, 
resulting in decreased binding affinity for rifampicin. Antibiotics targeting bacterial metabolic processes, 
such as sulfanomide, induce bacteria to acquire para-aminobenzoic acid, an alternative for the synthesis of 
folic acid, and thereby become resistant. Finally, by reducing the accumulation of antibiotics and increasing 
efflux or decreasing influx of antibiotics, bacteria can become more resistant. For these determinations, a 
standardized broth is used, which may not mimic the situation encountered in vivo. Recent examples of 
bacterial antibiotic resistance are New Delhi Metallo-Betalactamase (NDM) (104) and Extended Spectrum 
Beta-lactamases (ESBL) (105) in Gram-negative bacteria. Methicillin resistance in Staphylococcus aureus 
(MRSA) (75) and vancomycin resistance in Enterococci (VRE) (106) are examples of potentially epidemic re-
sistance among Gram-positive bacteria (from: http://textbookofbacteriology.net/resantimicrobial_3.html, 
Todar’s Online Textbook of Bacteriology)
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aIM Of ThIS ThESIS:
The primary aim of the research described in this thesis was to gain more insight into 
host pathogen interaction between Staphylococcus aureus and the human host by 
specifically studying the IgG (subclass specific) humoral response against staphylococ-
cal virulence factors in humans with different interactions with S. aureus, the kinetics 
of the production of several of these immune modulators during biofilm formation, 
and finally, by studying the production of biofilm in staphylococcal bacteremia to gain 
better understanding of persistence of bacteremia. When the immune system fails to 
clear an infection, clinicians use antibiotics to treat infections. The secondary aim of 
this thesis was, therefore, to find antibiotics with truly novel modes of action directed 
against infections with multi drug resistant ESKAPE pathogens.
hOST PaThOgEn InTERaCTIOnS
The primary focus of research of this thesis was the pathogenesis of S. aureus infections. 
The humoral immune response can be used as a readout system indicating to which 
bacterial virulence factors the patient has been exposed and, thus, which antigens were 
expressed by the bacteria in vivo (3-6). By comparing these responses between differ-
ent groups of individuals, including carriers versus non-carriers, healthy controls versus 
infected patients, either acutely so or patients repeatedly or chronically infected ones, 
S. aureus virulence factors may be linked to certain carriage or disease states. This thesis 
aimed to increase our insight into the antibodies produced against various virulence 
factors in persons with varying levels of S. aureus exposure. New insights generated here 
will increase our understanding of the sequence of events during bacterial pathogen-
esis, and possibly facilitate the development of a vaccine, a preventive target that has 
remained elusive so far. Another important bacterial virulence factor is the switch of the 
growth mode from planktonic life to biofilm-associated life (8,9) (Figure 1). In vitro stud-
ies on pathogenic behavior of bacteria are generally performed in nutrient rich broths, 
facilitating rapid and exponential growth; such conditions are devoid of the stresses 
posed by the host’s innate and adaptive immune responses and of the stress induced 
by antibiotics. We present an in vitro model system which we posit to better mimic in 
vivo growth conditions of these pathogens. (47, 48). Indeed, S. aureus grows differently 
and expresses different virulence factors when their growth conditions are changed (47, 
48). I here studied the relationship between biofilm production and virulence factor 
production. Immune modulator production has so far only been described in mature 
biofilms, when the biofilm is already formed and viable, and recalcitrant to (immune or 
antibiotic) clearance. I showed that virulence factors, of which several were identified 
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in the previous research, are already produced by the bacteria early in the formation of 
biofilm. By better understanding the formation of biofilm and the virulence factors in-
volved, I aimed to develop new strategies for treatment and biofilm formation may even 
be prevented. I further studied the role of biofilm formation in S. aureus bacteremia, 
which is defined as the presence of viable bacteria in the bloodstream. Bacteremia can 
be classified as complicated or uncomplicated, identifiable by clinical markers including 
the persistence of fever and positive blood cultures for more than 72 hours after the 
initiation of appropriate treatment (45). In many cases blood cultures remain positive 
for multiple days despite appropriate parenteral antibiotic therapy (45). Patients with 
complicated infection have a significantly poorer prognosis compared to patients with 
uncomplicated infection (46). As complication status can only be definitively deter-
mined after 72 hours of directed therapy, I studied what factors, either bacterial or host 
associated, influence complication status. Early determination of complicated infection 
based on either bacterial or host factors could lead to improved treatment strategies, 
and better outcomes for SAB patients.
nOvEl anTIbIOTICS
If the pathogen is successful in evading the immune system, clinicians use antibiotics to 
treat infections. As a secondary goal, I aimed to generate novel targets for antimicrobial 
drug discovery. In this thesis, two possible leads were followed: first, actinomycetes were 
induced to produce novel compounds that have activity against multi-drug resistant ES-
KAPE pathogens by using novel culturing techniques. As actinomycetes are responsible 
for 60% of all antibiotics used in clinical practice today, mining them and inducing them 
to produce novel compounds is a promising strategy. Secondly, I tested derivatives of 
gramicidin S for toxicity and antimicrobial activity to facilitate their further development 
as novel therapies against multi-drug resistant pathogens. Developing novel therapeu-
tics with novel modes of action is essential to be able to continue treatment of patients 
in hospitals.
OuTlInE Of ThIS ThESIS:
In Chapter 2 we analyze several human serum collections for presence of IgG-antibodies 
directed against S. aureus virulence factors. I measure total IgG (IgGt), and subclass IgG1 
and IgG4 antibody responses directed against 40 S. aureus antigens in serum obtained 
from patients suffering from four different types of staphylococcal infection from three 
distinct geographical locations. I also determine IgGt, IgG1 and IgG4 responses against 
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the same 40 virulence factors in sera obtained from Dutch healthy carriers, Dutch non-
carriers and Dutch patients suffering from epidermolysis bullosa, a chronic skin condi-
tion associated with S. aureus colonization and infection. IgG4 responses, indicative of 
repeated and prolonged exposure, are found in all human sera, but these responses are 
only directed against a restricted panel of 17 virulence factors: alpha toxin, CHIPS, ETA 
and B, HlgB, IsdA, LukD, E, F and S, SCIN, SEC, SSL1, 3, 5 and 9 and TSST-1. I subsequently 
studied the production of virulence factors during biofilm formation of a selection of 
these immune modulators: alpha toxin, CHIPS, SCIN and TSST-1 from this cohort, but we 
also measured FlipR and Nuc. These virulence factors are measured in developing bio-
films and described in Chapter 3. Bacteria grow in biofilms to evade the host immune 
system, but immune modulator production has only been described by late phase expo-
nentially growing cells or mature biofilms, leading to the following question: how does 
S. aureus evade the immune system long enough to attain maturity, if it only produces 
immune modulators when they are already safe in a mature biofilm? I further studied 
biofilm in the context of bacteremia: biofilm could be a key player in (persistence of ) 
bacteremia, as discussed in Chapter 4. S. aureus bacteremia can have a complicated 
(over 72 hours) or uncomplicated (under 72 hours) course. This chapter focuses on host 
factors and bacterial factors, such as biofilm formation (under antibiotic pressure), that 
may play a role in determining the complication status of this bacteremia.
Actinomycetes are already a valuable source of antibiotics: approximately 60% of all 
clinically used antibiotics originate from this group of bacteria. Chapter 5 focuses on 
the use of different growth media with actinomycetes strains from remote locations to 
induce the production of novel antimicrobials, with potent activity and broad spectrum 
against multi-drug resistant ESKAPE pathogens. Chapter 6 discusses small antimicrobial 
peptide antibiotics gramicidin S, which was already discovered in the 1940, but was 
found too toxic for systematic usage. Here I design new derivatives suitable for systemic 
use by changing its peptide structure, with the aim of retaining antimicrobial activity 
but reducing toxic side effects. In Chapter 7, I summarize and discuss the results of our 
studies.
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abSTRaCT
IgG4 responses are considered indicative for long-term or repeated exposure to particu-
lar antigens. Therefore, studying IgG4-specific antibody responses against Staphylococ-
cus aureus might generate new insights into the respective host-pathogen interactions 
and the microbial virulence factors involved. Using a bead-based flow-cytometry assay, 
we determined total IgG (IgGt), IgG1 and IgG4 antibody responses to 40 different S. 
aureus virulence factors in sera from healthy persistent (non) nasal carriers and patients 
with various staphylococcal infections from three distinct countries. IgGt responses 
were detected against all tested antigens. These were mostly IgG1 responses. In con-
trast, IgG4 antibodies were detected to alpha toxin, CHIPS, ETA and B, HlgB, IsdA, LukD, 
E, F, and S, SCIN, SEC, SSL1, 3, 5 and 9 and TSST-1 only. Large inter-patient variability was 
observed, and the type of infection or geographical location did not reveal conserved 
patterns of response. As persistent S. aureus carriers trended towards IgG4 responses 
to a larger number of antigens than persistent non-carriers, we also investigated sera 
from patients with epidermolysis bullosa (EB), a genetic blistering disease associated 
with high S. aureus carriage rates. EB patients responded immunologically to signifi-
cantly more antigens than non-carriers and trended towards even more responses than 
carriers. Altogether, we conclude that the IgG4 responses against a restricted panel of 
staphylococcal antigens consisting primarily of immune modulators and particular tox-
ins indicate important roles for these virulence factors in staphylococcal pathogen-host 
interactions, such as chronicity of colonization and/or (subclinical) infections.
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InTROduCTIOn
Staphylococcus aureus is responsible for more deaths annually in the USA than HIV/AIDS 
and tuberculosis combined (1), (2). S. aureus infections can range from mild skin and soft 
tissue infections (3) to more severe bacteremia (4) and osteomylitis (5), and they can be 
resolving or chronic. S. aureus is able to persistently adhere to the anterior nares of 30% 
of all humans, while in the remaining population this opportunistic pathogen is never 
or only incidentally detectable (6), (7), (8), (9). It has long been established that nasal 
colonization is associated with an increased chance of infection (10), (11), (12). In epi-
dermolysis bullosa (EB) patients, a genetic blistering disease that leaves patients highly 
susceptible to S. aureus colonization, nasal carriage rates of 50-80% have been reported, 
and 75-100% of their skin wounds are culture positive for S. aureus (13), (14), (15), (16), 
(17). Interestingly, although EB patients interact frequently with S. aureus, bacteremia is 
seldom reported in these patients (18).
Numerous S. aureus virulence factors have been identified (19), (20), (21), (22), (23), 
(24). However, the precise roles of most of these virulence factors during colonization 
and pathogenesis in humans have remained largely unclear, as determination of in vivo 
expression of bacterial virulence factors is technically challenging. Burian et al. showed 
by a qPCR analysis on samples from 4 persistent nasal carriers that the adhesin genes 
clfB, fnbA and isdA, and the immune modulator gene chp are expressed in vivo (25). In an 
artificial inoculation study, clfB proved essential for colonization in humans (26).
Instead of direct in vivo detection of virulence factors, the human antibody response 
can be used as an indicator for the in vivo expression of S. aureus virulence factors 
(27), (28), (9), and (29). Our group has published several reports on human immune 
responses to S. aureus. Persistent carriers have higher IgG titers directed to TSST-1 than 
persistent non-carriers (9). During bacteremia, patients developed significantly higher 
IgG responses than age-matched uninfected controls. These responses were directed 
to the immune modulators SSL1 and 5, and SCIN, and the toxins gamma-hemolysin B 
and leukocidin F (28), indicating that these virulence factors are produced in vivo dur-
ing infection. Furthermore, Algerian patients suffering from various S. aureus infections 
showed higher IgG responses directed to ETA, ETB, HlgB, LukD, E and S, SEA, SEE, SEH 
and SEM compared to controls (30).
When IgG responses are studied usually only the total IgG (IgGt) levels are measured. 
However IgGt is composed of 4 different subclasses, each with distinct biological 
functions and induction patterns (31). IgG1 responses, which represent approximately 
60% of IgGt, are primarily directed against proteins. They are induced within a week 
of infection, peak between one and two weeks and resolve after two to three weeks 
(32). IgG1 functions as a pro-inflammatory signal inducing Fc receptor-mediated and 
complement-mediated phagocytosis. IgG4 antibodies, which represent approximately 
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5% of IgGt, are produced after prolonged exposure, typically taking months or years 
(33), (32). IgG4 antibodies are reported to not or weakly activate complement via the 
classical pathway in contrast to IgG1 antibodies. Furthermore IgG4 antibodies are cor-
related with tolerance after allergy (31), (34), (33), they have a low binding affinity to 
Fc receptors on phagocytes, and IgG4-mediated opsonophagocytosis is reportedly less 
efficient than IgG-mediated opsonophagocytosis (35).
The aim of our present study was to determine whether analysis of IgGt, IgG1 and 
IgG4 directed against virulence factors of S. aureus could help elucidate the location 
and duration of exposure to these bacterial factors during infection. Using a previously 
developed bead-based flow-cytometry assay (xMap, Luminex) (9, 28) we measured 
total IgGt, IgG1 and IgG4 antibody responses directed to 40 different S. aureus virulence 
factors in sera from patients suffering from 4 different S. aureus infections originating 
from 3 geographical locations. In addition, we studied the humoral responses in sera 
from healthy carriers, non-carriers and EB patients with well documented S. aureus 
colonization status, all from the Netherlands. We looked for infection-specific responses 
to the virulence factors of S. aureus and the IgG subclasses involved. Furthermore, we 
determined IgG subclass/IgG total ratios to determine the contribution of the different 
subclasses to the IgGt response to S. aureus. By studying these responses, we obtained 
new insights on the (chronicity of ) human exposure to S. aureus and the virulence fac-
tors involved, which have implications for anti-staphylococcal vaccine development.
MaTERIalS and METhOdS
Serum from healthy volunteers and patients
We included serum from 19 Dutch persistent carriers and 26 Dutch persistent non-
carriers (9). An individual was defined as a persistent nasal carrier when 3 out of 3 nasal 
swabs taken 2 weeks apart were positive and as a persistent non-carrier when all swabs 
were negative for S. aureus (9). All swabs were processed as described by Nouwen et al. 
(36). In addition, we included sera isolated from 10 Dutch patients with bacteremia at 
diagnosis and 1, 2 and 3 weeks after diagnosis (37), and sera from 13 EB patients (18). 
Furthermore, serum samples were included from 10 patients without S. aureus-related 
infections admitted to the Mustapha Pacha Hospital, Algiers, Algeria and patients with 
either S. aureus skin infections (n=10), joint infections (n=10), or respiratory infections 
(n=10) 14 days (range 7-34) after strain identification (30). Serum samples were collected 
from 60 healthy Sudanese volunteers at the University of Khartoum and 25 Sudanese 
citizens with S. aureus skin infections. The Medical Ethics Committee in the Erasmus 
Medical Centre approved the study (MEC-2007-106) for work performed in Rotterdam, 
the Netherlands. The Medical Ethics Committee of the University Medical Center Gron-
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ingen approved the collection of sera from EB patients (approval no. NL27471,042,09). 
Local ethical committees reviewed and approved both Algerian (30) and Sudanese 
studies. All serum donors provided written informed consent.
antigens
The antigens used were isolated upon over-expression and comprised 10 cell wall-
associated and 30 secreted S. aureus antigens: Alpha toxin (A-Tox); chemotaxis inhibi-
tory protein of S. aureus (CHIPS); clumping factors A and B (ClfA and ClfB); extracellular 
fibrinogen-binding protein (Efb); exfoliative toxins A and B (ETA and B); fibronectin 
binding proteins A and B (FnbpA and B); γ hemolysin B (HlgB); iron-responsive surface 
determinants A and H (IsdA and H); leukocidin (Luk) S-PV, LukF-PV, LukD-PV, and LukE-
PV; S. aureus surface protein G (SasG); staphylococcal complement inhibitor (SCIN); 
serine-aspartate dipeptide repeat protein D and E (SdrD and SdrE); staphylococcal en-
terotoxins A-E, G-J, M-O, Q, and R (SEA - SEE, SEG - SEJ, SEM - SEO, SEQ, SER); staphylococ-
cal superantigen-like proteins 1, 3, 5, 9, and 11 (SSL1, SSL3, SSL5, SSL9, and SSL11) and 
toxic shock syndrome toxin 1 (TSST-1) (30, 38-50) (Table S1). Besides S. aureus antigens, 
IgGt (16-16-090707, Athens Research & Technology, Athens, Georgia, USA), IgG1 (16-16-
090707-1M, Athens Research), and IgG4 (16-16-090707-4M, Athens Research) were used 
to assess whether cross-reactivity existed between subclass-specific detection antibod-
ies. Beads without antigens were used as a negative control.
Measurement of anti-staphylococcal antibodies
IgGt antibodies in serum directed against the different S. aureus antigens were simulta-
neously quantified in a multiplex assay using a bead-based flow cytometry technique 
(xMap; Luminex Corporation), following previously described protocols (9), (51), (28). 
The Median Fluorescence Intensity (MFI) was determined as the median fluorescence 
of 100 beads and is used as measure of immunoglobulins bound to the antigens 
coupled the beads. IgGt was detected using Goat-Anti-Human IgG-PE from Jackson 
Immuno Research (Newmarket, Suffolk, United Kingdom). Subclass-specific responses 
were determined using monoclonal mouse anti-human-IgG1 of IgG1 subclass (05-3300, 
Zymed, Paisley, United Kingdom), or monoclonal mouse-anti-human-IgG4 of IgG1-k 
subclass (05-3800, Invitrogen, Paisley, United Kingdom). All subclass-specific antibodies 
were detected using IgG Goat Anti Mouse-PE (Abcam, Cambridge, United Kingdom). To 
assess cross reactivity between subclass-specific detection antibodies, IgG1 and IgG4 
were coupled to microspheres and incubated with the anti-IgGt, anti-IgG1 or anti-IgG4 
detection antibodies. As a positive control, pooled serum from 36 healthy volunteers 
was used.
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data analysis
Coefficient of variation (CV) values were determined by dividing the standard deviation 
of the measurements by the mean of the measurements. Values with a CV exceeding 
25% were excluded from further analysis. Control beads without protein coupled were 
included in each experiment to determine non-specific binding. The non-specific MFI 
values were subtracted from the antigen-specific results. Groups were compared using 
a Mann Whitney U test in IBM SPSS Statistics 20. Bonferroni correction was applied to P 
values to correct for multiple testing. The ratios were calculated by dividing the IgG (sub-
class) signal by the IgGt signal. The median of these ratios is shown in the (supplemental) 
figures, to determine subclass-specific contributions to the IgGt signal and to facilitate 
inter-group comparisons. An increase of signal in the bacteremic patients was defined 
as a ratio >1 for all time points and this ratio was calculated by dividing the signal of the 
later time points by the first time point.
RESulTS
validation of Igg subclass-specific luminex assay
To compare S. aureus antigen-specific IgG levels in serum samples, the bead-based 
multiplex Luminex assay was applied as described previously (28), (30), (52), (51), and 
the level of cross-reactivity between our detection antibodies for IgG1 and IgG4 and 
coupled antibodies was assessed by incubating a bead mixture containing IgGt, IgG1 
and IgG4 with either the anti-IgG1 antibody or the anti-IgG4 antibody. IgG1 antibod-
ies showed (291/10759)*100=2.7% cross-reactivity to IgG4-coupled antibodies. IgG4 
antibodies gave (65/16096)*100 = 0.4% cross reactivity to the coupled IgG1 antibodies. 
Thus, less than 5% cross reactivity of the detection antibodies was observed. The CV 
values ranged between 5% and 37% and, on average 20% of all measurements had to 
be excluded for exceeding the CV value cut-off of 25%, comparable to previous reports 
(9, 28, 51-55). High CV’s were measured mainly for low MFI signals in the IgG4 Luminex 
assays (<1000 MFI). In all determinations done here, human pooled serum gave median 
MFI values of 2883 (range 49 – 15655) for IgGt, of 794 (range 6 – 16700) for IgG1 and 73 
(range 0 – 9379) for IgG4. Taken together, we conclude that our Luminex assay is suitable 
to determine both total and subclass-specific responses against S. aureus antigens.
Iggt, Igg1 and Igg4 anti-staphylococcal antibodies in an algerian discovery 
cohort
To expand our previous IgGt data (30), the IgGt, IgG1 and IgG4 responses directed 
against 40 S. aureus antigens were determined in a discovery cohort of Algerian patients 
with either S. aureus joint (10 patients), respiratory (10 patients) or skin infections (10 
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patients) and 10 Algerian control patients. Significant differences in IgGt, IgG1 and IgG4 
between groups are shown in Table S2A.
IgG subclass / IgG total ratios were calculated to determine the contribution of the 
different subclasses to the IgGt response to 40 different S. aureus antigens. IgG1, which 
constitutes approximately 60% of IgGt (31), (32), showed responses directed to almost 
all tested S. aureus antigens, similar to results obtained for IgGt (Fig. 1A). Strikingly, in all 
groups we observed IgG4 responses against a restricted panel of antigens consisting 
of alpha toxin, CHIPS, ETA and B, HlgB, IsdA, LukD, E, F, and S, SCIN, SEC, SSL1, 3, 5 and 
9, and TSST-1 (Fig.1B), with only few individuals showing high responses against alpha 
toxin, ETB, IsdA, SEC, SLL3 and 5 (Fig. 1, A and B). These S. aureus virulence factors are 
almost all secreted immune-modulators. No defined patterns of IgG1 or IgG4 responses 
were observed for the different types of S. aureus infection. Skewed ratios for IgG4/IgGt 
for SER and SSL11 in joint infections and SEB in respiratory infections were caused by 
single patients with high responses. The interquartile ranges of all ratios are given in Fig. 
S1, A and B.
anti-staphylococcal Iggt, Igg1 and Igg4 antibodies in an expanded cohort of 
Sudanese patients with S. aureus skin infections and healthy controls
To study the antibody responses in skin infections in a larger cohort from a different 
geographical setting, we measured the relative IgGt, IgG1 and IgG4 levels in sera of 25 
Sudanese patients with S. aureus skin infections and 60 healthy Sudanese volunteers. 
For this purpose, the same antigens were used as in the above analysis of the Algerian 
serum sets (except SasG and SEB). Significant differences in the IgGt, IgG1 and IgG4 lev-
els between groups are shown in Table S2B. IgG1 responses against all tested antigens 
were detected both in sera from patients and healthy controls, similar to the Algerian 
discovery cohort (Fig. 2A). Intriguingly, also for the Sudanese serum sets, IgG4 antibody 
responses were detected against alpha toxin, CHIPS, ETA, ETB, HlgB, IsdA, LukD, E, F and 
S, SCIN, SEC, SSL1, 3, 5, 9 and 11 and TSST-1 (Fig. 2B). Interquartile ranges of all ratios are 
given in Fig. S2, A and B. Altogether, the sera from Algerian and Sudanese patients and 
the respective control sera revealed IgG4 responses to a similar sub-set of the tested 
antigens.
Induction of Iggt, Igg1 and Igg4 anti-staphylococcal antibodies during 
progression of bacteremia
As previous reports have shown that anti-staphylococcal IgGt responses reach peak 
values after a median of 21 days after diagnosis of bacteremia (range 5-50) (37), (28), 
we studied the contribution of IgG1 and IgG4 to the increase of IgGt. We determined 
the IgGt, IgG1 and IgG4 levels to 40 S. aureus antigens in serum samples taken at acute 
phase, 1, 2 and 3 weeks after diagnosis of bacteremia in 10 Dutch patients. For the last 
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 figure 1: Ratios of Igg1/Iggt and Igg4/Iggt in sera from 40 algerian volunteers.
A: Median of the ratios of IgG1/IgGt in sera from 10 Algerian patients with either joint (dark grey), respira-
tory (light grey bars) or skin (white bars) S. aureus infections, and sera from 10 Algerian control patients 
without S. aureus infection (black bars). On the x-axis the 40 tested S. aureus antigens are listed. The y-axis 
shows the median of the ratios of the IgG1/IgGt signal for each particular antigen. Dotted lines mark 60% 
(the reported ratio of IgG1/IgGt), 30% (50% of this reported value) and 90% (150% of this reported value)
B: Same as for Figure 1A, but showing the IgG4/IgGt ratios. The dotted line marks 5%, which is the reported 
ratio of IgG4/IgGt.
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 figure 2: Ratios of Igg1/Iggt and Igg4/Iggt in sera from 25 Sudanese patients with S. aureus skin 
infection and 60 healthy Sudanese volunteers.
A: Median of the ratios of IgG1/IgGt in sera of 25 Sudanese patients with S. aureus skin infection (white bars) 
and 60 Sudanese volunteers (black bars). On the x-axis the 38 tested S. aureus antigens are listed (note that 
SasG and SEB were not included in this particular analysis). The y-axis shows the median of the ratios of the 
IgG1/IgGt signal for each particular antigen. Dotted lines mark 60% (the reported ratio of IgG1/IgGt), 30% 
(50% of this reported value) and 90% (150% of this reported value).
B: Same as for Figure 2A, but showing the IgG4/IgGt ratios. The dotted line marks 5%, the reported ratio of 
IgG4/IgGt.
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time point, 3 samples were not available. Antigens against which increased responses 
could be determined were counted. Indeed, the IgGt level was increased during the 
3 week observation period with bacteremic patients, specifically showing increased 
responses to 6-23 antigens (median 16.5) (Table S3, A and B). Patients showed increased 
IgG1 responses during the 3 week observation period to 1-21 antigens (median 11.5) 
(Table S3,A and B). Ratios of IgG1/IgGt were calculated for antigens showing an increase 
in IgGt, IgG1 and IgG4 signal (Fig. 3A). Notably, the IgG1/IgGt ratios did not vary over 
time, showing that an increase in IgGt was mainly caused by an increase in IgG1. The 
IgG4 responses were poorly conserved between patients and, also in these serum sets, 
these responses were only detectable in a restricted panel of antigens, namely: alpha 
toxin, CHIPS, ETA and B, HlgB, IsdA, LukD, LukE, LukF, LukS, SCIN, SEC, SSL1, 3, 5 and 9, 
and TSST-1 (Fig. 3B). During a period of 3 weeks after the onset of bacteremia, patients 
showed increased IgG4 responses to 0 – 13 antigens (median 6.5) (Table S3,A and B). 
Ratios of IgG4/IgGt were calculated for antigens showing an increase in IgGt, IgG1 and 
IgG4 signal. This showed that the IgG4/IgGt ratios did not change over time. Thus, the 
IgG4 signals increased together with IgGt signals. Interquartile ranges of all ratios are 
given in Fig. S3, A and B.
anti-staphylococcal Iggt, Igg1 and Igg4 antibodies in a cohort of dutch 
volunteers with long-term S. aureus exposure
To determine whether carriers and non-carriers differed in their immune responses 
against S. aureus, serum was collected from 19 persistent nasal carriers and 26 persistent 
nasal non-carriers. Significantly higher IgGt levels directed to TSST-1 were measured 
for carriers than non-carriers. Significantly higher IgG1 levels directed to TSST-1 were 
measured for carriers than non-carriers. Finally, carriers showed significantly higher IgG4 
levels directed to TSST-1 than non-carriers (Table S3C). Also, the numbers of antigens 
to which responses were detectable were determined. Non-carriers showed IgGt and 
IgG1 responses to similar numbers of antigens as carriers, but trended towards fewer 
IgG4 responses (mean of 2.68, range 0-11) than carriers (mean 2.95, range 0-12) (Fig. 4). 
Based on these findings, we studied sera of EB patients to determine whether long-term 
exposure to different S. aureus types influenced the numbers of antigens to which IgG4 
responses are elicited. Previous studies had shown that up to six different types of S. 
aureus could be cultured from individual patients with EB (18) (16), (17). IgGt showed 
similar levels compared to a previous report (18). EB patients differed significantly from 
non-carriers in IgGt responses to ClfA and in IgG4 responses SCIN. EB patients differed 
significantly from carriers in IgGt responses to ClfA and IgG4 responses to SCIN.
Notably, while IgG4 responses to the same restricted panel of antigens were observed 
in EB patients as for the other groups described above, the EB patients showed IgG4 
responses to significantly more antigens than non-carriers (mean 5.38 , range 1-11 
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figure 3: Ratios of Igg1/Iggt and Igg4/Iggt in sera from 10 dutch bacteremic patients during dis-
ease progression
A: Median of the ratios of IgG1/IgGt in 10 Dutch bacteramic patients during disease progression. White 
bars, IgG1/IgGt ratio at diagnosis. Light grey bars, IgG1/IgGt ratio 1 week after diagnosis. Dark grey bars, 
IgG1/IgGt ratio at 2 weeks after diagnosis. Black bars, IgG1/IgGt ratio 3 weeks after diagnosis. On the x-axis 
the 17 antigens with increase in either IgGt, IgG1 and IgG4 signal are depicted. The y-axis shows the median 
of the ratios of the IgG1/IgGt signal for each particular antigen. The dotted lines mark 60% (the reported 
ratio of IgG1/IgGt), 30% (50% of this reported value) and 90% (150% of this reported value).
B: Same as for Figure 3A, but showing the IgG4/IgGt ratios. The dotted line at 5% marks the reported ratio 
of IgG4/IgGt.
40 Chapter 2
versus mean 2.68, range 0-11, p=0.0013), and they showed a trend towards responding 
to more antigens than S. aureus carriers (mean 5.38, range 1-11 versus mean 2.68, range 
0-12, p=0.1275) (Fig. 4). This implies that the intense exposure of EB patients to different 
S. aureus types results in increased numbers of staphylococcal antigens to which IgG4 
responses will develop.
dISCuSSIOn
In the present study, we investigated the IgG subclass-specific responses directed 
against 40 different S. aureus virulence factors. These responses were measured in the 
sera from patients from 3 geographical locations suffering from 4 different types of S. 
aureus infections. In addition, we studied the humoral response in sera from healthy hu-
man carriers, non-carriers and patients suffering from epidermolysis bullosa, with well 
documented S. aureus colonization status, to gain more insights into the bacterial fac-
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figure 4: number of S. aureus antigens to which Igg4 responses were detectable in sera from 19 
dutch carriers (circles), 26 dutch non-carriers (squares) and 13 dutch Eb patients (triangles)
Dutch carriers showed a trend to IgG4 serum responses to more antigens than non-carriers (mean 2.95 , 
range 0-12 versus mean 2.68, range 0-11, p=0.0339). EB patients showed IgG4 responses to significantly 
more antigens than non-carriers (mean 5.38, range 1-11 versus mean 2.68, range 0-11, p=0.0013), and 
trended towards more IgG4 responses than carriers (mean 5.38 , range 1-11 versus mean 2.98, range 0-12, 
p=0.1275). Mean and SEM are plotted.
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tors involved in pathogen-host interaction. Total IgG responses were detected against 
almost all antigens in our panel, in agreement with our previous analyses (9, 30, 37), 
(28). IgGt responses consisted mostly of IgG1 responses, consistent with the previously 
reported finding that IgG1 composes of 60% of IgGt (31), (32). In contrast, in all serum 
sets analyzed here we observed that IgG4 antibodies, which represent approximately 
5% of the IgGt response, were detected to a core panel of S. aureus antigens consisting 
almost exclusively of secreted immune modulators, irrespective of the type of human-
pathogen interaction.
IgG4 responses were observed against alpha toxin, CHIPS, ETA and B, HlgB, IsdA, LukD, 
E, F and S, SCIN, SEC, SSL1, 3, 5 and 9, and TSST-1. These immune modulators interact with 
both the human innate and acquired immune systems on many levels. Innate responses 
affected are chemotaxis, which is modulated by CHIPS (56), extravasation, modulated 
by SSL3 and SSL5 (57), complement activity, which is modulated by SCIN (58), and TLR2 
signaling, which is affected by SSL3 (59). SEC and TSST-1 modulate adaptive responses 
by non-antigen directed binding of MHC II with T cell receptors, resulting in polyclonal 
T cell activation (60). Neutrophils are targeted by the γ-hemolysin family (HlgB, LukD, E, 
F and S) (20), desmosomes are targeted by exfoliative toxins (ETA and B) (61), and alpha 
toxin lyses mononuclear immune cells and platelets (62). SSL9 binds to monocytes and 
dendritic cells, and it blocks the complement system (63, 64), and no clear function has 
thus far been described for SSL1. Interestingly, patterns of IgG4 response varied exten-
sively between volunteers, indicating that each person is exposed to different virulence 
factors and/or reacts differently. The different exposure to virulence factors could be 
explained by the fact that various genetic backgrounds of S. aureus contain different sets 
of virulence factors and variation may also be due to differences in regulators or gene 
expression in various strains (65), (29), (66), (67), (68), (69), (24).
IgG4 responses were found to be directed against more different antigens in EB 
patients than in healthy non-carriers. EB patients are highly susceptible to blistering 
upon minor trauma due to mutations in structural proteins of the epidermis and the 
epidermal-dermal junction. Most likely as a consequence of their fragile skin, 62% to 
75% of these patients are nasal S. aureus carriers. EB patients with chronic wounds show 
higher carriage rates than patients without chronic wounds (16), (18). Importantly, S. 
aureus wound colonization was detected in 92% of the EB patients with chronic wounds 
and 69% of the patients without chronic wounds (13), (16). Serial sampling of three 
wounds, the left and right anterior nares, and the throat revealed that 58.3% of the EB 
patients with chronic wounds and 43.5% of the EB patients without chronic wounds 
carried alternating S. aureus types over a period of ~2 years and, during this period, 
the same S. aureus type was only encountered in 42.5% of all sampled patients (17, 
18) (16),(70). This suggests that these patients were exposed to diverse staphylococcal 
virulence factors over a prolonged period of time. Accordingly, our present IgG4 data 
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indicate that repeated exposure to S. aureus in EB patients has led to IgG4 responses 
directed against more different staphylococcal antigens, although we cannot exclude 
that other forms of (previous) exposure might result in the development of IgG4. Intrigu-
ingly, our IgG4 data indicate a chronic and repeated exposure for all humans to S. aureus, 
and indicated that repeated exposure as in EB patients leads to higher levels of IgG4 
responses directed against more antigens than is the case in healthy volunteers. Not all 
staphylococcal isolates produce all of the virulence factors tested in the present study, 
and it therefore seems likely that some of them have a higher potential to elicit an IgG4 
response than others. Importantly, the presence of IgG4 levels against S. aureus antigens 
in human individuals may be an indication of past (chronic) or repeated exposure, pos-
sibly in the form of a-symptomatic, self-limiting infections or colonization (33), (32).
IgG4 is important in neutralizing antibody responses during tolerance after allergy 
(34), (71), vaccine development (72) and immune therapy (73). The increased interest 
in IgG4 is predominantly caused by the fact that IgG4 antibodies activate the immune 
system to a lesser degree by Fc receptor-mediated and complement-mediated phago-
cytosis than other IgG subclasses, making IgG4 ideal for passive immunization therapies. 
Our finding that EB patients have the widest spectrum of IgG4 responses, while being 
fairly resistant to bacteremia may prove interesting clues for further vaccination re-
search: possibly new vaccination strategies should induce neutralizing IgG4 antibodies 
by repeated exposure, although a protective role of other adaptive immune responses 
cannot be excluded.
The findings we report here were generated in several cohorts, each from distinct 
geographical locations. As with many clinical studies, acquiring sufficient samples and 
finding appropriately matched controls is challenging, laborious and time-consuming. 
Therefore, we performed an explorative analysis with descriptive statistics based on 
study cohorts that were relatively small. Accordingly, no power analysis could be done 
prior to measurement. In this respect, it has to be noted also that previous reports have 
shown large inter patient variability (9, 19, 28, 30, 37). Nevertheless, we still observed 
the restricted panel of antigenic immune modulators to which IgG4 responses were 
mounted in all cohorts analyzed. This observation that IgG4 responses are mounted to 
a restricted panel of secreted immune modulators of S. aureus is novel and therefore 
of value to report. Differences between non-carriers and carriers with respect to the 
number of antigens responded to, as shown in Figure 4, reach significance without 
correction (p < 0.05), but do not remain significant after the Bonferroni correction (p 
< 0.0167). We observe a clear trend in the number of antigens showing IgG4 responses 
and exposure to S. aureus, but larger longitudinal follow-up studies based on power 
analyses and initial results will be needed to further substantiate these findings.
To the best of our knowledge, this is the first report on IgG4 responses directed to 
S. aureus antigens. As we found little cross-reactivity between the different subclass-
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specific detection antibodies, we conclude that our Luminex assay is robust, and has 
potential for application with other clinically relevant pathogens. Lastly, our study 
demonstrates a remarkable variation in the composition of the human subclass-specific 
antibody responses to various antigens of S. aureus, predominantly secreted immune 
modulators. This has been consistently observed since the start of measuring such 
antibodies and is fully in line with the outcomes of our previously published analyses 
(9, 19, 28, 30, 37). Our present data suggests that there is widespread (asymptomatic) 
exposure to this S. aureus in the community and this applies to all groups studied here, 
from infected patients to persistent nasal non-carriers. We therefore hypothesize that 
interactions between humans and S. aureus occur extensively and repeatedly and are 
even more diverse than currently appreciated. This might have major implications for 
research on the respective host-pathogen responses in vivo and for the development of 
immunotherapeutic strategies such as active and passive vaccination.
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abSTRaCT
Immune modulators have been reported to be produced by mature biofilms and dur-
ing different stages of planktonic growth of Staphylococcus aureus (S. aureus). Little is 
known about their production during the early stages of biofilm formation, raising the 
following question: how does S. aureus protect itself at these stages from the innate im-
mune responses? Therefore we determined the expression of the immune modulators 
Chemotaxis inhibitor Staphylococcal protein (CHIPS), Staphylococcal complement in-
hibitor protein (SCIN), Formyl peptide receptor-like 1 inhibitor (FLIPr), Gamma-hemolysin 
component B (HlgB), Leukocidin D, E, and S (LukD, LukE and LukS) and Staphylococcal 
Enterotoxin A (SEA) during in vitro biofilm formation in Iscove`s Modified Dulbecco`s 
Medium (IMDM) at different time points using a competitive Luminex assay and Mass 
Spectrometry. With both methods we demonstrated the presence of immune modula-
tors SCIN and CHIPS already during the early stages of biofilm formation. Using green 
fluorescence protein (GFP) promoter fusion technology, we also confirmed scn and to 
lesser extent of chp gene transcription during the early stages of biofilm formation. 
Further, we were able to demonstrate that SCIN could inhibit human complement acti-
vation by early biofilm. Our in vitro data indicate that S. aureus is able to modulate the 
innate immune system already during the early stages of biofilm formation.
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InTROduCTIOn
Biofilms are reported in 80% of all bacterial infections (1) and they are composed of 
clusters containing bacteria with heterogeneous metabolic activity (2-5). These bacterial 
clusters are embedded in a matrix composed of extracellular DNA (eDNA), proteins and/
or polysaccharides from endogenous and exogenous origin (6). Staphylococcus aureus 
(S. aureus) is well-known for its ability to form biofilms causing a broad range of biofilm 
related infections, including chronic osteomyelitis (7, 8), endocarditis (9), chronic wound 
infection (10, 11) and infections of indwelling medical devices (11). S. aureus biofilm-
related infections are of concern as they are associated with treatment failure and can 
act as persistent foci of infections, even after administration of adequate antibiotic 
therapy (1, 12). The fact that host immune responses and antibiotics penetrate poorly 
into the biofilms (13) and the presence of bacteria with low metabolic activity within 
the biofilm (3) lead to reduced treat-ability of these staphylococcal biofilm-associated 
infections.
During the early phase of the maturation phase of biofilm formation the production of 
immune modulators like SCIN and CHIPS has been ascertained (2). CHIPS and SCIN are 
known to be produced by planktonically growing S. aureus. These molecules can inhibit 
chemotaxis and subsequently phagocytosis by host immune cells (20). In this study we 
focused on the kinetics of immune modulator production and expression during early 
biofilm formation. Both in mature planktonic growth and in mature biofilms, S. aureus 
are known to produce immune modulators (2, 5). However, little is known about the 
early stages of biofilm formation, raising the question how sessile S. aureus in the first 
stage of biofilm formation escapes from the rapid response of the complement system 
and avoids opsonophagocytosis by neutrophils? To study this, we determined the pres-
ence of immune modulators CHIPS, SCIN, FLIPr, HlgB, LukE, LukD, LukS and SEA during 
the development of S. aureus biofilms and ascertained the effect of SCIN during the early 
stages of biofilm formation on complement activation.
MaTERIalS and METhOdS
bacterial strains and growth conditions
Clinical and laboratory S. aureus isolates were used in this study (Table 1). S. aureus 
confirmation was performed by Bactec (Becton Dickinson, Breda, the Netherlands) and 
Slidex Staph Plus (bioMerieux, Zaltbommel, the Netherlands) agglutination assays. All 
wild type S. aureus strains were grown on TrypticaseTM Soy Agar with 5% sheep blood 
(TSA) overnight at 37°C. The GFP containing strains were plated on TSA supplemented 
with 10 µg/mL chloramphenicol.
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Immune modulators’ genes determination
All strains were tested for the presence of immune modulator genes (scn, chp, flir, hlgB, 
lukE/D, luks and sea), according to a PCR protocol as described previously (23).
biofilm mass assessment
S. aureus cells grown overnight on TSA were suspended in 4 mL of 0.9% NaCl until OD660 
of 2.0 (± 0.2). One microliter of this suspension was added to 199 μL Iscove’s Modified 
Dulbecco’s Medium (IMDM) (Gibco, Bleiswijk, The Netherlands) in separate wells of a 
sterile flat-bottom 96-well polystyrene tissue culture plate (CELLSTAR® Greiner Bio-One, 
Oberosterreich, Germany) (24). Plates were incubated for 1, 2, 4 and 24 hours with 150 
rpm orbital shaking at 37°C. At these times points, formed biofilms in the wells were 
washed twice with 200 μL sterile water, air dried for 30 minutes and stained for 2 
minutes with 30 μL of 1% crystal violet (Sigma Aldrich, Zwijndrecht, The Netherlands). 
Excess crystal violet was removed by washing the plates 5 times with 200 µL of sterile 
water. Biofilms were dissolved in extraction solution containing 50% dH2O, 40% ethanol 
(Sigma Aldrich, Zwijndrecht, The Netherlands) and 10% acetic acid (Sigma Aldrich, Zwi-
jndrecht, The Netherlands). Finally, to determine the biofilm mass, the amount of crystal 
violet was measured spectrofotometrically at 490 nm with a micro-plate reader (Epoch 
2 Microplate reader, BioTek instrument, Inc., Winooski, VT, USA)
Production of immune modulators during S. aureus biofilm formation
To determine the production of immune modulators during biofilm formation of S. 
aureus, we cultured S. aureus M82 (ST20), M116 (ST239), RWW50 (ST8) and Newman as 
described above. We cultured the biofilm for either 1, 3 or 23 hours. At these time points 
Table 1: S. aureus strains used in this study.
S.aureus strain genetic 
background
description Source
M82 ST20 Isolated from a patient with an osteomyelitis infection in 
Indonesia
this study
M116 ST239 Isolated from a patient with an osteomyelitis infection in 
Indonesia
this study
RWW50 ST8 Clinical isolate from thecollection of MMIZ Erasmus MC, 
The Netherlands
W. van Leeuwen
Newman ST8 Laboratory strain  
8325-4 ST8 Wild type, GFP negative control A. Cheung
8325-4 GFP ST8 GFP positive control, Page repressor promoter cloned 
into EcoR1- Xbal site of pACL1484
S. Rooijakkers (30)
8325-4 scn-GFP ST8 scn Promoter cloned into EcoR1-Xba1 site of pACL1484 S. Rooijakkers (29)
8325-4 chp-GFP ST8 chp Promoter cloned into EcoR1-Xba1 site of pACL1484 S. Rooijakkers (29)
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we discarded the supernatant to remove all the non-attached or planktonic bacteria, 
washed the biofilm with 200 µL IMDM once and added 200 µL of fresh IMDM medium to 
wells and proceeded the incubation for 1 hour at the conditions described above. Sub-
sequently, we collected the supernatants, and labelled them as the 2nd, 4th, and the 24th 
hour biofilm supernatants. All individual supernatants from all time points produced by 
all different strains were filtered with 0.2 µm sterile filter (Whatman® GE Healthcare Life 
Sciences, Buckinghamshire, UK) and stored at -200 C until further determination. The 
supernatant collected after the 1st hour of incubation served as reference control.
Quantitation of biofilm derived immune modulators by competitive luminex 
assay
Collected supernatants, as described in the previous section, were three-fold diluted in 
PBS-BN buffer (PBS containing 1% bovine serum albumin [Sigma] and 0.05% sodium azide 
[pH 7.4]) to create a 1, 3, 9, 27 and 81 times dilution. The competitive Luminex assay was 
performed, as described previously (22, 25). Briefly, 30 µL of specified dilutions of biofilm 
derived supernatant were added to 30 µlL of 1/200 diluted HPS (human pooled serum) in 
U shape 96-well micro-plates (Greiner Bio-One, Oberosterreich, Germany) and incubated 
with continuous shaking (800 rpm) at 22 0C during 35 minutes on a Thermostat plus (Ep-
pendorf, Hamburg, Germany). Subsequently, 50 µL of these mixtures were directly used 
for the semi-quantitative determination of S. aureus biofilm derived immune modulators 
by Luminex bead based flow cytometry (Luminex Corporation). Essentially, this assay 
measures the level of unbound immune modulator specific IgG antibody remaining in the 
mixture after the 35 minutes of its incubation. For each immune modulator the fraction of 
specific IgG bound during the incubation can thus be calculated and taken to represent 
the amount of each immune modulator that was present in the supernatant. Antigens 
used in this assay were: Chemotaxis Inhibitor Staphylococcal Protein (CHIPS), Staphylococ-
cal Complement Inhibitor Protein (SCIN), Formyl Peptide receptor-like 1 inhibitor (FLIPr), 
Gamma-hemolysin component B (HlgB), Leukocidin D, E, and S (LukD, LukE and LukS) and 
Staphylococcal Enterotoxin A (SEA). All antigens were coupled to MagPlex beads (Luminex 
Corporation, Austin, TX, USA) according to the protocol as provided by the manufacture. 
The antigen concentration used for coupling was 2.5 µg per antigen per 106 MagPlex 
beads, as optimized previously (26). The beads were diluted to a final concentration of 
1,500 beads/µL. Negative control beads (beads to which no antigen was added during 
coupling) were included in all assays. The Luminex assay was performed as described 
previously (27) with one modification, we measured 50 beads per region, as optimized 
previously (26). All samples were analyzed on the Luminex BioPlex 200 System using Bio-
Plex® Manager software version 6.1 (Bio-Rad Laboratories, Inc., USA). All data are based on 
three independent experiments. The Median Fluorescence Intensity (MFI) values of these 
triplicates were averaged if the CV value was lower than 25% and the Standard Error of 
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the Mean (SEM) was calculated. Using the results of the competitive Luminex assay, log 
dose-response curves of assessed antigens were generated for all biofilm time-points and 
all S. aureus strains tested. The relative signal for the antigens tested in the test samples 
was calculated by comparing the Luminex signals of the test samples with the signal of the 
supernatant collected from the 1st hour of biofilm formation as our reference control. The 
reference control is defined as 1 unit per biofilm.
Identification of the immune modulators by mass spectrometry
One hundred microliters of supernatants derived from the 4th and the 24th hour biofilms 
formation of strains RWW50 (ST8) and Newman were precipitated at 1:10 v/v with ice-cold 
acetone (Sigma Aldrich, Zwijndrecht, The Netherlands) before further sample prepara-
tion. These mixtures were centrifuged for 10 minutes at 18407 x g at 4°C and pellets were 
washed twice with 50 µL of cold acetone (Sigma Aldrich, Zwijndrecht, The Netherlands). 
The final pellets were left to air dried for 30 minutes and subsequently dissolved in 10 
µL of 50 mM NH4HCO3 (Sigma Aldrich, Zwijndrecht, The Netherlands). Solution digestion 
was performed according to an adjusted protocol as described previously by Dekker, et al 
(28). Ten micro-liters of 0.2% Rapigest (Waters Corporation, Milford, MA) which was previ-
ously diluted in 50 mM NH4HCO3 (Sigma Aldrich, Zwijndrecht, The Netherlands) was added 
into 10 μL sample. This mixture then was reduced with 5 mM dithiothreitol (DTT) (Sigma 
Aldrich, Zwijndrecht, The Netherlands) at 60 °C for 30 minutes. After it cooling to room 
temperature, this mixture was alkylated in the dark with 15 mM iodoacetamide (Sigma 
Aldrich, Zwijndrecht, The Netherlands) at room temperature for 30 min, and digested 
overnight with 1:100 (w/w) trypsin (Promega, Madison, WI). Five percent trifluoroacetic 
acid (Sigma Aldrich, Zwijndrecht, The Netherlands) was added, to obtain a final concentra-
tion of 0.5% trifluoroacetic acid (pH<2). After 45 min of incubation at 37 °C the samples 
were centrifuged at 13,000 g for 10 minutes. Mass spectrometry and data analyses was 
performed as described elsewhere (28). Database search was performed against the 
uniprot_sprot_v151112 database (selected for Bacteria, 332280 entries).
Measurement of ChIPS and SCIn immune modulators transcription
To determine the transcription kinetics of immune modulators CHIPS and SCIN dur-
ing early biofilm formation, we selected GFP containing S. aureus strains (Table 1). In 
vitro biofilms were generated from all GFP-containing strains (Table 1) according to the 
method as described above. After 1 hour of incubation at 370C, the growth medium was 
replaced with 200 µL fresh IMDM medium. The biofilms were then incubated in FLUOstar 
Optima micro-plate fluorescence reader (BMG lab technologies) at 370C with 150 rpm 
periodic rotational shaking. The accumulation of fluorescence, as a measure of gene 
transcription, was determined automatically every 30 min over 20 hours of incubation 
with an excitation wave length of 485 nm, and emissions tracked at 520 nm with a gain 
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setting at 800. Median Fluorescence Intensity (MFI) of the chp promoter-GFP (CHIPS) and 
scn promoter-GFP (SCIN) were compared to the MFI of the GFP positive control and were 
depicted as relative percentage of the last. For visualization of fluorescence emission, 
biofilms were mounted onto a fluorescence microscope after 4 hours of biofilm forma-
tion. Before imaging, planktonic cells were removed by refreshing the medium.
Measurement of complement activation
We performed an ELISA inhibition assay for Human Complement 3a (C3a) and Comple-
ment 5a (C5a) to determine the ability of SCIN to modulate the activity of complement 
during the early stages of biofilm formation. Two hundred micro-liters of diluted human 
sera in IMDM (1:5000 for C3a assay and 1:50 for C5a assay) was added to 3 hours old bio-
films of the SCIN and CHIPS negative strain 8325-4 (Table 1) in the presence or absence 
of either 3 µg/mL recombinant SCIN (rSCIN) or recombinant CHIPS (rCHIPS). After 1 hour 
incubation at 370C, the supernatants were harvested and filtered with 0.2 µm sterile 
filter (Whatman® GE Healthcare Life Sciences, Buckinghamshire, UK) and processed 
according to the protocol of Human C3a and C5a ELISA KIT II (BD OptEIATM, San Jose, 
USA). C3a and C5a activation were measured at 450 nm (λ correction at 570 nm) using 
a Micro-plate reader (Epoch 2 Micro-plate reader, BioTek instrument, Inc., Winooski, VT, 
USA)
Statistical analysis
Statistical analysis was performed by using the Prism 5.0 package (Graph Pad Software, 
San Diego, CA, USA) and Microsoft Excel 2010. We used unpaired t-test for data analysis 
with ρ value ≤ 0.05 considered statistically significant. All experiments were indepen-
dently repeated at least three times and the mean with Standard Error of the Mean (SEM) 
or the median with range were depicted.
RESulTS
biofilm formation
Biofilm formation has been described as one of the important virulence factors of S. 
aureus. The ability to form biofilm was assayed by incubating our clinical isolates M82 
(ST20), M116 (ST239) and RWW50 (ST8) and the laboratory strain Newman and 8325-4 in a 
polystyrene micro-plate containing IMDM at 370C. All tested strains were able to produce 
detectable biofilms after 2 hours, and biofilms increased in a time dependent manner (Fig. 
1). However, despite being microscopically visible, we were not able to detect the 1st hour 
biofilms with the crystal violet staining procedure. Apparently, the biofilm formed during 
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the first hour contained either too few cells or were still loosely attached to the polystyrene 
surface and largely washed away during the staining procedure.
figure 1: biofilm formation of various S. aureus strains after 1, 2, 4 and 24 hours of incubation at 
37°C in IMdM. Incubation time points are plotted on the x-axis and the biofilm masses at 490 nm are plot-
ted on the y-axis. Error bars represent mean with range SE (n = 3).
detection of Immune modulator production of S. aureus biofilms by 
competitive luminex
Using the competitive Luminex assay (8, 22), we monitored the production of immune 
modulators CHIPS, SCIN, FLIPr, HlgB, LukD, LukE, LukS and SEA during the 2nd, 4th and the 
24th hours of biofilm formation. The presence of the immune modulator was calculated by 
determining the signal shift between Luminex signal of the 2nd, 4th or the 24th hour biofilm 
supernatant and the signal of the 1st hour supernatant (reference control) (Fig. 2A). Based 
on these calculations, the average immune modulator production per biofilm was gener-
ated as depicted in the Figure 2B-D. Four hours old biofilm of M82 (ST20), RWW50 (ST8) 
and Newman produced on average 1.3, 3.7 and 6.5 fold (ρ ≤0.05) (Fig. 2B) respectively, 
more CHIPS than the reference control. During the 4th hour of biofilm formation by strains 
M82(ST20), M116 (ST239), RWW50 (ST8) and Newman produced 1.3, 2.7, 2.3 and 12.7 units 
of SCIN per biofilm, respectively (Fig 2C). FLIPr was produced with averages of 1.3, 7.3 and 
5.3 units by strains M116 (ST239), RWW50 (ST8) and Newman, respectively, during the 4th 
hour of biofilm (Fig 2D). Other immune modulators such as HlgB, LukE, LukD, LukS and SEA 
were not produced by any of the tested strains (data not shown). Our ST239 strain lacks 
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the CHIPS gene, and M82 (ST20) does not have the FLIPr gene, therefore, these strains can 
be taken as negative controls for CHIPS and FLIPr respectively (Table 2).
figure 2: Production of the immune modulators ChIPS, SCIn and flIPR during the 2nd, 4th and 24th 
hour of biofilm formation of S. aureus M82 (ST20), M116 (ST236), RWW50 (ST8) and newman. Using 
the competitive Luminex assay we indirectly monitored the presence of several immune modulator by 
determining the shift of the Luminex signal between the supernatant of the 2nd , 4th and the 24th hour of 
biofilm compared to the 1st hour biofilm supernatants as our reference control (A). From this calculation 
the production was derived and expressed as mean ± SEM units/biofilm of immune modulators CHIPS (B), 
SCIN (C) and FLIPr (D) by S. aureus M82 (ST20), M116 (ST236), RWW50 (ST8) and Newman strain. S. aureus 
8325-4 strain are used as negative control for SCIN and CHIPS. Data are based on at least three separate 
experiments Note: the more Immune modulator present in the supernatant, the lower the signal observed, 
as the presence of un-captured specific IgG is inversely related to the presence of the immune modulators 
in the supernatants (A).
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Table 2: PCR results for immune modulators gene.
gene
detected by PCR in strain
8325-4 M82 (ST20) M116 (ST239) RWW50 (ST8) newman
chp (CHIPS) Neg Pos Neg Pos Pos
scn (SCIN) Neg Pos Pos Pos Pos
flr (FLIPr) Pos Neg Pos Pos Pos
hlgB (HlgB) Pos Pos Pos Pos Pos
lukD/E (LukD/E) Pos Pos Pos Pos Pos
lukS (LukS) Neg Neg Neg Pos Neg
detection of Immune modulator production of S. aureus biofilms by Mass 
Spectrometry
To confirm the production of immune modulators during the early stages of biofilm 
formation we performed Mass Spectrometry on supernatants collected at the 4th and 
figure 3: The kinetics of chp and scn transcription of S. aureus during 10 hours of biofilm formation. 
Transcription of the chp and scn promotor during the first 10 hours of biofilm formation are presented as 
percentage (%) of the positive control. Biofilm formation during the first 10 hours is represented by MFI’s of 
the GFP Positive control strain. Bars represent means with SEM (n = 3) (A).
Promotor activity of the positive control (B), chp (C) and scn (D) after 4 hours of biofilm formation are visual-
ized by fluorescence microscope. These pictures are representative of 3 independent experiments.
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the 24th hour of biofilm formation of strains RWW50 (ST8) and Newman. We were able 
to identify immune modulators CHIPS, SCIN and FLIPr in the 4th hours of biofilms super-
natant of RWW50 (ST8) and Newman. This result supports the hypothesis that immune 
modulators indeed may already be produced during the early stages of S. aureus biofilm 
formation.
Transcription of scn- and chp-promoters during biofilm formation
Based on the above results, the transcription of both scn and chp during biofilm forma-
tion was studied by applying GFP promoter fusion technology in the guise of scn- and 
chp-promoter-GFP fusion constructs cloned in 8325-4 strains in biofilm assays (29). As a 
positive control we used a constantly green 8325-4 strain (Table 1), previously described 
by Rooijakkers, et al. (30). The transcription of the chp- and scin-promoters during bio-
film formation was detectable after 2 hours of incubation and steadily increased until 
3.5 hours for chp and until 4 hours for scn. Transcription of the scn promoter was higher 
compared to chp-promoter throughout 10 hours of biofilm formation. This result cor-
responds with our finding that during early stages of biofilm formation more SCIN was 
detected than CHIPS.
figure 4: Inhibition of C5a release by SCIn. Human pooled serum was added to a 3 hours old biofilms of 
S. aureus 8325-4 in the presence or absence of rSCIN or rCHIPS. After 1 hour incubation at 370C, the released 
C5a was measured using an ELISA . Bars represent mean and SEM from 3 independent experiments.
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SCIn inhibits biofilm-induced C5a release
Considering the significant expression of SCIN and CHIPS already during the early stages 
of biofilm formation, we also studied whether these immune modulators can protect 
young biofilm from host innate immune responses such as complement activation. 
Therefore, we added recombinant SCIN or CHIPS protein during the 4th hour of biofilm 
formation to the SCIN and CHIPS negative strain 8325-4 and measured the formation 
of human complement component 3a (C3a) and complement 5a (C5a) in the presence 
of human serum. As can be seen in Fig. 4, we were able to show a significant reduction 
of C5a release in the biofilms spiked with rSCIN compared to the ones without rSCIN 
(p=0.024). Addition of rSCIN to biofilms did not reduce the biofilm-induced release of 
C3a (data not shown).
dISCuSSIOn
Using a competitive Luminex assay and Mass spectrometry, we were able to show that 
during the early stages of biofilm formation, S. aureus produces immune modulator SCIN 
and to a lesser extent CHIPS and FLIPr. Additionally, during this growth phase transcrip-
tion of genes coding for both CHIPS and SCIN was observed. These findings provide 
convincing evidence that SCIN and CHIPS are not only expressed during the exponential 
growth of planktonic cells (29) but also during the early stages of biofilm formation, and 
adds FLIPr to this list of early produced immune modulators. Archer et al. speculated 
on the production of immune modulators, including SCIN and CHIPS during the early 
stages of biofilm formation (2). Our observations confirm the earlier proposed produc-
tion of immune modulators during the early stages of biofilm formation.
Generally, S. aureus biofilm formation can be divided into four stages (14): attachment, 
adhesion-multiplication, maturation and dispersion. Attachment, occurring after 1-2 
hours of growth, involves elevated expression of cell wall-associated adhesins (15, 16). 
In the adhesion phase bacteria multiply and form small aggregates known as micro-
colonies embedded in biofilm associated protein (BAP) and secreted glycocalyx (17). An 
additional stage following the multiplication stage was later described by Moormeier, et 
al (18), and is called the exodus stage. During this stage, the production of DNAse facili-
tates the release of a subset of adhered bacteria, facilitating the formation of “tower-like” 
structures of biofilm (18). Next is the maturation phase, in which subsequently multilay-
ered cell clusters form a matrix of eDNA, proteins and polysaccharides (12, 19). The final 
stage of biofilm formation is dispersion, where the bacterial cells begin to dissociate 
from the biofilm as the result of protease and DNAse production, promoting bacterial 
detachment and seeding (5, 21).
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Although immune modulator production of biofilms was observed previously, par-
ticularly during the maturation stage, there is still little evidence available concerning 
the consequence of their presence. SCIN is present in 90% of all clinical S. aureus strains 
and it can reduce the complement mediated phagocytosis of planktonic cells as it is a 
potent C3 convertase inhibitor (20, 31). SCIN stabilizes C3 convertase molecules by caus-
ing dimerization of two convertases (32). These dimers prevent opsonophagocytosis 
(33) on one hand and also the formation of C5 convertases on the other hand. Under 
normal conditions the generation of C5 convertase will facilitate C5a release, which is an 
effective chemoattractant for phagocytes including the neutrophils toward the site of 
infection (33, 34). Therefore, SCIN has a major impact on the ability of the innate immune 
system to remove viable bacteria. In this study we show that recombinant SCIN was 
able to inhibit biofilm induced C5a release, however, we were unable to demonstrate 
that SCIN reduces C3a release. Thus, it seems that in our biofilm setting, the alternative 
pathway of complement activation occurs, resulting in C3a formation that cannot be 
blocked by SCIN as its’ blocking capacity is downstream in the complement cascade 
and depends on the generation of C3 convertases. Interestingly, we do see blocking of 
biofilm induced C5a after addition of SCIN, indicating that SCIN facilitated dimerization 
of C3 convertases and as such protects biofilms from the impact of the innate immune 
system as well. Furthermore, our data show that C5a is a good marker for de novo biofilm-
induced complement activation, allowing us to study the impact of different (bacterial) 
components on this part of the human innate immune system.
During the early stages of biofilm formation, S. aureus is able to manipulate the immune 
system, which could facilitate the survival of the biofilm-forming bacteria leading to the 
establishment of a biofilm. We anticipate that in addition to CHIPS, SCIN and FLIPr, other 
immune modulators are involved in this immune avoidance during the early stages of 
biofilm formation. Therefore, these results may serve as a steppingstone towards eluci-
dating the role of immune modulators in the establishment of biofilms in vivo. The setup 
used in this study is not only a rapid screening method to determine which factors are 
produced during the early stages of biofilm formation but it also allows us to determine 
their role in the establishment of a biofilm, which gives us opportunities to develop 
strategies to prevent this. For several reasons biofilms of S. aureus are an important clini-
cal problem (35), and helping the immune system to neutralize biofilm-forming bacteria 
will be tremendously beneficial to human healthcare.
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abSTRaCT
Introduction: Complicated and uncomplicated Staphylococcus aureus bacteraemia 
(SAB) are distinguished by host factors and persistence of infection (Infectious Disease 
Society of America (IDSA). Most studies on bacterial factors associated with complicated 
and uncomplicated bacteremia have been performed in areas with a high prevalence 
of MRSA. Currently, little is known about S. aureus strains causing complicated and un-
complicated bacteraemia in areas with low incidence of MRSA, such as the Netherlands.
Methods: 126 S. aureus strains were isolated from 126 consecutive patients with 
complicated and uncomplicated SAB. Clinical data and host factors were retrieved by 
chart review. All S. aureus strains were typed by Pulsed Field Gel Electrophoresis (PFGE). 
In a subset of 15 patients with complicated and 15 patients with uncomplicated SAB, 
antibiotic susceptibility to flucloxacillin, amoxicillin clavulanic acid, vancomycin, and 
ceftaroline fosfamil, spa type and capacity to form biofilm (under antibiotic pressure) in 
eukaryotic (IMDM) and prokaryotic (TSB+) growth media were determined.
Results: No differences in genetic background were found between strains isolated from 
patients with complicated (15) or uncomplicated SAB (15). All strains were susceptible 
to the antibiotics tested. Biofilm formation was similar for strains causing complicated 
and uncomplicated SAB, and more biofilm was formed in TSB+ than IMDM. In IMDM 
strains causing complicated SAB formed significantly more biofilm in the presence of 
vancomycin in comparison to uncomplicated SAB strains (p = 0.0173).
Conclusion: S. aureus strains causing complicated SAB formed significantly more bio-
film than strains causing uncomplicated SAB when grown under vancomycin pressure 
in IMDM. Although only few of our patients were actually treated with vancomycin,we 
hypothesize that in vitro vancomycin-resistant biofilm formation may represent an in 
vivo (stress) response that facilitates persistence of SAB infection.
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InTROduCTIOn:
S. aureus bacteraemia (SAB) is fatal in 20 – 40% of all cases (24) and it causes more deaths 
annually in America than HIV, hepatitis and tuberculosis combined (5, 6, 15). The Infec-
tious Disease Society of America uses several (host) factors to distinguish complicated 
from uncomplicated SAB: blood cultures remaining positive for more than 48 hours after 
initiation of directed therapy, fever persisting beyond 72 hours, endocarditis, indwell-
ing prosthetic material and metastatic infection all define SAB as a complicated SAB 
(19). The genetic background of the causative S. aureus also has been reported to be 
associated with mortality, as shown for USA300 (14). One important bacterial factor 
during SAB may be the ability of S. aureus to form biofilm; a collection of bacterial cells 
within an extracellular matrix composed of DNA, proteins and polysaccharides that is 
firmly attached to either a host or foreign substrate (4). Strains causing complicated 
SAB have been shown to produce a significantly higher amount of polysaccharides 
than strains isolated from cases of uncomplicated SABs in prokaryotic cell culture media 
(20). These data suggest that formation of biofilm may be a S. aureus characteristic that 
is more frequently present in strains causing a complicated SAB. Antibiotic treatment 
affects biofilm formation (11, 23), with reports showing vancomycin to induce biofilm 
formation in vancomycin-non-susceptible strains of S. aureus (12). Most of the studies 
regarding biofilm formation have been done in areas with a high prevalence of Methicil-
lin Resistant Staphylococcus aureus (MRSA). Currently, the capacity to form biofilm of S. 
aureus strains causing complicated and uncomplicated bacteremia in areas with low 
incidence of MRSA is not clear. Therefore, we determined whether S. aureus strains caus-
ing complicated SAB differ from strains causing uncomplicated SAB in the capacity to 
form biofilm in presence and absence of antibiotics in different media.
In vitro assays to study biofilm formation currently only use prokaryotic cell culture 
media, of which the chemical composition is not completely known such as: Brain Heart 
Infusion (BHI) or Tryptic Soy Broth (TSB) supplemented with glucose and sodium chloride. 
In well characterized S. aureus strains isolated from patients in the Netherlands (a low 
MRSA country), the association between bacterial factors, such as genotype, antibiotic 
resistance, biofilm formation (under antibiotic pressure) in either prokaryotic (TSB+) or 
eukaryotic and chemically defined culture medium (IMDM) with a complicated course of 
SAB was determined. More insight in persistence of SAB will bring better understanding 
of S. aureus pathogenesis, ultimately leading to better treatment strategies for SAB.
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MaTERIalS and METhOdS
Patient characteristics
All patients 18 years and older from whom a S. aureus strain was isolated from a blood 
culture at the microbiology laboratory of the Erasmus University Medical Centre, Rot-
terdam, were eligible. Inclusion was from July 2009 to June 2011. Only the first positive 
blood culture of a patient was included in the analysis. Strains obtained from patients 
without follow up blood cultures and from patients with poly-microbial infections were 
excluded (Fig. 1). Clinical data were retrospectively obtained by chart review. Hospital 
acquired infection was defined as an infection starting 48 hours after admission. Com-
munity acquired infection was defined as a positive blood culture taken within 48 hours 
of admission. Healthcare associated SAB was defined as a positive blood culture taken 
48 hours after admission in a patient, or from a patient that had been admitted up to 
3 months previously, or who lived in a nursing home, or a patient undergoing chronic 
hemodialysis. Complicated and uncomplicated SAB were defined according to the IDSA 
guidelines (19). This study was approved by the Medical Ethics Committee of the Eras-
mus University Medical Centre Rotterdam (MEC-2007-106).
genetic characterization of S. aureus
Pulsed-field gel electrophoresis (PFGE) of SmaI (Fermentas, Waltham, USA) digested 
chromosomal DNA from all S. aureus strains was performed as described previously (16). 
Concentrated bacteriophage lambda DNA (Bio-Rad laboratories, Veenendaal, The Neth-
erlands) was used to provide a molecular size marker. Banding patterns were interpreted 
according to the guidelines described by Melles et al (29). PCR fingerprints were visually 
 
 
figure 1: Flow chart of selected patients. In total, 187 patients were eligible for this study. After exclusion 
criteria were applied, 126 patients remained.
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inspected and evaluated with Bionumerics software (version 3.0, Applied Maths, Gent, 
Belgium)
Spa-typing was performed as described by Aires-de-Sousa et al. (28) and spa-se-
quences were analyzed using the Ridom StaphType software (Ridom GmbH, Würzburg, 
Germany).
In all cases S. aureus strains were freshly grown on Columbia blood agar plates (CBA, 
Becton Dickinson, Breda, The Netherlands) prior to experimental use.
MIC determination
Bacterial cells were cultured for 18-24 hours on Columbia blood agar (CBA) and sus-
pended in 0.9% NaCl to an optical density of 0.5 (±0.05) MacFarland and diluted 1:100 in 
Mueller Hinton Broth (MHB, Oxoid, Badhoevedorp, The Netherlands). Of this suspension 
100 μl was added to wells containing serial twofold dilutions of antibiotics: amoxicillin-
clavulanic acid (GlaxoSmithKline, Middlesex, United Kingdom), flucloxacillin (ACS Dobfar 
Generics, Luxembourg, Luxembourg), vancomycin (Xellia, Oslo, Norway) and ceftaroline 
fosfamil (Zinforo, Astra Zeneca, Zoetermeer, The Netherlands). Plates were incubated for 
18 hours at 37°C and MIC values were determined visually following the CLSI guidelines.
biofilm formation determination
S. aureus was grown overnight on CBA and suspended in 0.9% NaCl to an OD600 0.5 (± 
0.05). Of this suspension, 10μl was dispensed into wells of sterile flat-bottom 96-well 
polystyrene tissue culture plates (Greiner Bio-One, Alphen aan de Rijn, The Netherlands) 
containing 190μl Tryptic Soy Broth (TSB, Oxoid, Badhoevedorp, The Netherlands) with 
0.5% glucose and 3% NaCl (TSB+) or Iscove’s Modified Dulbecco Medium (IMDM, Gibco, 
Bleijswijk, the Netherlands). Plates were incubated for 18 - 24 h at 37°C with orbital 
shaking at 150 rpm. Subsequently, biofilms present in the wells were washed twice with 
sterile phosphate-buffered saline (PBS), air dried for at least 30 minutes at room tem-
perature and stained for 2 minutes with 1% crystal violet (Sigma Aldrich, Zwijndrecht, 
The Netherlands). Excess crystal violet was removed by washing the plates with dH2O 
5 times and the crystal violet was extracted in an extraction solution consisting of 50% 
dH2O, 40% EtOH (Sigma Aldrich, Zwijndrecht, The Netherlands) and 10% acetyl acid 
(Sigma Aldrich, Zwijndrecht, The Netherlands). Absorbance was measured using a micro 
plate reader (Bio-Rad, Hercules, USA) at 490 nm. Biofilm formation was determined at 0 
MIC and 1 MIC of each antibiotic. MICs were determined in Mueller Hinton Broth as de-
scribed previously for each separate experiment for flucloxacillin, amoxicillin-clavulanic 
acid, vancomycin and ceftaroline fosfamil. No ceftaroline fosfamil was used clinically, as 
this antimicrobial agent was not available until 2012 in the Netherlands. All experiments 
were performed in triplicate.
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Table 1. Baseline characteristics of 126 patients included in this study, and of a subset of patients with 
complicated or uncomplicated infection.
  All SAB Complicated SAB
(n = 15)
Uncomplicated SAB
(n = 15)
Men 78/126 (62%) 10/15 (66%) 8/15 (53%)
Age 21-88 37-85 22-86
Overall mortality 47/126 (37%) 7/15 (47%) 3/15 (20%)
Diabetes 31/126 (25%) 6/15 (40%) 2/15 (13%)
Prosthetic material present 36/126 (39%) 4/15 (27%) 0
Catheter in situ 61/126 (48%) 4/15 (27%) 0
Catheter removed 41/61 (67%) 4/15 (27%) 6/15 (40%)
Immune modulating suppressive therapy 40/126 (32%) 6/15 (40%) 5/15 (33%)
Origin of infection      
Hospital acquired 68/128 (52%) 3/15 (20%) 6/15 (40%)
Health care associated 40/126 (32%) 5/15 (33%) 5/15 (33%)
Community acquired 18/126 (14%) 7/15 (47%) 4/15 (27%)
Infection site      
Unknown 41/126 (32%) 10/15 (66%) 3/15 (33%)
Intravasculair 39/126 (31%) 2/15 (13%) 4/15 (27%)
Abcess 11/126 (9%) 1/15 (7%) 1/15 (7%)
Skin 9/126 (7%) 0 3/15 (33%)
Surgical Site Infections 7/126 (6%) 0 1/15 (7%)
Urosepsis 5/126 (4%) 0 1/15 (7%)
Osteomyelitis 3/126 (6%) 1/15 (7%) 0
Other† 11/126 (9%) 1/15 (7%) 2/15 (14%)
Endocarditis 9/37 (24%) 5/15(33%) 2/15 (13%)
Empirical therapy 97/126 (77%) 12/15 (80%) 0
Cephalosporins iv 22/97 (23%) 7/15 (47%) 7/15 (47%)
Amoxicillin-clavulanic acid iv 20/97 (21%) 2/15 (13%) 4/15 (27%)
Vancomycin iv 20/97 (21%) 1/15 (7%) 1/15 (7%)
Combination therapy$ 20/97 (21%) 3/15 (30%) 0
Duration therapy‴ 1 - 12 days
(median = 3)
1 - 9
(median = 2.5)
1 - 4 days
(median = 2)
Targeted therapy#      
Cephalosporins‡ 4/126 (3%) 1/15 (7%) 15/15 (100%)
Flucloxacillin / Cotrimoxazol 1/126 (1%) 0 0
Meropenem / Vancomycine 1/126 (1%) 0 0
Additional Rifampicin 51/126 (41%) 13/15 (87%) 0
Additional Gentamicin 30/126 (24%) 6/15 (40%) 2/15 (13%)
Duration Therapy 1 – 57
(median 13 days)
7 - 57
(median 15,5)
7 - 14
(median 11.5)
Culture Negative After 48 72 hours 34/126 (27%) 0/15 (0%) 15/15 (100%)
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Statistical analysis
Univariate analysis of host factors influencing SAB persistence was performed. Factors 
were subsequently analyzed by multivariate logistic regression analysis. Groups were 
compared using a Mann Whitney U test in IBM SPSS Statistics 20. Differences were con-
sidered to be significant when P-value ≤0.05.
RESulTS
Patient population
From 187 patients with SAB were eligible. Of these, 14 patients (7%) were excluded be-
cause they were treated in a hospital elsewhere and clinical data were not available. 21 
patients (11%) were excluded because their bacteremia was poly-microbial. Furthermore, 
26 patients (14%) were excluded because no follow up cultures were available. Mortality 
rate in the latter group was 9/26 (35%), not different from our study population. MSSA 
isolates were available from 126 patients, no MRSA strains were isolated during the study 
period (Table 1). The age ranged from 21 to 88 year and 78/126 (62%) were male. Empirical 
therapy was initially given to 97/126 patients (77%) with a median duration of 2-3 days 
(range 1-12 days) before it was switched to targeted therapy (Table 1). Targeted antibiotic 
therapy consisted mainly of flucloxacillin with additional rifampicin or gentamicin (Table 
1). Of the 126 patients, 34 (27%) were culture negative within 72 hours of treatment, of 
whom 15 patients with uncomplicated SAB, as defined by the IDSA criteria. The other 19 
patients were classified as complicated SAB based on secondary host-factors. Of the 92 
patients with positive cultures persisting beyond 72 hours after the start of appropriate 
antibiotic therapy, 15 patients with complicated SAB were selected. To increase the chance 
of finding bacterial factors, we chose patients with the least host factors from the IDSA 
definition for complicated SAB and excluded patients with multi-organ failure, or death 
(Table 1). Overall mortality was 37% (47/126), mortality was higher in the 15 patients with 
complicated SAB (47%) than in those with uncomplicated SAB (20%).
* Defined according to IDSA guidelines
# After culture results were known.
$ Consisting of ceftazidime with vancomycin (n = 2). Cefazolin with amoxicillin/clavulanic acid (n =1). Cef-
triaxone with doxycycline (n =1), amoxicillin/clavulanic acid (n =1), or amoxicillin (n =1). Cefotaxim with 
ciprofloxacin (n =4), amoxicillin / clavulanic acid (n =1) or vancomycin (n =1). Cefuroxime with amoxicillin/
clavulanic acid (n =1), vancomycin (n =4), gentamicin (n =2) or flucloxacillin (n =1).
†: 1 diabetic foot, 2 wound, 1 spondylodiscitis (1 in restricted cohort for complicated SAB), 3 heamatoma 
(1 in restricted cohort for uncomplicated SAB), 3 pcn (1 in the restricted for uncomplicated SAB) 1 drain 
neurosurgery
‡Cephalosporins = cefuroxim, cefotaxime, ceftazolin
‴ Duration of therapy before targeted therapy was initiated
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figure 2: PFGE and spa type of 126 strains. From the Ridom server, spa type could be correlated to MLST. 
By combining PFGE type and spa typing, several clusters are obvious: Cluster I, Pulsed Field Type D contains 
primarily ST45 (7/10 strains). Cluster II, Pulsed Field type B contains primarily ST5 (2/5 strains). Cluster III, 
containing Pulsed Field Type H, contains ST30 (3/3 strains)
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genetic analysis of S. aureus strains
All 126 MSSA strains causing SAB were typed using PFGE. Three main clusters emerged 
(Fig. 2). Cluster I comprised 26/126 (20%) S. aureus strains of PFGE type D. Cluster II in-
cluded 5 different PFGE types: F’’ (17 strains, 13%), A (14 strains, 11%), B (13 strains, 10%), 
F (7 strains, 6%) and C (15 strains, 12%), comprising a total of 66/126 of all strains (52%). 
Cluster III contained 15/127 (12%) of all strains, which all had PFGE type H. Other strains, 
19/126 (15%), were not part of these major clusters and formed smaller clusters (Fig. 2).
The 15 strains of patients with uncomplicated SAB and the 15 strains from patients 
with complicated SAB were spa-typed. Among the strains causing complicated SAB spa-
types t015 (3 times), t012 (2 times), t189 (2 times) and t311 (2 times), and, t008, t065, 
t116, t160, t576, t937, t3169 and t5325 were found (Figure 2). Uncomplicated SAB strains 
varied in spa type t084 (2 times), t026 (2 times), t002, t008, t012, t031, t050, t267, t306, 
t335, t371, t1050 and t1154 (Figure 2). Complicated and uncomplicated SAB strains were 
present in similar PFGE and spa-types, indicating that no genetic lineage was uniquely 
associated with complicated or uncomplicated SAB.
antibiotic Susceptibility
The susceptibility for amoxicillin with clavulanic acid, flucloxacillin, vancomycin and 
ceftaroline fosfamil was determined for the selected 30 SAB strains. All 15 strains from 
complicated and 15 strains from uncomplicated SAB were susceptible to the 4 tested 
antibiotics with MIC’s varying from 0.06 – 1 μg/ml for flucloxacillin (median 0.25 μg/ml), 
0.125 – 2 μg/ml for vancomycin (median 0.75 μg/ml), <0.06 – 4.0 μg/ml for amoxicillin-
clavulanic acid (median 1 μg/ml) and 0.125 – 1 μg/ml for ceftaroline fosfamil (median 
0.25 μg/ml). No significant differences in MIC values were found between strains from 
patients with complicated and uncomplicated SAB.
biofilm formation and biofilm formation Inhibition by antibiotics
We determined the capacity to form biofilm in TSB+ and IMDM for strains causing com-
plicated and uncomplicated SAB. Growth in TSB+ resulted in significantly more biofilm 
formation than in IMDM (p <0.05) (Fig. 3). This difference was evident for most, but not 
all strains tested: a few strains showed the reverse, i.e. more biofilm in IMDM than in TSB+ 
(Fig. 3). No significant difference in biofilm formation was found between strains ob-
tained from patients with uncomplicated (n=15) and complicated (n=15) SAB in either 
TSB+ or IMDM. We subsequently tested influence of beta-lactam antibiotics flucloxacillin, 
amoxicillin-clavulanic acid and ceftaroline fosfamil in TSB+ and IMDM on biofilm forma-
tion. Biofilm formation was reduced in the presence of beta-lactam antibiotics. Addition 
of either flucloxacillin or ceftaroline fosfamil at 1 MIC in TSB+ significantly reduced bio-
film formation compared to untreated biofilms for strains from both uncomplicated and 
complicated SAB (p < 0.0001, Figure 4A). No significant effect on biofilm formation was 
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observed by addition of beta-lactams when the bacteria were grown in IMDM (Figure 
4B). No differences between strains from uncomplicated and complicated SAB were 
measured in biofilm formation after 18-24 hours in TSB+ or IMDM under beta-lactam 
antibiotic pressure. We finally tested biofilm inhibition by the glycopeptide vancomycin. 
There was no significant difference in biofilm formation in TSB+ between strains causing 
complicated or uncomplicated SAB in the presence of 1 MIC of vancomycin. Strikingly, 
in the eukaryotic cell culture medium IMDM, strains causing complicated SAB formed 
significantly more biofilm in the presence of 1 MIC vancomycin than strains causing 
uncomplicated SAB (p = 0.0173) (Figure 5).
dISCuSSIOn
In our study, differences in bacterial factors between S. aureus strains causing complicat-
ed SAB and complicated SAB were studied. Antibiotic resistance, PGFE and spa-typing 
were not different in S. aureus strains causing complicated and uncomplicated SAB. 
Biofilm formation without antibiotics was similar, but biofilm formation in the presence 
of vancomycin in the eukaryotic cell culture medium IMDM was inhibited in S. aureus 
strains causing uncomplicated SAB.
Under vancomycin stress conditions in IMDM, SAB strains causing uncomplicated SAB 
were significantly less able to form biofilm compared to strains isolated from compli-
cated SAB. In nutrient-rich bacterial growth medium TSB+, however, no such distinction 
figure 3: Biofilm formed in TSB+ and IMDM by 15 strains causing complicated SAB (open circles) and 15 
causing uncomplicated SAB strains (circles symbols). Biofilm readings of individual strains in TSB+ are linked 
to readings in IMDM via lines
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figure 4: Biofilm formed by 30 selected strains in TSB+ (A) or IMDM (B). Antibiotics used are shown on the 
x-axis.
figure 5: Biofilm formation in IMDM medium by 15 strains causing complicated SAB (C) and 15 causing 
uncomplicated SAB (U) in the presence of 1x MIC of vancomycin.
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in the amounts of biofilm formed was observed between the two groups of strains: both 
were similarly affected by the presence of vancomycin in TSB+. Bacteria generally show 
different behavior in different growth media (23, 26): in eukaryotic growth media, which 
are relatively devoid of iron, S. aureus grows slower and produces much larger amounts 
of iron-regulated surface proteins such as IsdA, where they produce little IsdA in TSB 
(26). We studied biofilm formation in the chemically defined eukaryotic cell culture 
medium IMDM, as opposed to the standard TSB+ medium usually applied for biofilm ex-
periments. Generally, S. aureus biofilm formation was less pronounced when performed 
in IMDM instead of TSB+, indicating that conditions to form biofilm in vivo may well differ 
from those in laboratory media. We suggest that using eukaryotic cell culture medium 
better mimics the in vivo situation and indicates a good direction for future research.
Antibiotics do not only have direct effects on bacterial survival, as antibiotics have 
been reported to have an effect on S. aureus biofilm formation, (1, 12), with rifampicin in-
hibiting biofilm formation and, in contrast, gentamicin showing an induction of biofilm. 
We studied biofilm formation in the presence of antibiotics, using antibiotics routinely 
used in clinical practice to treat SAB. Generally, the strains produced less biofilm when 
grown under antibiotic pressure induced by adding 1 MIC of several agents to the ex-
periments. In contrast, S. aureus strains causing complicated disease were significantly 
less reduced in biofilm formation when grown under pressure of the glycopeptide van-
comycin in IMDM compared to uncomplicated SAB strains. The other beta-lactam 
antibiotics tested - amoxicillin-clavulanate, flucloxacillin and ceftaroline fosfamil - did 
not have such differential effects on biofilm formation in either of the growth media 
tested. It is already known that vancomycin resistance might be related to, but is not a 
causative factor of complication and mortality (11). In this study it was demonstrated 
that SAB with a higher vancomycin MIC is associated with an increase in 30-day mortal-
ity, irrespective of the antibiotic actually was used in treatment. All the strains in our 
study had MIC values for vancomycin of less than 2.0 ug/ml, similar to those reported 
in the study of Holmes (11), but we could not find significant differences in vancomycin 
resistance between uncomplicated and complicated SAB strains. Another explanation 
for the biofilm formation during vancomycin exposure may be that vancomycin induces 
transcriptional responses, especially the up-regulation of the cell wall stress stimulon 
VraSR, that are similar to the transcriptional responses to stresses induced by human 
derived antimicrobial peptides (27). So it could very well be that treatment with vanco-
mycin in our in vitro experiments actually reflects the natural exposure to antimicrobial 
peptides. Taken together, the ability of certain strains of S. aureus to maintain biofilm 
production under stress conditions encountered in vivo, including that exerted by 
antimicrobial therapy, might explain, the persistence of SAB in our cohort of patients. 
This observed persistence does seem related to a biofilm mode of growth and locations 
that are hard to treat, such as endocarditis and osteomyelitis, which are observed more 
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in the complicated group compared to the uncomplicated group of SAB. As biofilms 
are thought to mediate persistence of infection, we hypothesise that our finding could 
become relevant in distinguishing between complicated and uncomplicated episodes 
of SAB in an early stage of the infection.
We further attempted to discriminate strains causing complicated from those 
causing uncomplicated SAB by studying their genetic background. SAB genetics is 
related to mortality, with USA 300 showing an increased mortality for SAB compared 
to non-USA300 strains. In our study, neither PFGE nor spa typing were discriminatory 
for complicated SAB, and complicated and uncomplicated SAB strains occurred in the 
same PFGE and spa types. To our knowledge, this is the first study on the influence on 
persistence of SAB by different genetic backgrounds.
We compared two, relatively small, subsets of patients selected from the total cohort 
of SAB cases. Therefore, our results cannot be simply extrapolated to all strains causing 
complicated SAB and further studies are needed to confirm or refute our hypothesis that 
biofilm formation under appropriate conditions may discriminate complicated from 
uncomplicated episodes of SAB at an early stage of the diseases.
We finally studied differences in antibiotic susceptibility between complicated and 
uncomplicated SAB’s. No differences were found when comparing the antibiotic sus-
ceptibility to flucloxacillin, amoxicillin-clavulanic acid or ceftaroline fosfamil profiles of 
strains causing complicated versus those causing uncomplicated SAB. The IDSA advises 
6-8 weeks of intravenous antibiotic therapy for patients with complicated SAB, and 
2-4 weeks of therapy for patients with uncomplicated SAB. Rapid detection of strains 
prone to cause complicated SAB is an advantage over the current diagnostic methods 
which currently can take several days to establish. Testing the infecting strains ability to 
form biofilm under pressure of the glycopeptide antibiotic vancomycin in IMDM may 
facilitate more rapid determination of SAB complication status and help guide clinical 
management of SAB. Although our finding needs confirmation in other studies, use of 
bacterial factors may be a new approach to determine the risk of complicated SAB.
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SuMMaRy
The rapid emergence of multiply drug resistant (MDR) bacterial pathogens poses a ma-
jor threat for human health. In recent years, genome sequencing unveiled many poorly 
expressed antibiotic clusters in actinomycetes. Here we report a well-defined ecological 
collection of over 800 actinomycetes obtained from sites in the Himalaya and Qinling 
Mountains, and use these in a concept study to see how efficiently antibiotics can be 
elicited against MDR pathogens isolated recently from the clinic. Using 40 different 
growth conditions, 96 actinomycetes were identified - predominantly Streptomyces – 
that produced antibiotics with efficacy against the MDR clinical isolates referred to as 
ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and/or Enterobacter cloacae. Anti-
microbial activities that fluctuated strongly with growth conditions were correlated to 
specific antibiotics, including borrelidin, resistomycin, carbomethoxy-phenazine and 
6,7,8- and 5,6,8-trimethoxy-3-methylisocoumarin, of which the latter was not previously 
described. Our work provides insight into the potential of actinomycetes as producers 
of drugs with efficacy against recently emerged clinical isolates and also underlines the 
importance of targeting a specific pathogen.
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InTROduCTIOn
Infections caused by multiple drug-resistant bacteria continue to be a world-wide 
problem. Society currently faces rapidly growing resistance among Gram-positive and 
Gram-negative pathogens that cause infection in the nosocomial environment and the 
general community (Giske et al., 2008; Rice, 2008; Spellberg et al., 2008). Several multiple 
drug resistant (MDR) pathogens, especially Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Entero-
bacter spp. - collectively referred to by the acronym ESKAPE - cause the majority infec-
tions within the nosocomial environment (Rice, 2008). Current antimicrobial therapies 
have reduced efficiency or are inactive against these isolates, which leads to increased 
mortality among patients (Rice, 2008), and more people die of these increasingly antibi-
otic resistant pathogens than of HIV/AIDS and tuberculosis combined (Boucher & Corey, 
2008; Klevens et al., 2006). This underlines the urgent need for new antimicrobials.
The actinomycetes are a diverse family of filamentous bacteria that produce a wealth 
of secondary metabolites, including two-thirds of the antibiotics in clinical use (Miyadoh, 
1993; Okami, 1988). Of the actinomycetes, streptomycetes are particularly prolific an-
tibiotic producers, which grow as a branched multicellular network of hyphae, called 
the mycelium; on solid surfaces they reproduce through spores formed by a specialized 
aerial mycelium, which coincides with antibiotic production. Many studies have been 
conducted in search of novel actinomycetes (Lazzarini et al., 2000; Ng & Amsaveni, 2012; 
Singh et al., 2006; Takahashi & Omura, 2003; Thakur et al., 2007). However, the intensive 
screening programs in the pharmaceutical industry failed to yield significant numbers 
of novel drugs (Payne et al., 2007). New antibiotics have been estimated to occur at 
frequencies of less than one per million in randomly chosen actinomycetes grown un-
der routine conditions (Baltz, 2007; Baltz, 2008). Sequencing of Streptomyces genomes 
established the presence of silent antibiotic biosynthetic gene clusters, suggesting that 
the potential of these organisms for novel drug production is much larger than originally 
anticipated (Challis & Hopwood, 2003; Hopwood, 2007).
A major challenge is therefore to find ways to elicit the production of yet unknown 
antibiotics. Such strategies have been in use in industry for many decades, but the dis-
covery of cryptic antibiotics has renewed the interest in identifying specific conditions 
or agents that elicit the expression of antibiotics (Craney et al., 2012; van Wezel et al., 
2009; Zhu et al., 2013). An example is N-acetylglucosamine (GlcNAc), which in strepto-
mycetes is imported by the phosphoenolpruvate (PEP)-dependent phosphotransferase 
system PTS and converted into glucosamine-6-phosphate (Nothaft et al., 2010; Swiatek 
et al., 2012); once imported, it forms a signaling cascade with GlcN-6P acting as a ligand 
for the antibiotic repressor DasR, thereby rendering it inactive and triggering antibiotic 
production in Streptomyces coelicolor (Rigali et al., 2006; Rigali et al., 2008). Recently, 
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screening of a chemical library for new elicitor molecules resulted in the identification 
of chemical probes that activated antibiotic production by interfering with fatty acid 
biosynthesis (Ahmed et al., 2013; Craney et al., 2012). These approaches show the power 
of elicitors for rational drug discovery approaches.
Media composition has a major impact on antimicrobial agent production, with 
glucose and phosphate as well-known suppressors of antibiotic production (reviewed 
in (Sanchez et al., 2010; van Wezel & McDowall, 2011)). Clearly, screening under different 
growth conditions is a strategy that has been used by the pharmaceutical industry for 
many decades, although with less success in recent years (Payne et al., 2007). In this 
study we present a novel collection of actinomycetes from soil samples obtained from 
remote mountains and analyzed their antibiotic-producing potential. This provides new 
insights towards the efficacy of the antibiotics produced, against MDR pathogens that 
currently threaten the health of hospitalized patients. We identified a number of antibi-
otics whose expression varied greatly with the growth conditions, including a previously 
unidentified isocoumarin-type antibiotic.
METhOdS
Selective isolation of actinomycetes from soil
Soil samples were collected from the Qinling Mountains and the Himalaya Mountains 
(China). The Qinling samples were obtained from different places in Xi’an, Shaanxi 
Province, China, namely Shandi Village at longitude 109° 22΄ 39˝ and latitude 34° 3΄ 28˝, 
height 660 meters; Gepai Village at longitude 109° 30΄ 8˝ and latitude 33° 54΄ 54˝, height 
1088 meters; Muzhai Village at longitude 109° 22΄ 03˝ and latitude 34° 21΄ 02˝, height 
985 meters; Huafeng Village at longitude 108° 39΄ 4˝ and latitude 34° 00΄ 58˝, height 533 
meters; Daohe Village at longitude 108° 41΄ 10˝ and latitude 34° 00΄ 58˝, height 692 me-
ters; Langshan Village at longitude 109° 0΄ 53˝ and latitude 34° 1΄ 5˝, height 720 meters; 
Xinlian Village at longitude 108° 48΄ 16˝ and latitude 34° 1΄ 43˝, height 692 meters. The 
Himalayan sample was obtained at 5000 m height, collected near a hot water spring. 
Every soil sample was collected at a depth of 10 to 20 cm and put in sterilized plastic 
bags and stored at 4 °C before processing.
The soil was enriched with 6% yeast extract (Hayakawa & Nonomura, 1989), and 
dilutions plated onto selective media, which were modified starch casein agar (MSCA) 
(Küster & Williams, 1964), humic acid agar (HA) (Hayakawa & Nonomura, 1987), glucose 
casein agar (GCA) (soluble starch 15.0g, KNO3 0.5g, K2HPO4 0.5g, MgSO4·7H2O 0.5g, NaCl 
5.0g,KCl 5.0g, FeSO4·7H2O 0.01g ,vitamins 0.5mg, Agar 18.0g,add water to 1000ml, pH 
7.2~7.4), soy flour mannitol medium (SFM) or minimal medium (MM) (Kieser et al., 2000). 
Nystatin (50 µg/mL) and nalidixic acid (10 µg/mL) were added for the inhibition of fungi 
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and bacteria respectively during initial selection. Single actinomycete colonies were 
streaked onto SFM agar plates until pure cultures were obtained. Imaging of actinomy-
cetes by phase contrast, stereo microscopy and cryo-scanning electron microscopy was 
conducted as previously described (Colson et al., 2008).
Indicator microorganisms, growth conditions and antimicrobial assays
Bacillus subtilis 168 (no resistance markers) and E. coli ET8 (AmpR ApraR CamR KanR NeoR 
StrR TetR) were used as indicator strains. ET8 is a derivative of Escherichia coli ET12567 
(contains the cmr, aadA and tet genes that confer resistance to chloramphenicol, 
streptomycin and tetracyclin, respectively; (MacNeil et al., 1992)) harboring cosmid 
supercos 1 (Agilent technologies; contains the bla gene for ampicillin resistance and aph 
for resistance to kanamycin and neomycin), and in addition the apramycin resistance 
cassette aacC4. MDR clinical isolates E. faecium, S. aureus, K. pneumoniae, A. baumannii, 
P. aeruginosa and E. cloacae were obtained from Erasmus Medical Centre (Rotterdam, 
Netherlands). Indicator bacteria were cultured in LB media at 37 °C. Antimicrobial assays 
were conducted using the double-layer agar method. Briefly, MM agar plates, contain-
ing supplements as detailed in Table 1, were inoculated with actinomycetes. Plates were 
incubated for 4 days at 30 °C, or longer if lower temperatures were used, overlaid with LB 
top agar (0.6% w/v agar) containing one of the indicator strains pre-grown in liquid LB to 
exponential phase (OD500 0.4 - 0.6), and then incubated overnight at 37 °C. The following 
day, antibacterial activity was determined as zones of inhibition (in mm) surrounding 
the actinomycete colonies.
16S ribosomal gene sequencing and phylogenetic analysis
The 16S rRNA genes of the actinomycetes were amplified by PCR from liquid-grown 
mycelia using primers F1 (5’-GCGTGCTTAACACATGCAAG-3’) and R1 (5’-CGTATTACCGCG-
GCTGCTG-3’), corresponding to nt positions 15-34 and 465-483 of the 16S rRNA locus 
of S. coelicolor A3(2), respectively. PCRs were performed as described (Kieser et al., 
2000) and sequenced using oligonucleotide Seq F1 (5’-TGCTTAACACATGCAAGTCG-3’). 
Sequencing was done by BaseClear (Leiden, the Netherlands). 16S sequences were 
deposited in the GenBank database as a batch under the accession number BankIT 
1698416. 16S rRNA sequences were used as query for BLASTN analysis. Subsequently, 
a phylogenetic tree based on these partial 16S rRNA sequences was constructed, es-
sentially as described previously (Girard et al 2013). To that aim, sequences of known 
actinomycetes were retrieved from GenBank. Sequences were aligned with Mafft (Katoh 
et al., 2009). After visual inspection, alignments were trimmed for gaps where more than 
5% of the sequences were missing, using the Extractalign tool of the eBioX package 
(http://www.ebioinformatics.org/ebiox/). The phylogenetic tree was generated using 
maximum-likelihood algorithms with default parameters as implemented in MEGA 
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version 5 (Tamura et al., 2011). The tree reliability was estimated by bootstrapping with 
1,000 replicates. Since groupings supported by poor bootstrap values are not reliable, 
internal branches with a bootstrap value of less than 50% were collapsed so as to em-
phasize the reliable branching patterns.
Thin layer Chromatography (TlC) and high Performance liquid 
Chromatography (hPlC)
Cultures were extracted with ethyl acetate (EtOAc), which was then removed under 
vacuum at 400C, after which the residue was dissolved in methanol (MeOH). Chemi-
cal analysis was conducted by TLC and HPLC. Specifically, TLC silica gel 60 F254 (Merck, 
Darmstadt, Germany) plates were developed using chloroform (CHCl3) and MeOH as the 
solvent system and visualized under UV light 254 nm and 365 nm; HPLC analysis was 
performed using an Agilent Technologies 1200 series chromatographic system with a 
photodiode array detector (DAD) and separated on a Phenomenex Luna C18 column 
Table 1. Media supplements used to elicit antibiotic production. For details see Materials and Methods 
section.
No. Supplement No. Supplement No. Supplement
1 25mM GlcNAc (Fluka) 14 0.1% Vitamins (Vitamins With 
Minerals Tablets, Hangzhou, 
China) (W/V)
27 1% Cellobiose (W/V) (Sigma)
2 0.3% NaNO2 (W/V) (Fluka) 15 1% Xylose (W/V) (Sigma) 28 1% Galactose (W/V) (Merck)
3 0.7% KNO3 (W/V) (Merck) 16 0.6% Yeast extract (W/V) 
(Bacto)
29 1% Lactose (W/V) (Sigma)
4 pH 10 (adjusted using 5M 
NaOH)
17 0.5% Malt extract (W/V) 
(Bacto)
30 1% Mannose (W/V) (JANSSEN, 
Belgium)
5 pH 8 (adjusted using 5M 
NaOH)
18 0.8% Peptone (W/V) (Difco) 31 1% Saccharose (W/V) (BDH)
6 pH 6 (adjusted using 2M HCl) 19 0.001% Jasmonic acid (W/V) 
(Sigma)
32 0.5% Trehalose (W/V) 
(Brunschwig)
7 pH 4 (adjusted using 2M HCl) 20 2.5% Fungal extract (W/V) (In 
house extraction)
33 0.8% Dextrin (W/V) (Merck)
8 1% Starch (W/V) (Difco) 21 1.2% Milk powder (W/V) 
(Friso)
34 0.5% Glycine (W/V) (Merck)
9 1% MgCl2 (W/V) (Merck) 22 2% Oatmeal (W/V) 35 0.5% Cellulose (W/V) (Sigma)
10 0.1% CaCl2 (W/V) (Merck) 23 1% Maltose (W/V) (Sigma) 36 0.1% Glucosamine (W/V) 
(Sigma)
11 0.6% NaCl (W/V) (Merck) 24 0.8% Glucose (W/V) (Sigma) 37 1% Chitin (W/V) (Sigma)
12 1% Casein (W/V) (Difco) 25 1% Fructose (W/V) (Sigma) 38 High temperature (45 °C) for 
overnight
13 25 mM Na-K-Phosphate buffer 26 1% Arabinose (W/V) (Sigma) 39 Low temperature (4 °C) for 
overnight
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(4.6 mm x 250 mm, 5 μm) with MeOH-water as the mobile phase, applying a gradient of 
20% - 100% MeOH over 40 min at a flow rate of 1 mL/min. The TLC-bioautography assay 
was done by placing the developed TLC plate onto the bioassay petri dish overlaid with 
soft LB agar (Hispanagar) (0.6%) containing Bacillus subtilis as an indicator. Following 
two hour incubation, the TLC plate was removed and incubated overnight at 37 °C. A 
control plate was also processed using the same solvents excluding test material to 
ensure the TLC and solvents themselves do not affect the growth of the indicator strain. 
The activity assessment was based on inhibition zones of the indicator strain.
For chromatographic methods we used normal phase silica gel (Merck, Darmstadt, 
Germany; pore size 60 Å, 230-400 mesh), Sephadex LH-20 (Pharmacia, The Netherlands), 
reversed-phase C18 semi-preparative HPLC and preparative TLC (PLC silica gel 60 F254 
TLC (Merck, Darmstadt, Germany)).
nMR and mass spectrometry
Structure elucidation of pure active compounds was done by nuclear magnetic reso-
nance (NMR) measurement and mass spectrometry (MS) analysis. The spectra of 1H NMR, 
correlation spectroscopy (COSY), J-resolved, heteronuclear single quantum coherence 
(HSQC), heteronuclear multi-bond correlation spectroscopy (HMBC), and 13C attached 
proton test (APT) of purified compounds were recorded on a 600 MHz DMX-600 spec-
trometer (Bruker, Karlsruhe, Germany) operating at a proton NMR frequency of 600.13 
MHz (1H) and 150.13 MHz (13C). The specific 1H NMR experiment measurement param-
eters were set as described (Kim et al., 2010).
Fourier Transform Mass Spectrometry (FTMS) (Bruker) was used to determine the 
exact mass of the compounds. The analyses were performed by DI-nanoESI-MS in the 
positive ion mode using the automated Advion NanoMate Triversa system (type ‘A’ chip) 
coupled to a LTQ-FT Ultra (Thermo Fisher Scientific).
RESulTS
a collection of actinomycetes and growth conditions to elicit antibiotic 
production
A new collection of actinomycetes was created from soil samples obtained from un-
spoiled areas in the Qinling and Himalaya Mountains (China). In total 816 different acti-
nomycetes were recovered from the soil samples (see Materials and Methods section for 
details). The strains were initially tested for their ability to inhibit the growth of indicator 
strains B. subtilis 168 and of E. coli ET8, which carries several resistance cassettes. The vast 
majority of the actinomycetes inhibited growth of B. subtilis even under routine growth 
conditions, and production of antibiotics with efficacy against Gram-positive bacteria 
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was therefore only pursued with MDR pathogens (see below). When analyzing inhibition 
of E. coli ET8, 108 actinomycetes inhibited its growth under control growth conditions, 
while an additional 207 could also be induced by at least one of the media supplements 
to inhibit growth of ET8; in other words, a total of 315 out of 816 strains (39% of the 
strain collection) produced inhibitory activity against this multi-resistant Gram-negative 
strain. Of the 40 different growth conditions, pH 10, starch (1% w/v) and peptone (0.8% 
w/v) had the strongest stimulatory effect on antibiotic production. The strongly stimula-
tory effect of high pH values is particularly noteworthy as it by no means a common 
condition for screening of antibiotics. All growth conditions also repressed antibiotic 
figure 1. Quantification of induction or repression of antimicrobial activity in actinomycetes against 
E. coli ET8 depending on the growth conditions. Numbers on vertical axis represent growth conditions 
as listed in Table 1 and those on the horizontal axis represent the total number of actinomycetes whose 
antibiotic production was either induced or repressed under each of the 40 growth conditions. Strains were 
grown on MM agar plates with 0.5% mannitol and 1% glycerol as carbon sources, with or without additives, 
and then overlaid with top agar containing indicator strain E. coli ET8. Inhibition zones were then measured 
as zones of clearing. Only significant changes (changes of more than 1 mm and 10% in diameter) in the size 
of the zones in all replicates of the triplicate experiment were considered.
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production by a number of the species in the collection (Figure 1). As an example, we 
compared the producing capacity of eight Streptomyces species from the collection, 
namely MBT1, MBT7, MBT11, MBT12, MBT22, MBT27, MBT28 and MBT33, which were all 
grown on MM agar plates or MM with added GlcNAc, starch or peptone, or MM pH 10. 
Again using E. coli ET8 as the indicator strain, the inhibition zones varied strongly per 
species and by growth conditions (Figure 2). MBT1 and MBT12 inhibited growth of E. 
coli ET8 most strongly when grown on routine MM agar, while production of antibiotics 
by these species was blocked by growth at pH 10; conversely, MBT7 and MBT11 were 
induced by growth at pH 10. Antibiotic production by MBT22 and MBT33 was induced 
by GlcNAc, while the same compound repressed antibiotic production by MBT27 and 
MBT28 (Figure 2).
To see if the specific changes to the growth media - and in particular growth at pH 
10 - affected the susceptibility of the indicator strains against antibiotics, we determined 
the inhibition zones for reference antibiotics against E. coli ET8 and B. subtilis. This 
showed that the zone of inhibition caused by ampicillin, apramycin, chloramphenicol 
or kanamycin did not increase when the indicator strains were grown at pH 10 (Supple-
mental Figure S1). These data corroborate that the growth conditions did not affect 
the susceptibility of B. subtilis or E. coli, but instead elicited antibiotic production in the 
actinomycetes.
figure 2. antimicrobial activity of eight actinomycetes against E. coli ET8 under five different growth 
conditions. Strains were grown on MM agar plates with 0.5% mannitol and 1% glycerol as carbon sources, 
with or without additives. 1, no additives; 2, 25 mM GlcNAc; 3, pH adjusted to 10; 4, starch (1% w/v); 5, 
peptone (0.8% w/v). The experiment serves as a representative example of the inducibility of antibiotic 
production in actinomycetees, under the chosen conditions. For details on the effect of elicitors on the 96 
strains we refer to Supplemental Tables S1 and S4.
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analysis of 96 promising strains for antibiotic production against MdR clinical 
isolates
Based on the screening of the strain collection, the 96 actinomycetes most prolific 
antibiotic-producing actinomycetes were identified, with their antibiotic production 
typically induced under specific growth conditions. Of these 96, in total 89 strains were 
identified as Streptomyces (Zhu, 2014; Supplemental Table S2 and Supplemental Figure 
S2). Other genera were Kitasatospora (MBT63, MBT64, MBT66 and MBT69), Nocardia 
(MBT52), Micromonospora (MBT87) and Amycolatopsis (MBT80). All of the 96 actinomy-
cetes inhibited B. subtilis when grown on MM agar plates (not shown). To obtain detailed 
insight into their producing capacity, antibiotic production was further assessed with 
the multi-resistant E. coli ET8 as the indicator strain. For this, the actinomycetes were 
grown for four days on MM agar, MM agar with starch (1% w/v), MM agar with peptone 
(0.8% w/v) or MM agar at pH 10, and inhibition zones determined (Supplemental Table 
S1). This revealed that all strains were able to inhibit growth of E. coli ET8 under at least 
one of the growth conditions.
The antibiotic-producing potential of the 96 strains that all showed strong antimi-
crobial activity against the MDR E. coli strain ET8 was then assessed for possible clinical 
relevance, by analyzing their ability to inhibit the growth of six MDR clinical isolates. 
These clinical isolates were all isolated recently at the Erasmus Medical Center (Rot-
terdam, The Netherlands). The resistance profile of these isolates (Supplemental Table 
S3) was determined as MIC values using the VITEK II (BioMerieux) system (AST-P586 
for E. faecium, AST-P608 for S. aureus and AST-N140 for K. pneumoniae, A. baumannii, P. 
aeruginosa and E. cloacae).
In accordance with previous reports on antimicrobial susceptibility (Burt, 2004; Nair 
& Chanda, 2006), Gram-positive pathogens (S. aureus, E. faecium) were more sensitive 
to the antibiotics produced by the actinomycetes than Gram-negative pathogens (A. 
baumanii, E. cloacae, K. pneumoniae, P. aeruginosa) (Supplemental Table S4). An example 
of the differential antimicrobial activity produced by 24 of the actinomycetes of the 
collection against the six pathogens is shown in Supplemental Figure S3. Growth of the 
Gram-positive MRSA (methicillin-resistant S. aureus) was inhibited by 82 of the actino-
mycetes grown on routine MM agar plates, and by another 10 strains when they were 
grown under specific conditions. Under the same growth conditions, 53 actinomycetes 
inhibited growth of the Gram-positive E. faecium and an additional 36 actinomycetes 
inhibited E. faecium under other growth conditions. Most Gram-negative bacteria were 
inhibited by some 40% of the actinomycetes growth on MM agar plates, namely K. pneu-
moniae by 41 strains, A. baumannii by 37 strains and E. cloacae by 34 strains. Changing 
the growth media activated antibiotic production against the latter three pathogens 
in another 16, 27 and 15 strains, respectively. Notably, the opportunistic pathogen P. 
aeruginosa was extremely resilient, with only seven of the 96 actinomycetes able to 
94 Chapter 5
exert some degree of growth inhibition to this strain when grown on standard MM agar 
plates. However, antibiotic production against P. aeruginosa could be elicited in 33 of the 
89 non-producing actinomycetes by growth on MM with added starch or peptone, or at 
pH 10 (Figure 3A).
figure 3. Inducibility of antimicrobial activity of 96 selected actinomycetes against MdR pathogens 
and effect of media conditions.
(a) Bar diagram of total number of actinomycetes that could inhibit the indicated MDR pathogens when 
grown under non-induced (light grey) or induced (black) conditions. (b) Bar diagram of the number of ac-
tinomycetes that were induced to produce antibiotics with efficacy against the MDR strains by growth on 
MM at pH10 (hashed), MM with starch (black) or MM with peptone (small dots). Antimicrobial assays were 
conducted using the double-layer agar method (see Materials and Methods section). The tested pathogens 
were Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudo-
monas aeruginosa and Enterobacter cloacae.
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It is important to note that actinomycetes that inhibited one Gram-negative pathogen 
often did not inhibit any of the other Gram-negative pathogens, which strongly suggests 
that different antibiotics were produced (Supplemental Table S4). As an example, strains 
MBT32, MBT44, MBT94 and MBT96 only inhibited growth of A. baumannii while they had 
no effect on growth of the other MDR Gram-negative clinical isolates of K. pneumoniae, E. 
cloacae and P. aeruginosa, while, conversely, MBT82 only inhibited the growth of E. cloa-
cae. Intriguingly, MBT10 (when grown on MM with added peptone) exclusively inhibited 
the growth of MDR P. aeruginosa and none of the other Gram-negative pathogens, even 
though P. aeruginosa was by far the most resilient of all pathogens in our analyses.
Expectedly, antimicrobial activity varied significantly with the growth conditions (Fig-
ure 3B). When grown on MM with starch, antibiotics were produced with activity against 
the Gram-positive E. faecium and S. aureus in 21 and five actinomycetes, respectively, 
for MM at pH 10 this was the case for 20 and nine actinomycetes, and for MM with pep-
tone for 16 and two actinomycetes, respectively. For the induction of antibiotics active 
against K. pneumoniae and A. baumannii, increasing the pH to 10 was most effective, 
activating the production of antibiotics by 17 actinomycetes against A. baumannii and 
by 12 against K. pneumoniae. When grown on MM with starch or peptone, seven and 
eight strains inhibited growth of A. baumannii, respectively, and for K. pneumoniae these 
numbers were four and three, respectively.
Venn diagrams (Figure 4) visualize the specificity of the antibiotics produced by the 
96 actinomycetes. Despite the multiple resistance cassettes present in E.coli ET8 for de-
replication purposes, all of the 96 strains inhibited growth of this indicator strain under 
at least one of the growth conditions. Furthermore, 30 out of 96 actinomycetes could 
be activated by one or more growth conditions to produce antibiotics against all of the 
tested MDR pathogens (Supplemental Table S4). Considering the broad resistance spec-
tra of these pathogens, this underlines the potential of these actinomycetes in terms of 
antibiotic production. Of these, 34 actinomycetes had the potential to produce antibiot-
ics active against P. aeruginosa and K. pneumonia, six specifically inhibited growth of P. 
aeruginosa and not of K. pneumonia, while the reverse was true for 23 actinomycetes. 
This strongly suggests that many of the actinomycetes produced different antibiotics. 
In a similar comparison but now with the Gram-negative E. cloacae and A. baumannii, a 
total of 44 actinomycetes were active against both MDR pathogens, with 20 only against 
A. baumannii, and five only against E. cloacae. Comparing the Gram-positive MDR patho-
gens E. faecium and S. aureus, 86 out of 96 tested actinomycetes were active against 
both indicator strains, six of which were specific against S. aureus and three specific 
against E. faecium (Figure 4).
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Identification of antibiotics
The activity-guided assay demonstrated that all actinomycetes produced varying levels 
of growth inhibiting bio-activities. However, a question that needed to be answered 
was as to what extent the growth inhibition was indeed caused by antibiotics with pos-
sible application as clinical drugs, rather than representing general disruptive activities. 
Examples of the latter include surfactants, acids or lytic agents and agents with a mode 
of action that can also have a detrimental effect on eukaryotic cells, including agents 
that target DNA, induce cell lysis or damage the cell membrane. Therefore, bio-activities 
that fluctuated strongly depending on the growth condition, were selected for further 
characterization. For this validation study, Streptomyces species MBT28, MBT70, MBT73 
and MBT76 (all part of the sub-collection of 96 actinomycetes) were selected as they 
showed strongly inducible activity and therefore served as reference strains for this 
study. Importantly, as discussed below, all of the antimicrobial bio-activities that were 
characterized were indeed identified as antibiotics. However, it should be noted that all 
of the strains produce multiple antibiotics (not shown), and the entire antibiotic-pro-
figure 4. venn diagrams of antimicrobial activities of 96 selected actinomycetes against different 
groups of pathogens. Numbers refer to the number of actinomycetes that produced antibiotics that in-
hibited the indicated MDR pathogens, under any of the four conditions listed in Figure 4. The groups of 
pathogens are (a) Enterobacter cloacae, Acinetobacter baumannii and E. coli ET8, (b) Klebsiella pneumoniae, 
Pseudomonas aeruginosa and E. coli ET8, and (C) Staphylococcus aureus, Enterococcus faecium and E. coli ET8.
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ducing capacity of the strains is currently under investigation. A summary of the data is 
presented below. For details on the compound isolation procedure the reader is referred 
to Supplemental data file 1, and for NMR data the reader is referred to Supplemental 
data file 2 and Supplemental Figures S4 and S5.
A bioactivity that was specifically produced by Streptomyces sp. MBT73 on MM with 
starch (see HPLC chromatograms in Figure 5A) was isolated as 4.6 mg of a pure orange 
compound with a molecular formula of C22H16O6 based on an ESI-MS [M + Na]+ accurate 
mass of m/z 375.08926. This compound was identified by NMR analysis on the isolated 
compound as the antimicrobial and anticancer compound resistomycin ((3, 5, 7, 10-tet-
rahydroxy-1, 1, 9-trimethyl-2H-benzo [cd] pyrene-2, 6(1H)-dione), which was described 
previously and produced by Streptomyces resistomycificus, Streptomyces griseoincarnatus 
and Streptomyces aurantiacus (Sajid et al., 2011; Vijayabharathi et al., 2011). The proton 
NMR spectrum is presented in Supplemental Figure S4. Further confirmation was pro-
vided by genome sequencing, which revealed a gene cluster with high similarity (95% 
nucleotide level; not shown) to that of the previously published resistomycin gene 
clusters from S. griseoincarnatus and S. aurantiacus.
An antibiotic induced during growth at high pH from Streptomyces sp. MBT28 (Figure 
5B) was isolated as 8 mg of a pure and colorless compound with a molecular formula of 
C28H43NO6 based on an ESI-MS [M + Na]+ accurate mass of m/z 488.30438. The compound 
was identified by NMR analysis as the antimicrobial, antiviral and antimalarial agent bor-
relidin (2-(7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxooxacyclooctadeca-
4,6-dien-2-yl)-cyclo-pentane-carboxylic acid; (supplemental Fig. S4)). Borrelidin is a 
natural product first identified in Streptomyces rochei (Wakabayashi et al., 1997). The 
gene cluster was identified by genome sequencing in MBT28 (not shown), and shared 
89%, 97% and 93% nt identity to the borrelidin biosynthetic gene clusters of S. rochei, S. 
parvulus and S. griseus, respectively.
Growth on MM with peptone elicited the production of at least three distinct anti-
bacterial agents in Streptomyces sp. MBT70, as shown by thin layer chromatography 
(Figure 5C). For one of these, 1.9 mg of a pure and brown compound was obtained. The 
compound was readily characterized by NMR on the purified compound (Supplemen-
tal Figure S4) as 1-carbomethoxy-phenazine, with a molecular formula of C14H10N2O2 
(Römer, 1982). Phenazines are produced by pseudomonads and actinomycetes, and the 
biosynthetic gene clusters from Streptomyces MBT70 and of Streptomyces cinnamonensis 
(Karnetová et al., 1983) share 95% nt identity (not shown).
Growth of Streptomyces sp. MBT76 on MM with peptone resulted in the isolation of 
two active compounds (see HPLC chromatograms in Fig. 5D). For the first compound 2.3 
mg of a colourless compound was obtained with a molecular formula of C13H15O7 based 
on the ESI-MS [M + Na]+ accurate mass of m/z 273.0905. For the second compound, 
2.8 mg of a yellowish solid with the same predicted molecular formula of C13H15O7 
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figure 5. Induction of antibiotic production. Resistomycin, borrelidin, and 1-carbomethoxy-phenazine, 
and the isocoumarins 5,6,8-trimethoxy-3-methylisocoumarin and 6,7,8-trimethoxy-3-methylisocoumarin 
were produced by Streptomyces species MBT73, MBT28, MBT70 and MBT76, respectively, under specific 
growth conditions. (a) HPLC chromatograms (366 nm) of EtOAc extracts of MBT73 grown under control 
conditions (MM; top) and starch-supplemented cultures (middle); purified resistomycin (bottom) is pre-
sented as control. (b) HPLC chromatograms (245 nm) of EtOAc extracts of MBT28 grown under control con-
ditions (MM; top) and at pH 10 (middle); purified borrelidin (bottom) is presented as control. (C) Thin layer 
chromatography of extracts of MBT70 grown in (from left to right) 1, MM; 2, MM with 25mM NAG; 3, MM 
with peptone; 4, MM pH10; 5, MM with starch. TLC solvent was a 10:1 mixture of chloroform and methanol. 
The TLC plates show: i, separated compounds under UV 366nm; ii, separated compounds under UV 254 
nm; iii, antimicrobial activity against B.subtilis via an agar overlay assay. (d) HPLC chromatograms (366 nm) 
of EtOAc extracts of MBT76 grown under control conditions (MM; top) and peptone-supplemented cultures 
(middle); purified 5,6,8-trimethoxy-3-methylisocoumarin (bottom) is presented as control. (E) Chemical 
structures of the identified antibiotics.
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(ESI-MS [M + Na]+ accurate mass of m/z 273.0932). NMR analysis showed that the two 
compounds were similar but distinct isocoumarin-type compounds. The first isocouma-
rin was identified as the previously described 6,7,8-trimethoxy-3-methylisocoumarin 
(Hegde et al., 1989), while the second isocoumarin was identified as 5,6,8-trimethoxy-
3-methylisocoumarin, which has not yet been described in the literature. For details on 
the 1H and 13C NMR data of the isocoumarins see Supplemental Figure S5, Table S5 and 
Supplemental Data File 1. These data show that the observed antimicrobial activities 
were caused by pharmaceutically relevant natural products.
All compounds were tested for antimicrobial activity against the ESKAPE pathogens, 
using MIC assays as described in the Methods section. 1-carbomethoxy-phenazine, bor-
relidin, resistomycin and the novel compound 5,6,8-trimethoxy-3-methylisocoumarin, 
showed activity against the Gram-positive E. faecium (Table 2). However, the known 
isocoumarin 6,7,8-trimethoxy-3-methylisocoumarin did not display noticeable anti-
microbial activity. Borrelidin and resistomycin inhibited growth of the Gram-negative 
strains A. baumannii and K. pneumoniae, with resistomycin showing very strong activity 
(MIC <0.3 μg.ml) against both of the Gram-negative MDR pathogens, while borreldin 
showed similarly strong activity against K. pneumoniae, but only mild activity against 
A. baumannii. No bioactivity was found for any of the compounds against MRSA, nor 
against the Gram-negative pathogens E. cloacae and P. aeruginosa.
Table 2. MIC values (μg/ml) for the isolated antibiotics against the ESKAPE pathogens.
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1-carbomethoxy-phenazine 37,5 >37,5 >37,5 >37,5 >37,5 >37,5
Borrelidin 9,375 >37,5 18,75 0,29 >37,5 >37,5
Resistomycin 0,59 >37,5 0,15 0,29 >37,5 >37,5
5,6,8-trimethoxy-3-methylisocoumarin 18,75 >37,5 18,75 >37,5 >37,5 >37,5
6,7,8-trimethoxy-3-methylisocoumarin >37,5 >37,5 >37,5 >37,5 >37,5 >37,5
dISCuSSIOn
In this work, we have isolated over 800 actinomycetes from remote mountain areas in 
the Qinling and Himalaya Mountains and tested their capacity to produce antimicrobial 
agents with efficacy against Gram-positive and Gram-negative bacteria, and in particular 
antibiotics that inhibit growth of one or more of the six MDR ‘ESKAPE’ pathogens isolated 
recently from a nosocomial environment in The Netherlands. The observed bioactivity 
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profiles of the actinomycetes underlined the importance of screening for antibiotics 
against specific pathogens, in addition to the search for a broadly applicable antibiotic. 
Gram-negative pathogens are a major problem in the nosocomial environment (Rice, 
2008) and therefore many screening efforts focus on finding novel antibiotics that target 
these pathogens. In our study, 82 of the 96 isolates that were identified as the best an-
tibiotic producers of the strain collection, inhibited the Gram-positive MRSA even when 
grown on control MM agar plates and 53 inhibited E. faecium, while a significantly lower 
number of strains inhibited growth of Gram-negative MDR pathogens when grown on 
these standard media. Many of the actinomycetes that produced antibiotics against the 
Gram-negative MDR K. pneumoniae or E. coli under a certain growth condition did not 
inhibit P. aeruginosa and vice versa. In fact, P. aeruginosa, which is the major pathogen 
found in cystic fibrosis lungs (Davies, 2002), was by far the most resilient of the six 
clinical isolates tested, with only seven of the 96 best antibiotic producing strains of 
our collection inhibiting growth of this bacterium under routine growth conditions. 
For comparison, 34 of the 96 strains inhibited growth of K. pneumoniae, which is also a 
very dangerous MDR pathogen recently associated with major outbreaks in hospitals. It 
is therefore particularly interesting to note that Streptomyces strain MBT10 exclusively 
inhibited the growth of MDR P. aeruginosa and none of the other Gram-negative patho-
gens, and we are therefore currently investigating the possible application of this strain 
for the development of drugs against this dangerous opportunistic pathogen. These ex-
periments underline that specific antimicrobial agents that act against a certain patho-
gen may have advantages over traditional broad spectrum agents, whereby resistance 
development and side effects could potentially be reduced (Fischbach & Walsh, 2009). 
An example of the success of antibiotics acting against a specific clinical pathogen is the 
recent development of the lipopeptide antibiotic surotomycin for treatment of diseases 
caused by Clostridium difficile, an anaerobic spore-forming Gram-positive bacterium of 
the lower gastrointestinal tract (Tran et al., 2013). With the rapidly increasing occurrence 
of MDR pathogens in the clinic, the development of drugs with efficacy against specific 
infectious diseases appears to be a logical strategy.
Screening under different growth conditions is a strategy that has been used by the 
pharmaceutical industry for many decades, but the low success rates in the more recent 
years led to a steep decline in drug discovery efforts (Payne et al., 2007). We analyzed the 
efficacy of the strains of our collection against MDR pathogens that currently threaten 
the health of patients in the nosocomial environment, whereby the strains were grown 
under 40 different growth conditions. This included more traditional growth conditions 
as well as novel ones, such as the addition of GlcNAc, which inhibits the activity of the 
global antibiotic repressor DasR and was previously shown to activate antibiotic pro-
duction, including the cryptic polyketide Cpk in S. coelicolor (Rigali et al., 2008). However, 
of the conditions tested in this study, in particular high pH values (pH 10) appeared to be 
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a promising new condition for screening, as it efficiently elicited antibiotic production. 
Previous studies on productivity by the fungus Sclerotinia sclerotiorum using a pH range 
between 5-9 showed optimal production at pH 7 (Song et al., 2012). We here show that 
the effect of pH varies from strain to strain, and that in fact there is strong potential of us-
ing in particular high pH values for screening purposes, while low pH (acidic conditions) 
was less effective in our assays. Perhaps counter-intuitively, growth at high pH did not 
affect the susceptibility of the indicator strains B. subtilis or E. coli, nor did it noticeably 
influence growth and development of the actinomycetes. As an example of application 
of pH 10 during screening, strain MBT68 inhibited growth of E. faecium, P. aeruginosa, K. 
pneumoniae, E. cloacae and A. baumannii only when grown on MM with pH 10. With the 
observed strong effects on antibiotic production in many of the strains in our collection, 
very high pH appears to be a very promising growth condition for antimicrobial screen-
ing efforts.
Detailed analysis of the antimicrobial compounds produced by a number of the 
isolates identified both new and previously identified compounds. This is exemplified 
by the metabolic profiles of four Streptomyces species grown under various conditions, 
which revealed inducible borrelidin production at high pH by MBT28, peptone-inducible 
production of 1-carbomethoxy-phenazine by MBT70 and of both 5,6,8- and 6,7,8-trime-
thoxy-3-methylisocoumarin by MBT76, and starch-inducible resistomycin production 
by MBT73. It should be noted that - as is often the case for streptomycetes - all of the 
four strains can produce multiple antibiotics, so that not all antimicrobial activity can 
be explained by the identified compounds (not shown). Borrelidin and resistomycin are 
commercially highly relevant natural products. Borrelidin is a nitrile-containing macro-
lide that acts as a potent inhibitor of both bacterial and eukaryotic threonyl-tRNA syn-
thetases (Habibi et al., 2012; Nass & Hasenbank, 1970), while resistomycin is a pentacyclic 
polyketide metabolite that inhibits RNA polymerase (Haupt et al., 1975), HIV-1 protease 
(Roggo et al., 1994) and apoptosis (Shiono et al., 2002) and was first applied as drug 
for the treatment of tuberculosis. 1-carbomethoxy-phenazine is known to have weaker 
antimicrobial activity. Of the isocoumarins, 6,7,8-trimethoxy-3-methylisocoumarin acts 
on calmodulin-sensitive cAMP- and cGMP-phosphodiesterases (Hegde et al., 1989), 
while its antimicrobial activity has not yet been described. Applicability of isocoumarins 
as an antibiotic, and in particular also that of the novel antibiotic 5,6,8-trimethoxy-3-
methylisocoumarin discovered in this work, should be analysed in more detail.
In conclusion, thorough analysis of a novel collection of actinomycetes from soil 
samples obtained from remote mountains shows their antibiotic-producing potential 
when grown under a range of different growth conditions, of which high pH proved to 
be particularly efficient. The study provides new insights in the efficacy of antibiotics 
produced against recently isolated MDR pathogens, and identified a number of antibiot-
ics whose expression varied greatly with the growth conditions, including a previously 
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unidentified isocoumarin-type antibiotic. In particular, the highly differential sensitivity 
of the various MDR ‘ESKAPE’ pathogens to the antibiotics produced by the actinomy-
cetes, underlines that an important strategy may be to search for drugs that target a 
specific pathogen.
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abSTRaCT:
Development of new antibiotics is declining whereas antibiotic resistance is rising, her-
alding a post-antibiotic era. Antimicrobial peptides such as gramicidin S (GS), exclusively 
topically used due to its hemolytic side-effect, could still be interesting as therapeutic 
compounds.
By modifying the amino-acid composition of GS, we synthesized GS analogues. We 
now show that derivative VK7 has a lower MIC (7.8–31.2 μg/ml, median 15.6 μg/ml) 
against strains of multi-drug resistant (MDR) Klebsiella pneumoniae, Acinetobacter bau-
mannii, and Pseudomonas aeruginosa than GS has (3.9–62.5 μg/ml, median 31.3 μg/ml). 
Low MICs for both VK7 and GS were observed for Staphylococcus aureus and Enterococ-
cus faecium. VK7 showed reduced hemolysis and less lactate dehydrogenase release. All 
compounds were fully bactericidal at MIC values. Modification of GS enables production 
of novel derivatives potentially useful for systemic treatment of human infections.
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InTROduCTIOn
Six bacterial pathogens with a propensity for developing multi-drug resistance (MDR) 
are specifically warned for by the Infectious Disease Society of America (IDSA) (ESKAPE: 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter bau-
mannii, Pseudomonas aeruginosa, and extended spectrum beta-lactamase (ESBL)-pro-
ducing Enterobacteriaceae). These species are causing the majority of human infections 
and efficiently acquire additional resistance traits [1], which implies that new antibiotics 
have to be effective against these actively evolving MDR pathogens. The incidence of 
vancomycin-resistant Enterococci (VREs) has increased dramatically over recent years [2]. 
S. aureus, especially methicillin-resistant S. aureus (MRSA), currently causes more deaths 
in the USA annually than HIV and tuberculosis combined [2]. ESBLs continue to be on 
the rise and limit treatment options [3]. P. aeruginosa is becoming increasingly resistant 
to multiple classes of drugs [4], whereas Acinetobacters are naturally resistant to many 
classes of antibiotics [5]. Increasing antibiotic resistance leads to extended hospitaliza-
tion, rising treatment costs, and increased morbidity and mortality.
The rise of antibiotic-resistant pathogens has sparked research into currently disre-
garded antimicrobial peptides including gramicidin S (GS). GS is naturally produced by 
Aneurinibacillus migulanus [6] and was first discovered in 1941 [7]. GS shows antimicro-
bial activity against both Gram-positives and Gram-negatives in a MIC range from 4–64 
μg/ml [8]. The lowest MICs are seen for Gram-positive bacterial species [9]. Despite its 
good antimicrobial activity, GS cannot be used systemically due to its hemolytic side-
effect [10] and is therefore only applied topically to treat superficial infections [11]. GS is 
a cyclic, C2-symmetrical deca-peptide with the sequence cyclo(Pro-DPhe-Leu-Orn-Val)2. 
The two Pro-DPhe dipeptides form two type II β-turns, and the two Leu-Orn-Val stretches 
form an antiparallel β-sheet. GS has been reported to kill bacteria by forming pores in 
the outer membranes [8]. Native GS is a natural scaffold for amino acid alteration in 
such a way that antimicrobial activity is retained but toxicity is reduced. In previous 
attempts to modify GS, several strategies have been followed: nonnatural amino-acids 
were included [12], the size of the ring has been modified [8], and the β-turn region [13] 
and β-strand region have been changed [14]. Still, few new derivatives of GS have been 
identified that show retention of antimicrobial activity with reduced toxicity [8, 15–18]. 
We here study the β-strand-modified GS analogue VK7 [14] and the β-turn modified 
derivative 20 [13]. Studying naturally occurring antimicrobial peptides such as GS could 
help with the design and development of novel derivative drugs to combat multi-drug 
resistance.
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MaTERIal and METhOdS
ESKaPE panel collection and characterization
Except for the S. aureus USA 300 and MRSA 252 strains [19], ESKAPE strains were col-
lected at the Department of Medical Microbiology and Infectious Disease in the Erasmus
Medical Centre, Rotterdam, The Netherlands. Thirty clinical isolates of E. faecium (5), 
S. aureus (5), K. pneumonia (5), A. baumannii (5), P. aeruginosa (5) and E. cloacae (5) were 
isolated from January 2010 to October 2011 from different wards (Table 1). All strains 
were cultured on Columbia agar plates with 5 % sheep blood (Becton Dickinson, Breda, 
The Netherlands) overnight at 37 °C before antibiotic susceptibility testing. Antibiotic 
resistance was determined using disk diffusion following Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines and VITEK2 (bioMérieux, Zaltbommel, The Netherlands) 
following manufacturer’s protocol; susceptibility was determined using EUCAST break-
points [20].
MIC determination
Antimicrobial activity of GS and derivatives (Fig. 1) was determined following the CLSI 
guidelines and in triplicate [21]. Briefly, bacterial cells were cultured overnight on Co-
lumbia agar plates with 5 % sheep blood (Becton Dickinson, Breda, The Netherlands). 
Colonies were suspended in 0.9 % NaCl to a density of 0.5 McFarland, then diluted 1:100 
in Müller–Hinton Broth (MHB, Oxoid, Badhoevedorp, The Netherlands); 100 μl of this 
suspension was added to wells containing GS, derivatives 3, 20, or VK7 ranging from 
a concentration of 0.95 μg/ml to 62.5 μg/ml in MHB. Ninety-six well plates (Greiner Bio 
One, Alphen aan den Rijn, The Netherlands) were incubated for 18–24 hours at 37 °C, 
and MIC values were determined visually. To determine whether antimicrobial activity 
was bactericidal, 200 μl of the suspension was plated onto new Columbia agar plates 
with 5 % sheep blood, and colonies were counted.
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Table 1: 
Strain #  3 20 GS VK-7
Enterococcus faecium 1 7,8 15,6 3,9 3,9
2 7,8 15,6 3,9 3,9
3 7,8 7,8 3,9 3,9
4 7,8 7,8 3,9 3,9
5 7,8 3,9 3,9 3,9
Staphylococcus aureus 1 31,3 7,8 3,9 7,8
2 7,8 3,9 3,9 3,9
3 62,5 62,5 7,8 15,6
4 31,3 7,8 3,9 7,8
5 31,2 7,8 3,9 7,8
Klebsiella pneumoniae 1 62,5 62,5 31,3 15,6
2 31,3 62,5 62,5 15,6
3 62,5 62,5 62,5 15,6
4 31,3 62,5 31,3 15,6
5 15,6 15,6 7,8 15,6
Acinetobacter baumannii 1 31,3 62,5 31,3 15,6
2 31,3 62,5 62,5 7,8
3 62,5 62,5 31,3 15,6
4 62,5 62,5 15,6 15,6
5 31,3 62,5 62,5 31,2
Pseudomonas aeruginosa 1 31,3 62,5 31,3 7,8
2 31,3 31,3 31,3 7,8
3 31,3 31,3 31,3 7,8
4 62,5 62,5 62,5 7,8
5 62,5 62,5 62,5 7,8
Enterobacter cloacae 1 3,9 7,8 3,9 7,8
2 3,9 7,8 7,8 15,6
3 7,8 7,8 3,9 7,8
4 3,9 1,95 1,95 7,8
5 62,5 62,5 62,5 15,6
toxic dose 50% (hemolyse) 41,6 nd 35,2 nd
toxic dose 50% (LDH) 49,8 62,5 18,7 nd
MIC lowest values 3,9 1,95 1,95 3,9
MIC highest values 62,5 62,5 62,5 31,2
TI following hemolysis range 0,66 - 10,67 nd 0,56 - 18,05 nd
TI following LDH release range 0,80 - 12,77 1 - 32,05 0,30 - 9,59 nd
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hemolysis assay
Hemolysis assays were performed as described before [13]. Freshly drawn heparinized 
blood from healthy volunteers was centrifuged for 10 min at 1000 g at 10 °C. The pel-
let was washed three times with 0.9 % saline and diluted with saline to a 1/25 packed 
volume of red blood cells. Triton-X100 (1 %) was used as a positive control. GS or deriva-
tive 3, 20, and VK7 were diluted in 100 μl PBS in U bottom 96-well plates (Greiner Bio 
One). Serial dilution resulted in a concentrations ranging from 62.5 μg/ml to 0.95 μg/
ml. DMSO (Sigma–Aldrich, Zwijndrecht, The Netherlands) was used as a solvent control. 
Subsequently, 50 μl of the red blood cell suspension was added to the wells, and the 
plates were incubated at 37 °C for 4 h. After incubation, the plates were centrifuged 
at 1, 000 g at 10 °C for 4 min, and 50 μl of the supernatant of each well was dispensed 
into new flat-bottom 96-well plates (Greiner Bio One), and absorbance was measured 
at 415 nm in a Bio-Rad 680 spectrophotometer (Bio-Rad, Veenendaal, The Netherlands). 
OD values were plotted as a percentage of the positive control. Experiments were per-
formed in triplicate.
Cytotoxicity testing
Human colorectal adenocarcinoma cells (HT-29, ATCC number HTB-38, Wesel, Germany) 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Bleiswijk, The 
Netherlands) with 10 % FCS (Gibco) and penicillin–streptomycin (Gibco). Colourless 
DMEM (Gibco) with 1 % FCS (Gibco) was used as assay medium. HT-29 cells were seeded 
at a density of 2.0 × 10^4 cells/well in a Costar flat-bottom 96-well plate (Corning, 
Amsterdam, The Netherlands) and incubated overnight. Serial dilutions of GS and de-
rivatives were added and incubated for 4 h at 37 °C. Plates were centrifuged for 10 min 
at 1,000 g, and the amount of LDH in the supernatants was determined (LDH release 
kit, Roche, Woerden, The Netherlands) following the protocol. Cytotoxicity testing was 
independently repeated three times.
Therapeutic indices
The therapeutic index was defined as a measure of toxicity, either the 50 % hemolysis or 
the 50 % LDH release, divided by the lowest and highest MIC values seen for each strain 
tested. Therapeutic indices are given as a range to be compared between GS and its GS 
derivatives to determine improved performance.
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RESulTS
Cohort collection and characterization
Five strains each of E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and 
E. cloacae were collected from various wards of the Erasmus MC in 2010 and 2011 (Table 
1). Extensive antibiotic resistance was observed. S. aureus and E. faecium showed resis-
tances to penicillins, cephalosporins, lincosamides, tetracyclines, macrolides, fusidic 
acid, aminoglycosides, carbapenems, (fluoro)quinolones, oxazolidonones, monoxycar-
bolic acid, nitrofuran derivatives, rifamycins, sulfanomides, and glycopeptides. Extensive 
drug resistance was also observed among K. pneumoniae, A. baumannii, P. aeruginosa, 
and E. cloacae including aminoglycosides, (ureido)penicillins (in combination with beta 
lactamase inhibitors), fluoroquinolones, polymyxins, carbapenems, nitrofuran de-
rivatives, and trimethroprim with sulfamethoxazole. Each strain showed a unique profile 
with resistance to several clinically used antibiotics.
MIC determination
GS was active against S. aureus and E. faecium at 3.9–7.8 μg/ml (median 3.9 μg/ml) (Fig. 2).
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MIC values against E. cloacae, P. aeruginosa, K. pneumoniae and A. baumannii for GS 
ranged between 3.9–62.5 μg/ml (median 31.3 μg/ml).
The beta-strand variant VK7 showed activity against S. aureus and E. faecium in the 
range of 3.9–15.6 μg/ml (median 3.9 μg/ml), comparable to parental GS. VK7 showed 
activity in the range of 7.8–31.2 μg/ml (median 15.6 μg/ml) against E. cloacae, P. aeru-
ginosa, K. pneumoniae, and A. baumanii. The MIC values against all P. aeruginosa and A. 
baumannii strains and most K. pneumoniae strains are 2- to 8-fold lower for VK7 than the 
GS MIC values.
The β-turn variant 20 showed slightly reduced activity against S. aureus and E. faecium 
as compared to GS. MIC values for compound 20 were in the range of 7.8–62.5 μg/ml 
(median 7.8 μg/ml). Derivative 20 showed activity against E. cloacae, P. aeruginosa, K. 
pneumoniae, and A. baumannii in the range of 1.95–62.5 μg/ml (median 62.5 μg/ml), 
which is slightly less than measured for the parental compound.
Derivative 3 showed activity against S. aureus and E. faecium in the range from 
7.8–62.5 μg/ml (median 7.8 μg/ml), which is slightly less than parental GS. Derivative 3 
shows activity against the MDR Gram-negative strains E. cloacae, P. aeruginosa, K. pneu-
moniae, and A. baumannii in the range from 3.9–62.5 μg/ml (median 31.3 μg/ml), which 
is comparable to the parental compound. All compounds tested were bactericidal, as 
sub-culturing of medium from wells without visible growth on agar media did not result 
in detectable growth.
hemolysis assay and therapeutic indices
Hemolysis is clearly concentration-dependant. Canonical GS showed 50 % hemolysis at 
35.2 μg/ml (Fig. 3a). As the MIC values of GS varied from 3.9 to 62.5 μg/ml, the TIhem for 
GS was calculated to be between 0.56 and 18.5. Derivative 3 showed 50 % hemolysis at 
41.6 μg/ml (Fig. 3a), which is in a similar range as for the parental compound. As deriva-
tive 3 had MIC values varying from 3.9 and 62.5 μg/ml, the TIhem of derivative 3 was 
calculated to be 0.6 to 10.6, also comparable to the parental compound. This shows that 
derivative 3 is not an improved antibiotic in comparison with GS. VK7 and compound 
20 did not show hemolysis at 62.5 μg/ml, which was the highest concentration tested. 
Hence, the exact TIhem for compound 20 and VK7 could not be determined, but still, 
these derivatives are clearly less hemolytic than GS (Fig. 2).
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ldh release assay and therapeutic indices
The values of 50 % LDH release were 18.7 μg/ml for GS (Fig. 3b). As the MIC values were 
between 3.9 and 62.5 μg/ml, TILDH was calculated to be between 0.3 and 9.6. Derivative 
3 showed 50 % LDH release at 49.8 μg/ml. As the MIC values were between 3.9 and 62.5 
μg/ml, TILDH was calculated to be between 0.8 and 12.8, in the same range as docu-
mented for GS. Derivate 20 showed 50 % LDH release at 62.5 μg/ml. As MIC values were 
between 1.95 and 62.5 μg/ml, TILDH was calculated to be between 1 and 32.1 μg/ml, 
which shows slight improvement compared to GS. VK7 did not reach 50 % LDH release 
at concentrations tested here. Therefore, no TILDH could be calculated, indicating again 
that VK7 is less cytotoxic than GS (Table 1).
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dISCuSSIOn
Beta-strand modification of GS seemed to be promising for the development of new 
systemically applicable antibiotics. Derivative VK7 showed activity against E. cloacae 
which was equal to that of GS. Against all P. aeruginosa and K. pneumoniae and most 
A. baumannii there was a 2–8-fold increase in activity. The antimicrobial activity of VK7 
against Gram-positive MDR pathogens such as S. aureus and E. faecium was similar to 
that of GS. In addition, we observed reduced toxicity for VK7 towards human erythro-
cytes and the human colorectal adenocarcinoma cell-line HT-29. The β- strand-modified 
VK7 has the same overall secondary structure as GS, but probably displays an elevated 
cationic character counterbalanced by two robust hydrophobic adamantane groups. 
The data indicate that β-strand modification of GS can generate interesting new antibi-
otics combining antimicrobial activity and lowered toxicity.
The β-turn-modified derivative 20 showed reduced toxicity compared to the parental 
compound, with a slight decrease in antibiotic activity compared to GS, especially when 
used against Gram-negatives. This β-turn-modified derivative encompasses a substitut-
ed sugar amino acid (SAA) dipeptide isoster as turn mimetic. The six-ring SAA in our lead 
was found to have better conformational and hydrophobic characteristics than a 4-ring 
(oxetane) and 5-ring (furanoid) SAA [9]. Beta-turn modification could still be promising, 
as at least some reduction of toxic potential is observed. Not all modifications of GS have 
a positive effect on antimicrobial activity and toxicity: derivative 3 shows comparable 
antimicrobial activity to the parental compound but a similar toxicity profile.
The synthesis of modified GS derivatives has been reported by other groups [8, 12, 
15, 17]. One of the key factors important in the balance between cytotoxicity and anti-
microbial activity is overall hydrophobicity–hydrophilicity. Derivatives that are slightly 
less hydrophobic than the parental GS generally show good antimicrobial activity, while 
showing reduced hemolysis. Using solid- and liquid-phase organic synthesis, derivatives 
of GS can be obtained containing non-naturally occurring amino acids, which show 
reduced cytotoxicity and reduced hemolysis, while retaining antimicrobial activity.
Antimicrobial peptides may have a bright future in combating infection, as they 
generally do not have a single conserved target, but affect multiple bacterial processes. 
Modifications of the β-strand of GS in which the hydrophobic side chains have been 
varied are promising leads for the development of novel compounds. New derivatives 
of GS can possibly address the growing problem of multi-drug resistant bacteria and 
lead to new therapeutic compounds for systemic use, as is suggested on the basis of our 
current data.
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Infectious diseases remain a major burden on human health [53], despite many previous 
breakthroughs in various fields such as treatment, prevention and vaccination [54, 55]. 
This thesis focuses on the pathogen Staphylococcus aureus, which causes a broad range 
of infectious diseases: from acute bacteremia [56] to chronic osteomyelitis [57], from 
superficial skin infections [58] to deep-seated endocarditis [59] and from relatively mild 
abscesses [60] to life threatening pneumonia [61]. S. aureus, especially the methicillin 
resistant S. aureus variant MRSA and the emerging vancomycin resistant mutants [1-4], 
have complicated treatment of S. aureus infection. Infection is thus an increasing burden 
on human health [10-12]. It is, therefore, essential to develop new interventions against 
this pathogen. By gaining new insights in bacterial pathogenesis, novel interventions 
may be devised, including anti-staphylococcal vaccination and immunotherapy. Also, 
these insights might lead to the technology whereby bacterial behavior in vivo can be 
altered into a less pathogenic mode. Furthermore, antibiotics with new modes of action 
must be found to expand our options for applying conventional treatment approaches.
More insight into host pathogen interactions between S. aureus and humans, the 
primary aim of this thesis, was gained by studying: (I) how, in humans with different 
types of interactions with S. aureus, their humoral immune system responds to known 
staphylococcal virulence factors, (II) the (kinetics of ) production of virulence factors 
during biofilm formation, and (III) the link between (the formation of ) biofilm and persis-
tence of infection in patients suffering from staphylococcal bacteremia. The second aim 
of this thesis was to find new leads for antibiotics with novel modes of action directed 
against infections with multi-drug resistant ESKAPE pathogens. Actinomycetes, the 
origin of up to 60% of all clinically available antibiotics, were induced to produce novel 
compounds by culturing strains from remote locations in various laboratory conditions. 
Furthermore, gramicidin S was used as a scaffold to design new derivatives by adding 
non-naturally occurring amino-acids to attain reduced toxicity profiles, while retaining 
antimicrobial activity.
MaIn fIndIngS
In this thesis, we studied humoral immune responses directed against S. aureus viru-
lence factors produced in vivo. In Chapter 2 we studied IgG, as it is the most common 
isotype of antibody present in blood. IgG occurs in different subclasses, each with their 
own unique function in vivo [17, 18]. Importantly, we have found IgG4 responses against 
a broad panel of S. aureus derived immune modulators. IgG4 responses, which are in-
dicative of repeated and prolonged exposure [18], were found in all human sera against 
multiple S. aureus components. However, when we tested antibody responses against 
40 S. aureus virulence factors, we found these IgG4 responses only against a restricted 
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panel of 17 virulence factors: alpha toxin, CHIPS, ETA and B, HlgB, IsdA, LukD, -E, -F and 
-S, SCIN, SEC, SSL1, 3, 5 and 9 and TSST-1. These staphylococcal products are known to 
interact with and even counteract the human immune system on many levels. Among 
the innate immune responses that are affected are chemotaxis (by CHIPS), extravasa-
tion (by SSL3 and SSL5), complement activity (by SCIN) and TLR2 signaling (by SSL3). 
Neutrophils themselves are targeted by the γ-hemolysin family (HlgB, LukD, E, F and S) 
and alpha toxin lyses mononuclear immune cells and platelets. SSL9 binds to monocytes 
and dendritic cells [19], but its exact function remains unknown. SSL1 is a potent in-
hibitor of neutrophil matrix metalloproteinases (MMP’s), which are endopeptidases that 
degrade components of the extracellular matrix of human tissues, but also modulate 
inflammation [5]. SEC and TSST-1 modulate adaptive responses by non-antigen directed 
binding of MHC II with T cell receptors, resulting in polyclonal T cell activation [20]. 
Interestingly, IgG4 responses to these antigens were found to be dependent on the type 
of host pathogen interaction and/or on the carrier status of the individuals at the time 
they were sampled. We found IgG4 responses to be most commonly directed against 
immune modulators secreted by S. aureus, indicating that we as humans are repeatedly 
and perhaps chronically exposed to these virulence factors; most IgG4 responses were 
measured in sera from patients suffering from Epidermolysis Bullosa (EB). IgG4 class 
antibodies are correlated with the induction of tolerance in the framework of allergy 
therapies and with repeated or chronic exposure for other reasons [17, 23]. We, therefore, 
hypothesize that humans interact more extensively and repeatedly with S. aureus, than 
currently appreciated. This might mean that we need to adapt our view of interactions 
between S. aureus and humans, in either disease or carriage states. This concept may 
have implications for the development of effective immunotherapy, such as (active and 
passive) vaccination and immune modulation interventions in the treatment of S. aureus 
infections.
S. aureus does not only escape clearance by the immune system by producing immune 
modulators, but it also produces biofilm. Reportedly, 80% of all infections are biofilm 
related [24]. Late in the maturation phase of biofilms, staphylococcal cells disperse from 
the biofilm and seeding of distant sites may occur, together with the production of the 
immune modulators stated above [25, 26]. This leads to the question: how does S. aureus 
protect itself during the early stages of biofilm formation, if immune modulators are 
reportedly only produced late in biofilm formation? In Chapter 3 we show that some 
immune modulators are produced and secreted earlier than currently reported, and 
that they are produced for much longer periods of time. Our experiments with biofilm 
formation and virulence factor production were performed in the eukaryotic cell culture 
medium IMDM. Growing bacteria in eukaryotic cell culture media is a strategy followed 
by several other research groups [6, 7], as S. aureus has previously been reported to 
behave differently in eukaryotic medium compared to prokaryotic cell culture media. 
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We hypothesized that using eukaryotic cell culture medium mimics the situation bac-
teria will encounter in a human body better compared to using prokaryotic cell culture 
medium. We have used IMDM for experiments in Chapter 3 and 4. Most model systems 
use less well-defined bacterial growth media, that do not resemble the internal milieu of 
the human host at all. Bacterial cell culture media are also not constant in composition, 
they can vary from batch to batch, as their composition is not completely chemically 
defined. Better model systems are required to mimic the in vivo situation. The immune 
modulators we found in early biofilms are mainly directed against the early innate im-
mune system: CHIPS, SCIN and FLIPr. SCIN modulates C3b complement deposition and 
thereby C3b mediated opsonophagocytosis [27]. CHIPS binds to the C5a receptor and 
formylated peptide receptor inhibiting neutrophil chemotaxis [28]. FLIPr is a a potent 
FcγR antagonist. Using our model system we provided evidence for the production of 
these immune modulators in the beginning stages of biofilm formation, an area not 
previously researched. Further study in this direction may lead to better understanding 
of the process of virulence factor production during early versus late biofilm formation, 
facilitating a better understanding of the first phase of biofilm formation and possibly 
new (or better timed) treatment options.
Biofilm is seen in many different types of infection, and it plays an important role in 
resisting clearance. S. aureus in a biofilm is much less sensitive to clearance by the im-
mune system and to antibiotics compared to when it is growing in a planktonic form 
[24]. Biofilm hinders clearance by facilitating the trapping and physical exclusion of 
antibiotics and immune cells and proteins, in addition to secreting immune modulators 
(Chapter 3). Furthermore, a biofilm consists of bacterial cells in various metabolic states, 
reportedly making them heterogeneously sensitive to certain classes of antibiotics [30]. 
Persistence is seen in many infections, and causes significant concern in patients with 
S. aureus bacteremia; even when patients do receive adequate antimicrobial therapy, 
symptoms of invasive infection may last for prolonged periods of time and 10-20% of all 
patients die. The Infectious Diseases Society of America (IDSA) has produced a guideline 
that advises 6-8 weeks of intravenous antibiotic therapy for patients with complicated 
SAB (defined as patients that have positive blood cultures for more than 72 hours under 
appropriate therapy), and 2-4 weeks of therapy for patients with uncomplicated SAB 
(when the patient’s blood becomes culture negative within 72 hours of appropriate 
therapy) [31]. Rapid detection of the type of SAB is thus essential for treating patients 
correctly, but by definition, this takes up to 72 hours after treatment initiation to estab-
lish or refute. In Chapter 4, we searched for bacterial and host factors that could predict 
complications at an earlier stage. Strains causing complicated SAB, when cultured in the 
eukaryotic cell culture medium IMDM and in the presence of 1 x MIC of vancomycin, 
produced more biofilm than strains causing uncomplicated SAB. It was described by 
Pietiäinen et al. [8], that vancomycin induces transcriptional responses, especially the 
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up-regulation of the cell wall stress stimulon VraSR, that are similar to the transcriptional 
responses to stresses induced by human derived antimicrobial peptides [32]. Thus, the 
effect of treatment with antibiotics in our in vitro experiments may actually resemble the 
effects of natural exposure to host-derived antimicrobial peptides. Taken together, we 
hypothesize that the ability of certain strains of S. aureus to maintain biofilm production 
under stress conditions encountered in vivo, including stresses exerted by antimicrobial 
therapy, could explain, at least in part, the persistence of bacteremia in S. aureus infected 
patients. This direction of a more systems-based mode of research by combining media 
and antibiotics to better mimic the in vivo situation deserves more attention since it 
could possibly yield a better ex vivo model for staphylococcal infection. Such a model 
could also give more insight into the pathogenesis of S. aureus infections and possibly 
explain why biofilm is seen in so many infections: irrespective of the antibiotics actu-
ally used in clinical practice, the driving force behind biofilm formation could actually 
be our own immune system. Testing the infecting strains ability to form biofilm under 
vancomycin pressure in IMDM may be a rapid ascertainment of the probability that a 
SAB will be complicated or not, and so help guide clinical management of SAB.
For the treatment of infectious diseases, antibiotics are still the mainstay and will 
remain so in the foreseeable future. A worrying trend seen in the treatment of infec-
tious disease is the ever-increasing bacterial resistance to antibiotics. Not only is there 
currently extensive antibiotic resistance in our clinics, the IDSA is concerned that some 
pathogens are well on their way to become multi- or totally drug-resistant. These are 
Enterococcus spp. [33, 34], Staphylococcus aureus [10-12], Klebsiella spp. [35, 36], Acineto-
bacter baumannii [37, 38], Pseudomonas aeruginosa [39, 40] and Enterobacter spp. [41, 
42]. They have coined the acronym ESKAPE-pathogens. New therapeutic options are 
thus of the greatest importance. In Chapter 5 we have induced actinomycetes, already 
known to produce up to 60% of all antibiotics used in clinical practice, to produce 
novel compounds. By growing these actinomycetes in non-standard culture conditions, 
they started producing interesting molecules that can potentially be developed into 
medicines. We are currently only at the beginning of this approach, and estimates of 
microorganisms that can be cultured vary widely: in our work, only culturable actinomy-
cetes are used for research and induction purposes. Here, we show that the vast majority 
of tested actinomycetes can be induced to inhibit the growth of S. aureus. Many of the 
actinomycetes that produced antibiotics against one pathogen under a certain growth 
condition did not inhibit another, and vice versa, showing that choosing the correct 
culture condition is key. Of the various conditions tested, alkalinity (pH 10) appears to 
be promising for eliciting antibiotic production. The highly differential sensitivity of 
the various MDR ESKAPE pathogens to the antibiotics produced by the actinomycetes 
tested here underlines that an important strategy may be to search for drugs that target 
a specific pathogen.
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In Chapter 6 we focus on gramicidin S, a well-known and old antibiotic, that has not 
reached clinical practice for systemic usage due to its toxicity profile in humans [43-45]. 
By using gramicidin S as a scaffold, new derivatives were designed that have a different 
mode of action than classically used antibiotics [43-45]. Not all modifications of GS have a 
positive effect on antimicrobial activity and toxicity: one derivative showed comparable 
antimicrobial activity to the parental compound but had decreased toxicity towards eu-
karyotic cells. New derivatives of existing antimicrobial peptides may also have a future 
in combating infectious disease, as they generally do not have a single conserved target, 
but affect multiple bacterial processes and can possibly address the growing problem of 
multi-drug resistant bacteria and lead to new therapeutic compounds for systemic use.
MaIn COnCluSIOnS:
1: The finding of IgG4 responses against a range of S. aureus virulence factors indicate 
repeated and prolonged exposure to Staphylococcus aureus, much more extensively 
so than previously appreciated. These 17 virulence factors are alpha toxin, CHIPS, ETA 
and B, HlgB, IsdA, LukD, -E, -F and -S, SCIN, SEC, SSL1, 3, 5 and 9 and TSST-1.
2: In patients suffering from Epidermolysis Bullosa IgG4 antibodies were found directed 
against a wider range of virulence factors than carriers, and in carriers IgG4 antibod-
ies were found directed against a wider range of virulence factors than non-carriers, 
showing a descending order of the frequency of (immunological) interaction be-
tween S. aureus and its human host.
3: Staphylococcus aureus often forms biofilms. SCIN, CHIPS and FLIPr are important in 
the immune evasion of S. aureus in the early phase of biofilm formation. We humans 
are exposed to SCIN, CHIPS and FLIPr repeatedly and for prolonged periods of time.
4: Strains causing complicated SAB produce more biofilm than strains causing un-
complicated SAB when grown in eukaryotic cell culture medium in the presence of 
vancomycin.
5: Actinomycetes can be induced to produce novel antibiotics against MDR-ESKAPE 
pathogens, especially when grown in alkaline environments.
6: Modifications of the β-strand of GS, in which the hydrophobic side chains are 
modified provide promising leads for the development of compounds that are safer 
when compared to the parental compound, while retaining antimicrobial activity 
comparable to the parental compound.
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PERSPECTIvES On S. AurEuS RESEaRCh
No clear antibody response profile could be linked to the site or type of exposure to 
S. aureus (Chapter 2). This indicates that each host S. aureus interaction may have a 
unique virulence profile, which does not bode well for the prospect of vaccination and 
other immune based therapies. Patterns of IgG4 response varied extensively between 
volunteers, indicating that each person is exposed to different virulence factors. The dif-
ferent exposure to virulence factors could be explained by the fact that various genetic 
backgrounds of S. aureus contain different sets of virulence factors. Variation may also be 
due to differences in regulators and/or gene expression in various S. aureus strains [46-
49]. Further complicating this host pathogen interaction study is the fact that hosts may 
show different humoral responses. Host IgG4 responses were predominantly directed 
against secreted immune modulators of S. aureus, a constant finding since the start of 
measuring such antibodies [13-16, 50]. We hypothesize that host S. aureus interactions 
occur extensively and repeatedly and are even more varied than currently appreciated, 
regardless of disease state or carriage status. As IgG4 is indicative of repeated and 
prolonged exposure, we may be currently underestimating the interaction that occurs 
between the human host and the opportunistic pathogen S. aureus (Chapter 2). This 
might have major implications for research on host-pathogen responses in vivo and for 
the development of immuno-therapeutic strategies such as active vaccination. Patients 
suffering from EB are often chronically colonized with high densities of S. aureus while 
not frequently suffering from invasive S. aureus infections such as bacteremia, leading 
to the most responses against S. aureus virulence factors. This observation could be in-
teresting for further vaccination research: as IgG4 antibodies are produced mainly after 
repeated exposure, inducing them might require prolonged and repeated exposure.
Our experiments with virulence factor production (Chapter 3) and biofilm formation 
(Chapter 4) were performed in an eukaryotic cell culture medium (IMDM). Growing bac-
teria in eukaryotic cell culture media is a strategy followed by several other groups, as S. 
aureus behaves differently in prokaryotic medium compared to eukaryotic cell culture 
media [51, 52]. In eukaryotic growth media, which are relatively devoid of iron, S. aureus 
grows slower and produces much larger amounts of iron-regulated surface proteins 
such as IsdB, in comparison to TSB grown bacteria [52]. Conditions in vivo may well dif-
fer from those in laboratory media and we suggest that using eukaryotic cell culture 
medium better mimics the in vivo situation and indicates a good direction for future 
research. Although much is known about the production of virulence factors of mature 
biofilm, our knowledge is far from complete concerning early biofilms; we are still far 
from a complete insight into the kinetics of immune modulator production during the 
formation of biofilms. Other secreted virulence factors may also play a role in the escape 
from immune clearance, and the previously identified virulence factors warrant further 
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research. The results generated here are a stepping stone towards elucidating the role of 
virulence factors during biofilm formation, and gives a method to screen and determine 
which factors are important in pathogenesis in vivo. This test system was further used for 
studying the production of biofilm in the context of staphylococcal bacteremia (Chapter 
4). Complicated infections persist much longer than uncomplicated infections, and we 
researched if this difference could be caused by biofilm formation. We found that strains 
causing complicated SAB produce more biofilm than strains causing uncomplicated 
SAB when they were grown in IMDM with vancomycin. As vancomycin induces similar 
responses to host defense peptides [9], our finding may indicate that human immune 
system is actually the driving force in the production of biofilm. This cell wall stress could 
be used by bacteria as a signal that they are “inside the host” and in response to these 
signals they might alter their behavior, either by producing virulence factors and/or 
by forming biofilm. Taken together, we hypothesize that the ability of certain strains 
of S. aureus to maintain biofilm production under stress conditions encountered in 
vivo, including that exerted by antimicrobial therapy, could explain, at least in part, the 
observed persistence of bacteremic infection in our cohort of patients. This observed 
persistence does seem related to an aggregated form of life and sites of infection that 
are difficult to treat, such as endocarditis and osteomyelitis, which are associated with 
complicated form of SAB. These findings also highlight the importance of taking into 
account not only the host, but also the bacterium and finally the antibiotic therapy used 
when researching infectious diseases. Several avenues of research in this direction could 
be: the addition of components of the immune system, such as complement, serum, 
plasma and / or neutrophils (or other cells of the immune system) to growing bacteria 
or biofilms at time points when the bacteria would encounter these components in vivo 
during infection. Also, growing biofilms in flow conditions is an interesting route of new 
research that warrants future research, especially in the context of S. aureus bacteremia.
After primarily focusing on the bacterium and the host in the first half of this thesis, 
antibiotics take center stage in the second half of this work. Here we focus mainly on 
generating new leads for antimicrobials. New strategies in the treatment of infectious 
disease should follow a more targeted approach and find treatment options that are 
highly selective. Instead of broad spectrum antibiotics, more focused antibiotics could 
be useful, which only act on a sample of bacterial species. This would further necessitate 
the rapid identification of the pathogen responsible for disease. This route was followed 
in Chapter 5, where we researched actinomycetes that were culturable in laboratory 
setting, and found several likely leads, which were highly specific. Future study should 
be directed towards cultivating actinomycetes more in their natural habitat, which 
could lead to further new compounds. The culturable micro-organisms form the tip of 
the iceberg, with many strains not being researched as they cannot be cultivated yet. 
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By better culture methods [10] and better mimic systems, more biologically relevant 
findings will be generated.
Instead of targeted treatment, more broad-spectrum antibiotics remain useful, espe-
cially in empirical therapies. Chapter 6 focuses on one of these: gramicidin S has a very 
broad spectrum and targets the cell membrane of bacteria. Furthermore, gramicidin S 
works well against a wide spectrum of gram positive bacteria, and is slightly less effec-
tive against gram negative bacteria. As antimicrobial peptides generally do not have 
a single conserved target, but affect multiple bacterial processes, they could be very 
useful: resistance against such antimicrobials is slow and difficult to evolve, possibly 
allowing long usage of such therapeutics. We show here that β-strand modification of 
GS could generate interesting new antibiotics combining high antimicrobial activity and 
lowered toxicity and are thus promising leads for the development of novel compounds.
In conclusion, to remain able to treat S. aureus infections in the future we require a 
two-pronged approach:
1:  We need to know more about how Staphylococcus aureus actually causes different 
types of infection, so that we may be able to modulate and interfere with pathogenic 
behavior, either by vaccination or by alternative therapies.
2:  We need to continue searching for novel antibiotics: as soon as a new compound is 
approved for usage in humans, resistance against that compound occurs, necessitat-
ing even newer antimicrobials.
Combining these two avenues of research remains essential to help future health care 
patients; especially the elderly, the hospitalized patient population that routinely re-
quires antibiotic prophylaxis to remain free of infections, the ever increasing group of 
immunocompromised patients (HIV /AIDS, diabetics, transplanted persons) and other 
patients in the hospital. If we keep studying these 2 subjects, and research them in tan-
dem, we may be able to stave off a post antibiotic era, in which infections can be rapidly 
and effectively diagnosed but no longer treated.
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Infectieziekten blijven een groot effect op menselijke gezondheid hebben, ondanks 
doorbraken in meerdere gebieden zoals behandeling, preventie en vaccinatie. Dit 
proefschrift heeft als hoofdonderwerp de opportunistische pathogeen Staphylococcus 
aureus, die een breed scala aan ziektes veroorzaakt zowel in de algemene bevolking als 
in ziekenhuizen: van acute bacteriemie, tot chronische osteomyelitis, van oppervlakkig 
huidinfecties tot diepgelegen endocarditis. Het opduiken van meticilline-resistente 
varianten van S. aureus (MRSA) hebben de behandeling van deze infecties verder be-
moeilijkt. MRSA-infecties worden veelal met vancomycine behandeld, maar ook tegen 
vancomycine blijken dergelijke stammen resistent te kunnen worden. MRSA infecties 
geven daarmee een toenemende belasting van de gezondheidszorg. Het is daarom 
essentieel om nieuwe therapieën tegen deze verwekker te ontwikkelen. Door nieuwe 
inzichten in de bacteriële pathogenese kunnen nieuwe interventies ontwikkeld worden, 
zoals vaccinatie en immunotherapie. Mogelijk leiden deze inzichten ook tot interven-
ties, waarbij het gedrag van S. aureus in vivo aangepast kan worden zodat ze minder 
of geen schade aan de gastheer, en daardoor ziekte, veroorzaken. Daarnaast moeten 
antibiotica met nieuwe werkingsmechanismen gevonden worden, om het arsenaal aan 
behandelingsmogelijkheden uit te breiden.
Er is met het onderzoek beschreven in dit proefschrift meer inzicht verkregen in de 
interactie tussen S. aureus en de menselijke gastheer: op de eerste plaats is onderzocht 
hoe, in mensen met verschillende S. aureus interacties, het humorale immuunsysteem 
reageert op reeds bekende S. aureus virulentie factoren. Daarnaast is onderzocht hoe de 
productie van virulentie factoren tijdens de vorming van biofilm verloopt, en tenslotte 
is onderzocht of er een verband bestaat tussen de vorming van biofilms en aanhouden 
van S. aureus bacteriemie. Het 2e doel van het onderzoek beschreven in dit proefschrift 
was het vinden van antibiotica met nieuwe werkingsmechanismen, die werkzaam 
zijn tegen multiresistente varianten van bacteriën uit de zogenoemde ESKAPE groep 
micro-organismen; die ESKAPE groep bestaat uit de bacteriegeslachten en -soorten 
Enterococcus spp., Staphylococcus aureus, Klebsiella spp., Acinetobacter spp., Pseudomonas 
spp. en Enterobacter spp., die veel infecties veroorzaken en vaak antibioticaresistent 
zijn. Hiertoe werden Actinomyceten, de bron van ongeveer 60% van al onze klinisch 
gebruikte antibiotica, geïsoleerd uit exotische locaties en vervolgens gestimuleerd om 
nieuwe metabolieten met antibiotische werking te produceren. Daarnaast is het grami-
cidine S molecuul als uitgangspunt gebruikt om nieuwe derivaten te ontwikkelen met 
niet natuurlijk voorkomende aminozuren met als doel het behouden en vergroten van 
antibiotische activiteit en het verkleinen van de toxiciteit.
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vOORnaaMSTE bEvIndIngEn
In dit promotieonderzoek heb ik de humorale immuunrespons bestudeerd gericht te-
gen S. aureus virulentie factoren die geproduceerd werden in vivo. In hoofdstuk 2 heb-
ben we IgG bestudeerd, omdat dat het meest voorkomende isotype immuunglobuline 
in bloed is. IgG heeft verschillende subtypen, elk met een eigen functie in vivo. Ik heb 
IgG4 responsen gevonden tegen een breed scala aan S. aureus virulentie factoren. IgG4 
responsen wijzen in het algemeen op herhaalde en langdurige blootstelling aan een 
immunogeen. IgG4 gericht tegen S. aureus componenten werden in alle menselijke sera 
gevonden, en zij waren gericht tegen meerdere, maar niet alle onderdelen van S. aureus. 
Wij vonden IgG4 responsen gericht tegen 17 van 40 verschillende virulentie factoren die 
werden onderzocht; dat waren alfa-toxine, CHIPS, ETA en B, HlgB, IsdA, LukD, -E, -F en -S, 
SCIN, SEC, SSL1, -3, -5 en -9 en TSST-1. Van deze virulentie factoren is bekend dat ze op 
meerdere niveaus reageren met het immuunsysteem, c.q. de afweer van de mens tegen 
infecties tegenwerken. Belangrijke afweermechanismen die door deze virulentiefacto-
ren beïnvloed worden zijn de chemotaxis van witte bloedcellen (CHIPS), de extravasatie 
van witte bloedcellen (SSL3 en 5), complement activatie (SCIN), en TL2 signalering (SSL3). 
Neutrofiele granulocyten zijn gevoelig voor de toxische werking van S. aureus gamma 
hemolysines ( HlgB, LukD, E, F en S) en alfa-toxine grijpt aan op mononucleaire cellen en 
bloedplaatjes. SSL9 bindt aan dendritische cellen en monocyten, maar de exacte functie 
van dit eiwit is onbekend. SSL1 is een sterke remmer van metallo-proteases en endopep-
tidases van de granulocyten, die een rol spelen in ontsteking. SEC en TSST-1 grijpen aan 
op de verkregen afweer door niet-antigen gerelateerde binding van MHC-2 receptoren 
op T-cellen, wat resulteert in polyclonale T-cel activatie. De gemeten IgG4 responsen 
bleken afhankelijk van de type interactie tussen S. aureus en de menselijke gastheer. 
Daarnaast speelde de dragerschapsstatus van de individuen ten tijde van serumafname 
een rol. De gemeten IgG4 responsen waren vooral gericht tegen virulentiefactoren van 
S. aureus, die door de bacterie worden uitgescheiden. Deze waarnemingen geven aan 
dat mensen langdurig en herhaaldelijk blootgesteld worden aan deze virulentie facto-
ren. De meest uitgebreide IgG4 responsen werden gevonden in het bloed van patiënten 
die lijden aan de ziekte Epidermolysis bullosa. Omdat IgG4 responses gepaard gaan met 
de inductie tolerantie in de behandeling van allergie en met herhaalde en langdurige 
blootstellingen voor andere redenen, veronderstellen wij dat mensen in het algemeen 
langer en vaker met S. aureus in aanraking komen dat tot nu gedacht werd. Dit betek-
ent dat we onze kijk op de interactie tussen S. aureus en de mens enigszins bij moeten 
stellen, zowel met betrekking tot S. aureus dragerschap als met betrekking op infecties 
veroorzaakt door S. aureus. Dit concept kan ook gevolgen hebben voor het ontwikkelen 
van (passieve of actieve) vaccinaties en andere immuun-modulerende behandelingen 
van S. aureus.
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S. aureus ontsnapt niet alleen aan het immuunsysteem door het produceren van im-
muun modulerende virulentiefactoren, maar ook door het produceren van biofilms. In 
de wetenschappelijke literatuur worden biofilms van belang geacht bij ongeveer 80% 
van alle infecties. Vast staat dat eenmaal volgroeide biofilms cellen kunnen loslaten die 
uitzaaien en elders in het lichaam secundaire haarden (zogenaamde strooihaarden) 
kunnen vormen; daarbij produceren volgroeide biofilms veel van de eerder genoemde 
immuun-modulerende virulentiefactoren waarmee ze zich beschermen tegen de afweer 
van de gastheer. Of dergelijke virulentie factoren ook in de vroege fase van biofilm-
vorming geproduceerd worden was onduidelijk. Dit leidde tot de volgende vraag: hoe 
beschermt S. aureus zich tijdens de vroege fases van biofilm vorming tegen de gastheer 
afweer, als immuun-modulatoren alleen maar tijdens de late fase van biofilm vorming 
worden geproduceerd. In hoofdstuk 3 laten we zien dat bepaalde immuun-modulatoren 
eerder gemaakt worden dan tot nu toe werd aangenomen, en dat ze daarnaast langer 
geproduceerd worden dan eerst werd gedacht. Onze experimenten met de vorming 
van biofilm werden uitgevoerd in het eukaryote celkweek medium IMDM. Het kweken 
van S. aureus in eukaryoot medium is een strategie die gevolgd wordt door meerdere 
onderzoeksgroepen, omdat er aanwijzingen zijn dat S. aureus zich anders gedraagt in 
eukaryoot dan in prokaryoot celkweek medium. We stelden de hypothese dat de eu-
karyote kweekcondities een beter in vitro equivalent zijn van de situatie die de bacteriën 
in vivo tegen zullen komen dan de prokaryote media die tot nu toe veelal gebruikt wor-
den. Wij hebben dit eukaryoot medium gebruikt in hoofdstuk 3 en 4. De meeste andere 
model systemen gebruiken chemisch ongedefinieerde prokaryote kweekmedia, die niet 
overeenkomen met de samenstelling van het interne milieu van de mens. Daarnaast zijn 
deze prokaryote kweekmedia niet constant van samenstelling en kunnen er aanzienlijke 
verschillen tussen batches zijn, omdat de chemische samenstelling niet vastgelegd is. Er 
zijn betere in vitro modelsystemen nodig om de in vivo situatie na te bootsen.
De immuun modulatoren die wij vonden in jonge biofilms (CHIPS, SCIN en FLIPr) zijn 
vooral gericht tegen het aangeboren immuunsysteem. SCIN moduleert C3b depositie 
en heeft daardoor een effect op C3b gemedieerde fagocytose. CHIPS remt de chemo-
taxis van neutrofielen. FLIPr is een sterke antagonist van de receptor voor Fc-gamma. In 
ons modelsysteem hebben we bewijs gevonden voor de productie van deze immuun-
modulatoren in de vroege fase van biofilmvorming, een tot op heden weinig bestu-
deerde fase. Verder onderzoek in deze richting zal meer inzicht leveren in de productie 
van virulentie factoren in de vroege versus late fases van biofilmvorming. Mogelijk 
leidt een beter begrip van de vroege fases van biofilm tot nieuwe (of beter getimede) 
behandelmogelijkheden. 
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Biofilms worden gezien in vele soorten infecties, en spelen een belangrijke rol in de 
overleving van micro-organismen. S. aureus cellen zijn veel minder gevoelig voor het 
immuunsysteem en voor antibiotica als ze in een biofilm groeien dan wanneer ze plank-
tonisch groeien. Biofilms werken de behandeling van infecties tegen door het wegvan-
gen en het uitsluiten van antibiotica en gastheer componenten (hoofdstuk 3). Daarna-
ast bestaat biofilm uit bacteriële cellen in verschillende metabole toestanden, waardoor 
ze veelal verminderd gevoelig zijn voor bepaalde antibiotica, vooral die antibiotica 
die aangrijpen in het delingsproces zoals beta-lactam antibiotica. Persistentie van een 
infectie wordt vaak gezien en is bijzonder zorgwekkend in het geval van bacteriemie, 
waarbij levende bacteriën dagenlang in de bloedbaan kunnen blijven circuleren, zelfs 
als patiënten de juiste antimicrobiële therapie ontvangen. In dergelijke gevallen kunnen 
symptomen van invasieve infectie aanhouden en de sterftekans bij een S. aureus bacte-
riemie is dan ook nog steeds 10-20% De Infectious Diseases Society of America raadt in 
geval van gecompliceerde bacteriemie (gedefinieerd als onder de juiste therapie toch 
meer dan 72 uur positief blijvende bloedkweken) tussen de 6 tot 8 weken intraveneuze 
therapie aan, terwijl 2 tot 4 weken intraveneuze therapie volstaat voor patiënten met 
een ongecompliceerde bacteriemie. Snelle vaststelling van de complicatie status is dus 
essentieel voor de juiste behandeling van patiënten, maar per definitie duurt het min-
stens 5-7 dagen om door middel van dagelijks afgenomen bloedkweken vast te stellen 
wat die status is. In hoofdstuk 4 zochten we naar gastheer en bacteriële factoren die bij 
een bacteriemie een gecompliceerde status konden voorspellen in een vroeger stadium. 
Stammen die gecompliceerde bacteriemie veroorzaakten, als ze gekweekt worden in het 
eukaryote celkweek medium IMDM in aanwezigheid van het antibioticum vancomycine 
bleken significant meer biofilm te produceren dan stammen die een ongecompliceerde 
bacteriemie veroorzaakten. Vancomycine induceert bepaalde transcriptionele respon-
sen, in het bijzonder een verhoogde afschrijving van het celwand stress operon VraSR, 
een fenomeen dat overeenkomt met de responses die geïnduceerd worden wanneer S. 
aureus blootgesteld wordt aan antimicrobiële eiwitten van menselijke oorsprong. Wij 
hypothetiseren daarom dat het effect van behandeling met (bepaalde) antibiotica in 
onze in vitro experimenten zou overeen kunnen komen met de effecten van natuurlijke 
blootstelling aan gastheer afgeleide antimicrobiële eiwitten. 
Uit dit onderzoek concluderen wij dat de mogelijkheid van bepaalde S. aureus stam-
men om biofilm te blijven produceren onder stress condities die ze in vivo tegenkomen, 
zoals bijvoorbeeld door antimicrobiële therapie, een verklaring zou kunnen zijn voor de 
persistentie van S. aureus bacteriemie. Deze vorm van onderzoek, waarbij er rekening 
gehouden wordt met zowel het effect van antibiotica als effecten van het kweekmedium, 
verdient naar onze mening meer aandacht: het zou mogelijk leiden tot een beter ex vivo 
model voor stafylokokkeninfecties. Zo’n model geeft meer inzicht in de pathogenese van 
S. aureus infecties, en zou mogelijk verklaren waarom biofilm in zoveel infecties wordt 
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gezien: ons eigen immuunsysteem is mogelijk de drijfveer voor bacteriën om bioflms te 
vormen, en niet de antibiotica die gebruikt in de klinische behandeling van de infectie. 
Het testen van de mogelijkheid van de infecterende stam om biofilm te vormen in IMDM 
onder vancomycine druk zou, indien bevestigd in grootschaliger nader onderzoek, een 
snelle manier kunnen zijn om vast te stellen of een S. aureus bacteriemie gecompliceerd 
zal verlopen of niet, en zo helpen met de klinische behandeling van S. aureus infecties.
In de behandeling van infectieziekten zijn antibiotica een zeer belangrijke pijler, en dat zul-
len ze in de nabije toekomst ook blijven. Een zorgwekkende ontwikkeling in de behandel-
ing van infectieziekten is de immer toenemende resistentie tegen antibiotica. Niet alleen 
is er uitgebreide resistentie nu al aanwezig in de kliniek, mondiaal zijn er grote zorgen dat 
een aantal pathogenen volledig resistent tegen alle antibiotica zullen worden. Deze patho-
gene bacteriesoorten staan inmiddels bekend als de ESKAPE pathogenen (zie boven). Het 
ontwikkelen antimicrobiële middelen met geheel nieuwe werkingsmechanismen is daarom 
van het hoogste belang. In hoofdstuk 5 hebben we daartoe Actinomyceten, al bekend als 
bron van ongeveer 60% van alle klinisch gebruikte antibiotica, gestimuleerd om nieuwe 
metabolieten te produceren met antimicrobiële eigenschappen. Voor deze inductie zijn 
de Actinomyceten op niet standaard media gekweekt, maar onder bijzondere condities. 
Het overgrote merendeel van deze Actinomyceten bleek in staat om stoffen te produceren 
die de groei van S. aureus remmen. Actinomyceten die de groei van een micro-organisme 
onder een bepaalde omstandigheid remden, remden deze groei niet onder een andere 
kweekcondities. Van de verscheidene kweekcondities die wij hier hebben onderzocht leek 
vooral een basisch milieu (pH10) ervoor te zorgen dat de Actinomyceten antibiotica pro-
duceerden. De differentiële gevoeligheid van verschillende ESKAPE pathogenen voor de 
metabolieten geproduceerd door de Actinomyceten geeft aan dat in de zoektocht naar 
nieuwe antibiotica we niet alleen breed spectrum antibiotica moeten zoeken, maar juist 
stoffen met een beperkt antimicrobieel spectrum kunnen vinden.
In hoofdstuk 6 hebben we Gramicidine S onderzocht, een al lang bestaand antimi-
crobieel middel, dat niet in de kliniek gebruikt kan worden doordat het als bijwerking 
de rode bloedcellen oplost (hemolyse). We hebben in dit onderzoek het Gramicidine 
S molecuul als uitgangspunt gebruikt om nieuwe derivaten te maken die een ander 
aangrijpingspunt hebben dan de meeste antibiotica. Niet alle modificaties hadden een 
positief effect op de antimicrobiële activiteit en toxiciteit: één derivaat had een antimi-
crobiële activiteit die vergelijkbaar was met Gramicidine S, maar bleek een verhoogde 
toxiciteit voor eukaryote cellen te hebben. Nieuwe derivaten van bestaande antimicro-
biële peptiden hebben wellicht een toekomst in de bestrijding van infectieziekten, om-
dat ze niet specifiek één doelwit hebben, maar vaak aangrijpen op meerdere processen, 
wat het voor bacteriën moeilijker maakt om er resistent tegen te worden. 
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danKWOORd
Welkom bij het meest gelezen stuk van mijn proefschrift. Of althans, het stuk wat 
mensen als eerste gaan lezen. Zonder jullie was het niet tot dit eindresultaat gekomen. 
Tot zover het kortste dankwoord in de geschiedenis van promoties.
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Ik wil toch wat woorden tot een aantal mensen richten. Sta je er niet persoonlijk tus-
sen? Dat is geen onwil, dat is de haast geweest om alles op tijd af te krijgen tussen het 
afronden van het schooljaar aan de Hogeschool, het emigreren naar Hong Kong en de 
duizend-en-één andere zaken die ik nu aan mijn hoofd heb. Daarnaast wil ik niet een al 
te klef dankwoord schrijven, en door eerder groepen te benoemen zie je niemand over 
het hoofd.
Ten eerste, professor doctor doctor Alex van Belkum: jij bent degene die mij deze 
promotieplek aangeboden hebt in oktober 2009. Daarnaast heb je na je vertrek bij de 
Medische Microbiologie en Infectieziekten nog op afstand begeleid en geholpen bij de 
publicatie van hoofdstuk 6. Zonder jou hulp en advies was het boekje er niet gekomen. 
Hartelijk dank voor je inzet en hulp.
Professor doctor Verbrugh, geachte Henri: na het vertrek van Alex heb jij het stokje 
overgenomen als promotor en mij begeleid richting de eindstreep. Zeer veel dank voor 
het doorlezen en managen van het geheel. Daarnaast heb je als moderator en manager 
van de promotie opgetreden, waarvoor ik je ook zeer veel dank schuldig voor ben. 
Zonder de maandelijkse meetings met jou erbij was het boekje ook zeker niet afgeko-
men.
Doctor Willem van Wamel, dank voor je niet aflatende focus op detail. Zonder jouw 
focus, inspanning en scherpte was het boekje niet tot stand gekomen en zeker niet in 
deze vorm. Ik heb je door de jaren heen als stevige sparringpartner leren kennen, en 
waardeer de vele discussies die we over S. aureus gehad hebben erg. Dank voor het naar 
een hoger plan tillen van dit boekje.
Professor doctor Heiman Wertheim, Professor doctor Gilles van Wezel en Professor doc-
tor Hubert Endtz: hartelijk dank voor het plaatsnemen in de kleine commissie en het 
razendsnel doorlezen en beoordelen van deze thesis. In het bijzonder nog een dank aan 
Gilles, voor de aangename samenwerking aangaande actinomyceten.
Daarnaast zou ik ook de rest van de commissie willen bedanken voor hun tijd, aandacht 
en oppositie.
Geachte “oude” collega’s van het Erasmus Medisch Centrum: dank voor de vele borrels, 
de vele adviezen, de vele “komt wel goed schatje” momenten en het ondersteunen van 
mij tijdens deze route. Dank voor de vele gezellige en grappige momenten, maar ook 
dank voor de steun als het even tegen zat. En met hét bedoel ik zowel mijn persoonlijke 
leven als mijn academische carrière. Ik zou dan specifiek Carla willen noemen: dank voor 
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je Rotterdamse nuchterheid en dank voor je altijd beschikbare hulp om iets last minute 
te organiseren. Ook na mijn aanstelling bij de Hogeschool heb ik met velen van jullie 
contact gehouden, en ik hoop dat verder te onderhouden vanaf de andere kant van de 
wereld.
Geachte “nieuwe” collega’s van de opleiding Biologie en Medisch Laboratoriumonder-
zoek: dank voor het warme thuis wat jullie mij geboden hebben. Ik heb vaker gehoord 
dat ik een geboren onderwijzer ben (tot op het irritante af zaken uitleggen), en het is al-
tijd plezierig om daar dan ook betaald voor te krijgen. Ik heb in 3 jaar vele veranderingen 
gezien: stress om de visitatie, de opbouw van het nieuwe curriculum, de numerus fixus 
of de algemene dagelijkse gang van zaken als onderwijzer, die al stress genoeg geeft. 
Dank voor jullie geduld, luisterende oren en adviezen. Niet alleen om het promoveren 
toch af te ronden en om een betere onderwijzer te worden, maar ook om eens op mezelf 
te letten en wat rust te nemen. Ook jullie beloof ik vanuit Hong Kong te vertellen waar ik 
me mee bezighoud, en wellicht kan ik nog wat stageplekken voor jullie vinden, mogelijk 
vergezeld van een woordgrap. In het bijzonder dank aan mijn “broeder van een andere 
moeder” en paranimf Vincent de Beer. Ik zal je enthousiasme en nerdy referenties mis-
sen. Stay awesome!
Vrienden die niet onder de vorige categorieën vallen: dank voor het aanhoren van mijn 
problemen en sores. Dank ook voor de afleiding van genoemde sores, en de vele grap-
pige, gezellige en serieuze momenten samen. Mijn promotie leek een gebed zonder 
eind, maar er is nu toch echt een einde aan gekomen. In de komende maand heb ik meer 
tijd om sociaal te doen en te genieten van jullie aanwezigheid voor vertrek naar Hong 
Kong. Daarnaast wil ik in het bijzonder mijn andere paranimf Ben Lennarts bedanken. 
Je bent een rots van rust en een rock-ster van zelf reflectie. Dank voor het luisteren en 
adviseren als het weer eens niet vlotte met mijn promotie, en dank voor het spiegelen. 
Ik wens jou ook al het goede toe in je penthouse aan de Neude.
Douwe en Diete, dank voor de onvoorwaardelijke steun en geloof dat ik het goed zou 
afronden. Vanuit jullie vertrouwen is het mogelijk geweest het geheel af te schrijven 
en door te gaan als ik het niet meer zag zitten. Rogier, lijfelijke aanwezig en Wouter, in 
Portland, dank voor jullie adviezen als promovendi om zo dit ook tot een goed einde te 
krijgen. Dank voor de luisterende oren en het geduld.
Le nouveau famille merci pour l’aceuil chaleureux en Belgique. J’espere de vous revoir 
au autre en Hong Kong!
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Maude, wife, little lover. The dog days are over. In a month I will join you in Hong Kong, 
and our adventure together can truly start there. Thank you for being patient with me 
(mostly): making me work through last summer really was the push this thesis needed, 
and I got it from you. You make me a better person, and I am lucky to be married to you. 
I love you to Hong Kong and back and can’t wait to start our adventure together there. 
Je t’aime, mon PSdA.
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